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ABSTRACT 
Due to the physical limitations associated with the size of a hard 
gelatin capsule shell it has not been feasible in practice to present a 
low potency drug in the form of a sustained release multiparticulate 
delivery system. The aim of this work was to design a tablet which, on 
oral administration, rapidly releases intact polymer coated pellets in 
which the integrity of the cores and the release retarding membrane is 
preserved. 
A comprehensive study is made of the effect of uncoated pellet 
formulation and pelletization processing variables on the physical, 
skeletal and tensile properties of uncoated pellets. Investigation into 
the effect of the drying technique on the properties of uncoated pellets 
is also reported. This work has shown that the aqueous solubility of 
pellet components and the drying technique used has a marked effect on 
pellet diametral strength, elasticity, surface characteristics and 
in-vitro drug release. 
Pellets were coated using aqueous dispersions of polymethacrylate, 
ethylcellulose and silicone elastomer polymers. The effect of the film 
composition on tensile properties was studied by evaluating the 
mechanical properties of free-films using the technique of indentation 
hardness testing. The quality of the film coating and the effect of 
polymer loading was evaluated using in-vitro dissolution testing and by 
scanning electron microscopy. It was found that those polymeric film 
formulations whose tensile properties most resembled the tensile 
properties of the pellet cores resulted in films which were best able to 
withstand the applied stress associated with pellet compaction. Those 
films exhibiting significantly greater elasticity than the uncoated cores 
resulted in pellets which exhibited a tendency for instantaneous elastic 
recovery on removal of the applied load; tablet formation was therefore 
prohibited. 
Polymer coated pellets were successfully compacted into tablets with 
an inert direct compression blend comprising large particle size grades 
of lactose and microcrystalline cellulose. Pellet distribution within 
the tablet matrix (evaluated by image analysis of tablet sections, 
microphotography and uniformity of content data) failed to show evidence 
of particle segregation. Comparative in-vitro release profiles of 
compacted and non-compacted pellets shows that some physical damage is 
being caused to pellets as a result of the compaction process. 
Pellets are rapidly released from the matrix on disintegration of 
the tablet. Visual observation of released pellets indicated that they 
were intact, however microscopic examination revealed evidence of 
impaired surface quality. Pellet damage during compaction appears to be 
independent of the magnitude of the applied load and fracture of the 
polymer coating is restricted to those pellets in contact with the 
surfaces of the punches and die during tableting. 
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" This is not the end. It is not even the beginning of 
the end. But it is perhaps, the end of the beginning" 
Winston L. S. Churchill. 1942. 
" Writing a book is an adventure. To begin with, it is a toy 
and an amusement; then it becomes a mistress, and then it 
becomes a master, and then a tyrant. The last phase is that 
just as you are about to be reconciled to your servitude, you 
kill the monster, and fling him out to the public" 
Winston L. S. Churchill, 1949. 
" Where observation is concerned, chance favours only the 
prepared mind " 
Louis Pasteur, 1854. 
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CHAPTER 1 
GENERAL INTRODUCTION 
1 
The approach to sustained drug delivery described in this study 
involves the design and study of a rapidly disintegrating single-unit 
system comprising compacted polymer-coated multiparticulates. 
The presentation of polymer coated particles enclosed in a hard 
gelatin capsule is a popular delivery system in which the dangers of 
dose dumping and ineffective blood levels are avoided by distribution of 
the dose in multiple-units. It is recognised that a multiple-unit 
sustained release dosage form presents a highly preferable alternative to 
a single-unit system for oral administration (Davis et al. 1984). 
However due to the physical limitations associated with the size of a 
hard gelatin capsule shell it has not been possible to administer a 
medium- to high-dose drug in the form of a sustained release multi-
particulate delivery system. The aim of this work therefore was the 
design and study of a tablet dosage form which on oral administration 
rapidly releases intact polymer coated pellets with the integrity of 
pellet cores and the release retarding membrane being preserved. 
Advantages associated with sustained release delivery systems 
include the need for less frequent dosage administration, a prolongation 
of drug absorption and a reduction in peak plasma drug concentrations; 
this results in an overall increase in the therapeutic effect for any 
given dose of drug. Furthermore there is improved patient compliance and 
a reduction in unwanted side effects which may be associated with high 
peak plasma drug concentrations. Also for a multiparticulate system, it 
may be possible to reduce rapid delivery of an irritant drug to localised 
parts of the gut mucosa. 
The pharmacological advantages of multiparticulate sustained release 
delivery systems are numerous. Bechgaard and Nielsen (1978) reported 
that a multiple-unit dosage form presents a highly preferable alternative 
to the single-unit devices due to greater predictability and 
reproducibility of the therapeutic effect and a reduced risk of side 
2 
effects. These authors report that a monolithic sustained release 
delivery device is unable to reach the small intestine (the primary site 
of drug absorption) independently of gastric emptying. 
Gastric emptying is a function of many variables including the 
degree of distension of the stomach, the composition and viscosity of the 
stomach contents and pH, in addition to being subject to neural and 
hormonal control. The application of multiparticulates to sustained drug 
delivery systems essentially eliminates the dependence of the drug effect 
on gastric emptying since particles of diameter approximating 1mm are 
sufficiently small to pass through the pylorus between sphincter openings 
(Bechgaard and Nielsen 1978). This facilitates reproducible transport of 
drug to the optimum site of absorption; it avoids high local 
concentrations of drug since the multiparticulates are distributed over a 
larger surface area which in turn minimises the risk of local irritation 
of the gut mucosa. The transport of sub-units is largely independent of 
the presence and the nature of food in the stomach and the variation In 
the bioavailability of multiple-unit dosage forms is therefore less 
subject to variation in both gastric-emptying and intestinal transit 
time. 
Davi et al. (1984) discuss how the stomach handles solid objects 
greater than 2mm diameter in a different manner to smaller particles and 
emphasise the importance of the time the dosage form remains in the 
stomach in respect of product bioavailability. Ganderton (1985) 
discussed the advantages associated with a drug contained in several 
hundred particles compared with a monolithic system and how any occlusion 
by the gut contents of the dosage form will only affect a small 
proportion of the dose of a multiple-unit system as opposed to the entire 
dose for a monolithic delivery device. 
3 
Scope of this thesis. 
In this present work pellet formulations containing high percentages 
of the low potency drug ibuprofen were studied and manufactured using the 
technique of extrusion and spheronisation. Detailed consideration was 
given to the effect of formulation and manufacturing variables on the 
physical characteristics and release properties of pellets. The materials 
of uncoated pellet formulations must possess the inherent cohesive and 
plastic properties necessary for the formation of good quality extrudate 
suitable for spheronisation. A study of the technique of pelletization 
enabled the formation of spherical particles containing high 
concentrations of drug with regular shape, uniform size and smooth 
surface characteristics ideal for the application of a release retarding 
film coating. 
It is widely accepted that many pelletization processing variables 
are capable of influencing the fundamental properties of uncoated 
pellets. However a major objective of this present work was to elucidate 
the effect of the drying technique on the mechanical properties and 
surface appearance of spheronised particles. Much work has been reported 
on the effect of the formulation variables and processing variables 
associated with extrusion and spheronisation, but little attention has 
been paid to the nature and length of the drying process. This work has 
revealed that the drying technique employed as a pelletization unit 
process has a quantifiable effect on the diametral strength and 
elasticity of pellets, the in-vitro drug release and the surface 
characteristics of ibuprofen pellets. 
Sustained drug release was achieved by the application of a release 
retarding membrane to the pellets by the use of an aqueous polymeric 
dispersion. Film coating was performed using a fluidised bed apparatus. 
A comprehensive study was made of the effect of the nature of the polymer 
and formulation variables on the quality of the resultant film and its 
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suitability for use as a release retarding membrane for multi-
particulates, which by design must be able to withstand the stress 
associated with pellet compaction into a tablet matrix. Free-films 
comprising polymer systems of the polymethacrylates, ethylcellulose and 
silicone elastomer were prepared using a rotating polytetrafluoroethylene 
(PTFE) cylinder and the mechanical properties evaluated using the 
technique of indentation hardness. 
The tensile properties of both uncoated and coated ibuprofen pellets 
and placebo pellets were studied using a Single Particle Crushing 
Assembly. Particular importance was placed on elucidating the relative 
elasticities of pellet formulations and their diametral strengths; these 
pellet formulations were required to withstand the applied stress 
associated with the compaction process. The fundamental bonding forces 
determining the strength of pellets as a consequence of the pelletization 
process are discussed. 
Drug release from uncoated and coated pellets was evaluated uSlng 
in-vitro dissolution testing. The use of this diagnostic technique 
enabled a study to be made of the effect of the nature of the polymer, 
polymer loading, formulation variables and the overall film quality on 
the drug release mechanism(s) from coated pellets. Qualitative film 
evaluation was made using scanning electron microscopy. 
Tablet compression involved designing an inert direct compreSSlon 
diluent blend suitable for compaction with the polymer coated pellets. 
This blend was designed to enable the formation of a mechanically strong 
tablet which rapidly disintegrated in vitro yielding intact pellets. 
Tablet formulations composed of compacted polymer coated pellets 
containing 800mg ibuprofen are studied. The particle size of the 
excipients of the diluent blend and their relative proportions were 
carefully optimised. The minimum quantity of diluent necessary to fill 
the void volume within a tablet comprising compacted polymer coated 
5 
spheres was elucidated in order that the integrity of the pellets could 
be maintained and a mechanically robust tablet of low friability be 
produced. 
In-vitro drug release, diametral crushing strength and tablet 
friability studies were performed on resulting tablets. 
The tablets rapidly disintegrate in vitro releasing intact polymer-
coated sustained-release pellets; the effect of compression force on drug 
release is shown. It is evident that slight damage to the film coat 
occurs as a consequence of pellet compression resulting in a slightly 
increased drug release rate. This increase in release rate however is 
marginal and the mechanism of dissolution appears not to be significantly 
affected. 
Microphotographs of coated pellets prIor to compaction and those 
released from the tablet following disintegration, show that some pellets 
appear to undergo physical deformation on compression. 
Quantitative evaluation of the distribution of pellets within the 
compacted pellet tablet formulation was made by performing image analysis 
of sections of tablets composed of stained pellets. Quantitative 
evaluation of the pellet distribution within the diluent blend at the 
tablet surface, cross-sectional and side-view of the tablet is presented. 
Microphotographic evidence in support of the data relating to pellet 
distribution within the tablet matrix IS also presented. 
Investigations to determine the nature of the damage occurrIng to 
the film coat as a consequence of pellet compaction were carried out 
using scanning electron microscopy. Mehta and Jones (1986) discuss the 
importance of elucidating the integrity of polymeric films applied to 
dosage forms and how the technique of scanning electron microscopy 
provides a valuable tool facilitating qualitative evaluation of film 
coatings. Microphotography of tablet sections shows the effect of 
compaction on pellets at the tablet surface, cross-sectional and 
6 
side-views. 
In order to quantify the extent of pellet damage it was necessary 
to consider the effect of compaction on in-vitro drug release. 
Comparison of drug release profiles of coated pellets presented as 
tablets with similar pellets studied as free entities indicates that drug 
release is more rapid after pellet compaction. The extent of physical 
damage caused to the film coat by compaction may be quantified by 
examining these differences in the in vitro release profiles. 
Square-root-time profiles indicate largely linear release for both free 
pellets and pellets presented as tablets. It is postulated that although 
pellet compaction may slightly enhance the rate of drug release by 
causing physical damage to the film coat of some pellets, it has little 
influence on the mechanism of drug release. 
Figure 1.1. Schematic illustration of the compacted pellet concept. 
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CHAPTER 2 
STUDY OF THE EFFECT OF FORMULATION AND PROCESSING VARIABLES 
ON THE PHYSICAL PROPERTIES OF UNCOATED PELLETS PREPARED BY 
EXTRUS ION-SPHERONI SATION 
8 
2.1. Introduction. 
The physiological and pharmacological advantages associated ~ith a 
sustained release multiple-unit delivery system for oral administration 
have been discussed previously. The technique of pelletization lends 
itself extremely favourably to the presentation of low potency drugs in 
the form of a multiparticulate preparation due to it being possible to 
prepare pellets containing high percentages of drug (as high as 90%w/w). 
Furthermore a drug delivery system comprising polymer-coated 
multiparticulates embedded within an inert rapidly disintegrating tablet 
matrix offers a means of presenting a low potency or high-dose drug as 
a sustained release multiple-unit preparation. 
2.1.1. Pelletization by extrusion-spheronisation. 
Spheronisation is a technique of Japanese origin which enables the 
formation of spherical particles with advantages of regularity of shape, 
uniformity of size and smooth surface characteristics. These particles 
have low friability associated with few fines. The use of this technique 
facilitates the formation of pellets containing very high percentages of 
drug; this is advantageous in the administration of high-dose or low 
potency drugs. Conine and Hadley (1970) reported that in many cases it 
is possible to prepare spheres containing 90-95 percent of active 
ingredient. The maximum drug content which may be achieved however IS 
very much dependent upon the characteristics of the raw materials, in 
particular the binding and cohesive properties of the active 
ingredient(s). 
For active excipients which are insoluble in the presence of the 
granulating fluid, spheres containing as much as 90 percent drug may be 
achieved. 
The process of pellet formation leads to a densification of 
materials. This factor together with the high concentrations of drug 
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which may be achieved render spherical particles or pellets, an ideal 
preparation for presenting high dose drugs in the form of a solid oral 
sustained drug delivery device. 
The processing stages in the technique of extrusion-spheronisation 
are summarised in Figure 2.1. 
2.1.2. Detailed consideration of the pelletization process, 
The pelletization process involves sieving and dry mixing of the 
excipients in a granulator. Granulating fluid is slowly added to the 
blend with mixing; mixing continues until a heavy, plastic, cohesive mass 
results. The quality of the wet mass at this stage is critical as it 
facilitates or otherwise, the formation of cylindrical segments or 
extrudate and spheres as a consequence of the extrusion and 
spheronisation processing. The granulate is inherently quite dense and 
is free-flowing. 
blending/dry mixing of sieved excipients 
wet massing 
(mixing and hydration of materials) 
extrusion of moist material 
spheronisation of extrudate 
drying 
tray ~ ~ fluidised bed 
screening and sizing 
Figure 2.1. Summary of the stages involved In pelletization. 
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Granulated material is fed into the hopper of the extruder which 
consists of two contra-rotating cylinders, one of which is perforated and 
the other of which is solid. The material is forced through the holes of 
the perforated cylinder and the resultant product discharged as 
cylindrical segments or extrudate of uniform length. The length of the 
resultant extrudate is a function of the positioning of a cutting blade. 
The final sphere size approximates the diameter of the extrudate; it is 
however influenced by some processing variables including water content. 
spheroniser rotation speed and residence time. 
Reynolds (1970) indicated the importance of the granulated material 
being thoroughly and uniformly wetted, such that a dense uniform mass 
results which will exhibit sufficient plasticity to enable it to be 
forced through the perforated cylinder of the extruder forming smooth, 
uniform quality extrudate. 
Surface defects of extrudate In the form of roughness, cracks or 
circumferential ridges {termed "shark skinning"} must not be evident as 
this leads to poorly controlled processing {Rowe, 1985}. This is because 
initial breakage of the extrudate occurs randomly resulting in poorly 
shaped spheroids with a large particle size distribution. Excessive 
wetting at the granulation stage leads to serious problems in the 
spheronisation process, since particle agglomeration occurs thus impeding 
particle rounding. 
Extrudate is then formed into spheres by means of a Spheroniser or 
Marumeriser. This involves breaking the cylindrical segments into 
shorter lengths by the action of a grooved plate spinning in a horizontal 
plane within a stationary vertical cylinder. Secondary to this, 
extrudate is transported by centrifugal force to the periphery of the 
spheroniser plate and IS rounded by a rolling action generated by 
frictional forces and the rapid rotation of the roughened plate. The 
material is forced up the stationary wall of the spheroniser and as the 
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momentum is dissipated, it falls. This motion causes the material to 
form spheroids after a residence time upwards of a few minutes. 
Some solvent evaporation occurs with densification of material 
during the spheronisation process; a densification "clink" is audible as 
this occurs, beyond which stage further spheronisation will not result In 
further rounding of the pellets. If the material is not sufficiently 
plastic to enable sphere formation by the action of the rotating plate. 
water will still be evaporated off as densification occurs, however the 
resultant pellets will be more oval than spherical. 
The nature of the spheroniser plate and other factors, namely plate 
weight, rotation speed and residence time all influence the nature of the 
final product and must be carefully optimised. The final product must be 
of uniform spherical shape exhibiting smooth surface characteristics. An 
increase in the spheronisation speed and a prolongation of residence time 
will result In enhanced product density (Conine and Hadley 1970). As a 
generalisation however, the diameter of the spheres approximates the 
diameter of the extrudate. 
The penultimate stage In pelletization involves the drying of the 
spheres. Conine and Hadley (1970) and Reynolds (1970) both state that 
the pellets may be dried by conventional methods, including aIr drying, 
oven or tray drying and fluidised bed drying and that fluidised bed 
drying will result in a product of greater bulk density than by the other 
methods. Many authors including Jalal et al. (1972) and Zhang et al. 
(1990) report the use of the hot air oven for drying spheres. This work 
illustrates that the drying method is of paramount importance In 
determining the physical properties of uncoated spheres, including 
variables such as diametral strength, elasticity, pore structure and 
skeletal density. 
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2.1.3. The significance of inert excipients In pelletization. 
Pellet crushing strength, friability, size, shape and dissolution 
characteristics depend largely on the nature of the excipients used in 
pellet manufacture. The characteristics of the active ingredient is 
however of primary importance for pellets containing very high levels of 
drug. 
It IS widely accepted that microcrystalline cellulose is the 
excipient of choice as a filler, since it exhibits the elasticity and 
plasticity required for extrusion-spheronisation. It is a material which 
has the ability to take up water into its intraparticulate voidage and 
become readily deformable (Harrison et al. 1985). 
The process of extrusion requIres that the blend IS of a cohesive 
nature exhibiting a degree of plasticity facilitating sphere formation. 
The mass must be free-flowing but of sufficient binding capacity to 
enable sphere formation; if the binding capacity of the drug and other 
excipients IS not sufficient it may be necessary to add a binder. The 
literature frequently reports however that microcrystalline cellulose 
offers strong cohesive properties to the blend. Microcrystalline 
cellulose is used widely in the manufacture of spheres; as a wet mass it 
is readily deformable and its inclusion in the formulation will improve 
the extrusion process and extend the region of steady state flow 
(Harrison et al. 1985). It may be that the inclusion of a high 
proportion of microcrystalline cellulose in the product however will 
result in a higher incidence of surface defects to the extrudate. A 
reduction in the rate of extrusion may be all that IS necessary to 
restore the quality of the extrudate (Harrison et al. 1985). 
Ghebre-Sellassie (1989) reports that the penetration of liquid into a 
pellet is proportional to the porosity or mean pore-diameter of the 
pellet and that the porosity of the pellet therefore influences the rate 
of disintegration. For a porous system, the pellet will disintegrate 
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more rapidly with the possible benefits of faster drug release. 
The nature of the excipients used in pellet formulations contributes 
to the quality of the end product, including particle shape, smoothness, 
porosity, drug release characteristics and other physical parameters 
including diametral strength, elasticity and friability. The effect of 
the inert excipients on these parameters however becomes less important 
for pellet formulations containing high percentages of drug. 
2.1.4. Granulating fluid volume. 
The volume of water added to the blend at the granulation stage is 
critical. If the mass is too dry an excessive quantity of fines will 
result during the manufacturing process and In the end product. 
Conversely, too much granulating fluid will result In adherence of 
material to the equipment and particle agglomeration. 
Malinowski and Smith (1975) investigated the effect of the initial 
water content of the mass on the physical properties of the end product. 
They report that an lncrease in water content leads to increases in the 
spheroid flow rate, bulk density and overall mean sphere diameter. They 
also report reduced product friability and the generation of fewer fines 
with increasing water content. 
2.1.5. Processing variables and pellet quality. 
a) Extrusion. 
It is possible to modify the characteristics of the final product by 
adjusting the rate of extrusion of the granulated material. An increased 
extrusion rate will extend the region of steady state flow, with a 
corresponding improvement in the quality of the extrudate (Harrison et 
I 1985) Excessive extrusion rates in excess of the critical velocity a . . 
will lead however to surface defects or sharkskinning due to the 
generation of higher wall stresses during this process. In the interest 
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of final product uniformity therefore this critical velocity extrusion 
speed must not be exceeded. 
As previously discussed, for the extrudate to break evenly during 
the spheronisation process, it must be smooth and of uniform diameter. 
For extrudate exhibiting sharkskinning, random breakage will occur and 
this will result in non-spherical, non-uniform pellets with a wide 
particle size distribution (Bechgaard and Nielsen 1978). 
b) Spheronisation. 
Spheronisation plate weight, residence time and rotation speed all 
influence the nature of spheronised particles. Conine and Hadley (1970) 
reported that the shape, diameter and particle size distribution are all 
influenced by the spheroniser rotation speed. There is an optimum speed 
below which there IS no granule densification; only cylindrical granules 
will be produced due to an insufficient centrifugal force (Conine and 
Hadley, 1970 and Rowe, 1985). For a rotation speed In excess of the 
optimum, agglomeration of spheres will occur rapidly with the resultant 
material being overSIze. Several authors report that for any gIven 
formulation an increase in the spheroniser rotation speed will lead to 
increased bulk density [Conine and Hadley (1970), Malinowski and Smith 
(1975) and Woodruff and Nuessle (1972)], an increased granule flow rate, 
a decreased mean particle size, a decreased friability and an increased 
percentage of fines (Malinowski and Smith, 1975). 
The spheroniser residence time similarly affects the shape, diameter 
and particle size distribution of the spheroids. Assuming the minimum 
spheronisation rotation speed is exceeded then an increase in residence 
time will improve the sphericity of the pellets (Rowe, 1985). Increasing 
the residence time therefore leads to an increase in the granule flow 
rate (Malinowski and Smith, 1975), bulk density (Conine and Hadley, 1970 
and Malinowski and Smith, 1975) and the pellet density (Rowe, 1985). 
There will also be a decrease in the friability of the particles and a 
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reduction in the percentage of fines produced. 
c) Drying. 
Chein and Nuessle (1985) showed that for materials within the core 
formulation which are soluble in the granulating fluid, the drying rate 
has a significant effect on the disintegration time of the pellets. An 
increased drying rate will lead to an increase in solute migration and a 
corresponding increase in the spheroid disintegration rate. It is an aim 
of this study to demonstrate the effect of the drying method and 
therefore the drying rate, on the physical properties of pellets prepared 
using the techniques of extrusion and spheronisation, including its 
influence on the diametral strength of pellets, porosity and skeletal 
density and the in-vitro drug release characteristics. 
2.2. Materials and Methods. 
2.2.1. Materials. 
Ibuprofen (Boots Pharmaceuticals); Avicel PH101, RC591 and CL611 
(FMC Corporation) and lactose NF Fast Flo (Wisconsin Dairies, Foremost 
Ingredient Group) were used in the pellet formulations documented 
subsequently. Purified water BP was used in all massing procedures. 
2.2.2. Plant and Equipment. 
Detailed in Table 2.1 is the equipment used in the manufacture of 
uncoated pellets. Two manufacturing locations were used throughout the 
study representing bench scale and pilot scale equipment. The physical 
properties of pellets manufactured using equipment which differed only in 
capacity, resulted in products which are in essence very similar. This 
IS supported by data given hence. Bench scale formulations were studied 
at the academic establishment and pilot scale at the industrial 
establishment respectively. The batch sizes indicated represent the 
weight of dry solids. 
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L 0 CAT ION 
I 
academic industrial ! 
Hobart granulator Diosna P25 granulator 
(capaci ty 1.5kg) (capacity 4kg) 
Alexanderwerk GA65 Extruder Alexanderwerk GA65 Extruder 
Cal eva Spheroniser Caleva Model 15 Spheroniser 
(120mm diameter plate) 
Aeromatic AG Fluid Bed Dryer Aeromatic AG Fluid Bed Dryer 
(lkg capacity) (10kg capacity) 
0.59mm, 1.19mm and 1.41mm aperture sieves 
NB: Hot Air Oven (used only where indicated) 
Table 2.1. Equipment used In pelletization processing. 
2.2.3. Blending of raw materials. 
The solid excipients were weighed and passed into the granulator 
through a sieve of aperture 1.19mm, dry mixed for two minutes and the 
required volume of water added slowly to the blend (over 60 seconds) with 
the mixer on low setting. With the mixer on high setting the mass was 
blended for a period of time such that uniform distribution of the water 
resulted in granulated mass which was free-flowing but cohesive under 
compression. 
During the granulating stage the mIxer was stopped periodically and 
the mass redistributed thus eliminating any dead spots within the mixer 
and enabling redistribution of any material adhering to the wall of the 
mIxer. The end point of the mixing process IS very much dependent upon 
the nature of the mass of a given blend. This IS not only dominated by 
the nature and quantity of the excipients forming the mass but also by 
the quality of the mixing process. 
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2.2.4. Extrusion of granulate. 
The success of the extrusion process and the nature of the extrudate 
IS largely a function of the nature of the formulation and extrusion 
process itself. Granulate must be free-flowing, but cohesive and plastic 
enough to allow it to be forced through the perforated cylinder of the 
extruder. The extrudate must be of uniform diameter and length, with 
smooth surface characteristics and free-flowing. 
The rate of extrusion is critical. For smooth surface, uniform 
extrudate to be produced the rate of extrusion must be carefully 
controlled. The Alexanderwerk GA65 Extruder was operated with a 
perforated cylinder rotation speed of 98 rpm. 
2.2.5. Spheronisation. 
For each formulation the spheronisation rotation speed and residence 
time were carefully optimised in a preliminary feasibility study. 
Differences in the scale of the spheronisation equipment available and 
the spheronisation plate weights were therefore compensated for by 
adjustment of the rotation speed and residence times. Specific 
information relating to spheronisation plate weights, residence times and 
rotation speeds are given subsequently in Tables 2.2 to 2.5 inclusive. 
2.2.6. Drying. 
Pellets were dried uSIng either fluidised bed apparatus with an 
inlet temperature of 58 to 60°C, or by tray drying in a hot air oven 
uSIng a drying temperature of 45 to 50°C. Pellets containing either 
ibuprofen or lactose with microcrystalline cellulose were prepared in 
order that the effect of aqueous solubility of the main excipient on 
pellet physical properties could be evaluated, as a consequence of these 
two very different drying techniques. A fundamental difference In the 
two processes is the length of the drying process. It is postulated that 
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the lactose-containing pellets, in which the main excipient IS freely 
water-soluble, may be more susceptible to solute migration as a 
consequence of the slow water removal associated with tray drying, than 
the ibuprofen-containing entities. 
Quantitative consideration of the effect of the drying methodology 
on the physical and release properties of pellets is documented in 
section 2.3. 
2.2.7. Moisture content. 
All batches of spheronised material were dried thoroughly to a 
moisture content of not greater than 1%w/w. 
2.2.8. Sizing. 
Removal of agglomerates and fines was performed for each batch by 
gently passing dried material through a sieve of aperture 1.41mm and over 
a sieve of aperture 0.59mm prior to any quantitative evaluation of 
pellets. 
2.2.9. Determination of skeletal density and sample specific volume. 
A Multivolume Helium Pycnometer 1305 was used to determine the 
skeletal density and volume of uncoated pellets, which enabled 
calculation of the absolute density based on the weight of the sample. 
Use of the Micromeritics Multivolume Pycnometer 1305 enabled 
measurement of the skeletal volumes of pellets by observing the reduction 
in the gas capacity in the sample chamber as a direct consequence of the 
presence of the sample. Helium penetrates the smallest pores and surface 
irregularities and therefore the volume obtained enabled calculation of 
the ultimate theoretical density of the sample. 
The sample chamber loaded with the test sample was charged to a gas 
pressure of approximately 20 psig (PI); 1 psig is equivalent to 
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6.895 X 10- 3 MPa. This volume of gas was then allowed to expand into a 
second chamber (of known volume), previously at the same temperature and 
pressure; this results in a second pressure (P2). This pressure becomes 
progressively smaller as the sample size increases. The use of the mass 
balance equations for the gas enabled calculation of the sample volume, 
since the volumes of the empty sample chamber and the expansion chamber 
and the pressure drop ratio upon expansion, were known. 
It was necessary to ensure that the sample chamber and sample cup 
were free from particulate contamination before any measurements were 
made; the pycnometer was therefore cleaned thoroughly prior to use. For 
each formulation, the sample cup (of nominal volume less than 5cm3 ) was 
filled with pellets; the sample chamber was purged with Helium gas prior 
to reading to ensure the displacement of any residual alr or moisture 
which may have been present within the pore structure of the sample. 
The sample chamber was then charged to a Helium gas pressure (Pl) of 
approximately 19.5 ± 0.2 psig (equivalent to approximately 0.134 MPa), 
allowed to equilibrate and the pressure recorded. By opening the valve 
connecting the sample and expansion chambers, the Helium was then allowed 
to expand into the expansion chamber, equilibrate and the expansion 
pressure (P2) was recorded. The chamber was then vented and the pressure 
allowed to return to zero. This procedure was repeated 10 times for each 
sample and a mean value obtained. The weight of the sample and the empty 
sample cup were recorded at the end of testing; this ensured that the 
weight recorded reflected the true weight of the sample free of air and 
moisture vapour. 
Prior to use the instrument was calibrated by determining the sample 
volume of a precision ball bearing, which by design occupied the maximum 
possible volume of the sample cup. 
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2.3. Results and Discussion. 
2.3.1. Uncoated pellet formulation for a low potency drug. 
Tables 2.2 and 2.3 show the processing variables for pellet 
formulations containing high percentages of ibuprofen with Avicel PHlOl. 
For any dosage form containing inherently high percentages of the acti\·e 
ingredient, the characteristics of the drug will significantly influence 
the success of the manufacturing process and consequently the physical 
characteristics of the end product. The physical properties of the drug, 
the nature of other excipient(s) and their relative quantities are all 
factors which affect the success of the pelletization process. Avicel 
PHlOl is documented as enhancing the spheronisation process 
(Ghebre-Sellassie, 1989) not only for its use as an inert filler, but 
also for its binding capacity. Microcrystalline cellulose as a 
spheronisation enhancer imparts the binding properties necessary for 
pellet strength and integrity and also confers that plasticity necessary 
for extrudate and sphere formation. 
The extrusion and spheronisation technique was successfully applied 
here to pellet formulations containing up to 80%w/w ibuprofen with Avicel 
PHlOl. Increasing the drug content beyond 85% was however largely 
unsuccessful. The binding capacity of microcrystalline cellulose 
appeared to be exceeded for pellet formulations containing drug 
concentrations in excess of 80 to 85%w/w. If drug levels in excess of 
this were to be achieved it would be necessary to use an additional 
binder within the pellet formulation. Some pellets were therefore 
prepared containing RC591 and CL611 grades of Avicel. These grades of 
microcrystalline cellulose contain incorporated sodium carboxymethyl 
cellulose (NaCMC). It was elucidated by preparing pellets containing 
NaCMC-grades of Avicel that the price of increasing the drug loading 
beyond 85%w/w was impaired pellet quality. In addition, Ghebre-Sellassie 
(1989) reported that pellet systems containing NaCMC grades of 
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microcrystalline cellulose exhibited differing drug release mechanisms: 
NaCMC-containing pellets exhibit release properties characteristic of 
hydrogel matrices as opposed to those containing only microcrystalline 
cellulose, which behave as inert matrices. A consequence therefore of 
the increased binding capacity associated with the use of NaCMC is poor 
sphericity in addition to an influence on the drug release mechanism. 
The reported change in geometry of NaCMC-containing pellets behaving as 
water swellable hydrogel matrices when in contact with the aqueous 
dissolution medium (Ghebre-Sellassie, 1989) was considered to be an 
undesirable consequence associated with the use of these excipients, in 
return for a slightly increased drug loading (in excess of 80% 
ibuprofen). The processing conditions for those pellet formulations 
containing ibuprofen with Avicel PH101 therefore were optimised; details 
are given in Tables 2.2 and 2.3. 
The effect of the scale of manufacture on the resultant product was 
studied within the scope of this work. Pellets were prepared using 
laboratory and pilot scale equipment differing in the granulation and 
spheronisation stages (Table 2.1). Figure 2.2 illustrates the difference 
in the in-vitro release profiles for uncoated pellets containing 80%w/w 
ibuprofen prepared using laboratory and pilot scale equipment. It is 
apparent that the processing scale has little effect on the in-vitro 
release properties from such pellets. 
During processing it became evident that critical processing 
variables including the volume of the granulating fluid, the length and 
severity of the wet massing process, the rate of extrusion and the rate 
and extent of spheronisation, all had a significant effect on the quality 
of the resultant product. The manufacturing process was therefore 
carefully optimised for each pellet formulation. 
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processing scale pilot pi lot pi lot 
batch size (solids) kg 4.0 4.0 4.0 
ingredients (%w/w) 
ibuprofen 80 70 60 
Avicel PH101 20 30 40 
Purified water BP 52.5 57.5 62.5 
spheronisation details 
plate weight (kg) 5.543 5.818 5.656 
rotation speed (rpm) 552 600 649 
residence time (mins) 8 8 9 
drying method fluidised fluidised fluidised 
drying time (mins) 90 90 90 
moisture content (%w/w) 0.6 0.5 0.3 
Table 2.2. Effect of drug loading on the processing variables for 
uncoated pellets containing ibuprofen (pilot scale). 
processIng scale laboratory 
batch size (solids) kg 1.5 
ingredients (%w/w) 
ibuprofen 80 
Avicel PH101 20 
Purified water BP 56 
spheronisation details 
plate weight (g) 75 
rotation speed (rpm) 1438 
residence time (mins) 4 
drying method fluidised tray 
drying time (mins) 120 1440 
moisture content (%w/w) 0.36 0.30 
Table 2.3. Processing variables for fluidised bed and tray dried pellets 
containing 80%w/w ibuprofen (laboratory scale). 
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Figure 2.2. Effect of processing scale on in-vitro drug release from 
uncoated pellets containing 80%w/w ibuprofen. 
It became apparent that insufficient wetting of the granular material 
results in excessive fines generation and that an excess of oversize 
material may be attributable to too high a water content or binder 
concentration, or too high a spheronisation rotation speed. Optimisation 
of the moisture content at the wet massing stage yields spheres of 
particle size approximating the diameter of the extrudate. 
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processing scale pi lot pi lot pi lot 
batch size (solids) kg 4.0 4.0 4.0 
ingredients (%w/w) 
lactose NF Fast Flo 80 - 70 
Avicel PH101 20 100 30 
Purified water BP 37.5 112 45 
spheronisation details 
plate weight (kg) 4.908 6.014 5.006 
rotation speed (rpm) 603 502 602 
residence time (mins) 7 6 6 
drying method fluidised tray fluidised 
drying time (mins) 60 1440 90 60 
moisture content (%w/w) 0.63 0.6 no product 0.96 
Table 2.4. Formulation and processing variables for placebo pellets 
(pilot scale). 
processing scale pi lot pi lot pi lot 
batch size (solids) kg 4.0 4.0 4.0 
ingredients (%w/w) 
lactose NF Fast Flo 90 50 50 
Avicel PH101 10 50 50 
Purified water BP 27.5 60 50 
Isopropyl alcohol - - 10 
spheronisation details 
plate weight (kg) 4.373 5.708 5.357 
rotation speed (rpm) 502 653 499 
residence time (mins) 5 6 5 
drying method f1uidised f1uidised f1uidised 
drying time (mins) 45 90 90 
moisture content (%w/w) 0.5 0.6 0.8 
Table 2.5. Formulation and processing variables for placebo pellets 
(pilot scale). 
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2.3.2. Placebo pellet formulation. 
Placebo pellets formulations were studied for reasons which are 
discussed in Chapter 7. Optimised pellet formulations containing lactose 
and microcrystalline cellulose were therefore prepared at least in part. 
to ascertain the effect of the drying technique on the physical 
properties of pellets (section 2.3.5) as a function of the aqueous 
solubility of the pellet components. Tables 2.4 and 2.5 summarise the 
processing variables for those placebo pellets prepared. 
The effect of formulation variables on the diametral strength of 
both placebo and active pellets is discussed in Chapter 6. 
2.3.3. Particle Slze distribution. 
The particle size distribution of pellets directly affects the 
overall surface area. The particle size distribution must be as narrow 
as possible to ensure minimum variation in the coating thickness within 
the batch of pellets. Also for the compression of pellets into tablets, 
it is anticipated that segregation may be minimised by a narrow particle 
Slze distribution. 
Conine and Hadley (1970) reported that the mean particle size of 
pellets prepared by extrusion and spheronisation approximates the 
diameter of the extrudate. The GA65 Alexanderwerk Extruder used in this 
work was fitted with a perforated cylinder of screen size 1mm. Figure 
2.3 shows a typical particle size distribution for an optimised pellet 
formulation prepared using the technique of extrusion-spheronisation; 
some 85 per cent of the product has a particle size of between 1.0mm and 
1.25mm; there is little evidence of oversize or undersize material. It 
is apparent that the success of the pelletization process may be assessed 
to some extent by the quality of the particle size distribution of the 
dried product. 
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Figure 2.3. Particle size analysis of ibuprofen pellets containing 
80%w/w drug (pilot scale). 
In summary, optimisation of the processing variables of a 
pelletization process yields a product in which the mean particle size 
approximates the screen size of the perforated cylinder of the extruder. 
Particle size analysis was performed for all pellet formulations. 
2.3.4. Calculation of the skeletal density and the sample specific 
volume of uncoated pellets. 
The principle of operation of the Multivolume Pycnometer IS 
described in Appendix 1. 
The working equation for computation of sample volume is 
Vsamp = Veell - Vexp Equation 2.12 
(Pl/P2 - 1) 
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where Vsamp = sample volume 
VeeII = empty volume of the sample cell with the empty 
sample cap in place 
Vexp = expansion volume 
PI = charge pressure (psig) 
and P2 = expansion pressure (psig) . 
Calculation of the Vsamp value was performed uSIng a computer 
program provided with the apparatus; the results were however also 
checked by calculation to ensure accuracy. 
The density of a material is defined as weight per unit volume and 
may be expressed as follows: 
Osamp = Wsamp = gross weight - cup weight Equation 2.13 
Vsamp Vsamp 
where Osamp = sample density 
Wsamp = sample weight 
and Vsamp = sample volume. 
Sample specific volume (Usamp) is defined as the volume per unit 
weight and is calculated as follows: 
Usamp = Vs amp = l/osamp 
Wsamp 
Equation 2.14 
In summary, operation of the pycnometer depends upon charging the 
sample chamber to an elevated gas pressure (PI), followed by expanding 
the pressure into a precisely known expansion volume (Vexp ). Measurement 
of the final pressure (P2) enables calculation of the sample volume. The 
larger the sample volume the lower the final pressure P2, since larger 
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samples will reduce by displacement the amount of gas In the initial 
charge. 
Figure 2.S is a schematic illustration of the Micromeritics 
Pycnometer 130S: 
HELIUM 
VCELL5 
SAMPLE 
CHAMBER 
VSAMP 
OR V CALIB 
PRESSURE 
TRANSDUCER 
--- r- ---- --- . 
VEXP5 
_J _____ ~ 
VENT 
RATE 
VALVE 
Figure 2.S. Schematic diagram of the Micromeritics Multivolume 
Pycnometer 130S. 
2.3.4.1. Instrument calibration. 
Calibration values were determined by measurIng the PI and P2 
pressures using the Scm3 sample chamber both with an empty sample cup and 
with the precision steel ball of known volume supplied with the 
instrument. Table 2.6 shows the quantitatively determined Veell and 
Vexp values using previously described methods. 
Vee 11 8.S33 cm3 
Vexp 6.307 cm3 
Table 2.6. Computed calibration values for Veell and Vexp. 
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2.3.4.2. Sample calculation. 
Consider the following. A sample of uncoated fluidised bed dried 
ibuprofen pellets containing 80%w/w drug were placed in the Scm3 sample 
cup, purged with helium gas and charged to a pressure (PI) of 19.412 
pSlg (0.134 MPa). The helium was th~t allowed to expand into the second 
chamber and the pressure drop upon expansion enabled the determination of 
pz = 10.40Spsig (0.072 MPa). Using the calibration data for Ve e I1 and 
Vexp, the sample volume was computed using Equation 2.12. Vsamp=1.219cm3; 
this procedure was performed ten fold for each sample. The net sample 
weight was 1.447g. Table 2.7 shows the computed data for this sample. 
2.14: 
The specific sample volume (Usamp) was calculated using Equation 
Usamp = Vs amp = l/osamp 
Ws amp 
Equation 2.14 
Therefore, in this example, Usamp = 1/1.188 = 0.842 cm3 g-I. 
The skeletal properties of all pellet formulations studied were 
assessed similarly and the results are expressed graphically in the 
following figures. 
Figures 2.7 and 2.8 show the effect of drug loading on the skeletal 
properties of uncoated pellets containing ibuprofen and Avicel PH101. It 
is apparent that with increasing microcrystalline cellulose concentration 
there is a corresponding increase in pellet skeletal density. This is 
not unexpected on account of the nature of the inert component. 
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Figure 2.7. Effect of drug loading on the skeletal density of 
uncoated pellets containing ibuprofen and Avicel PH101. 
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Figure 2.8. Effect of drug loading on the sample specific volume of 
uncoated pellets containing ibuprofen and Avicel PHIOI. 
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parameter value 
mean sample volume (cm3 ) 1.218 
n 10 
SD (cm3 ) 0.00213 
%RSD 0.1:5 
computed sample density (g cm- 3 ) 1.188 
n 10 
SD (g cm- 3 ) 0.00213 
%RSD 0.179 
sample specific vo 1 ume (cm3 g- 1 ) 0.842 
n 10 
SD (cm3 g-l) 0.00134 
%RSD 0.159 
Table 2.7. Computed skeletal data for a sample of fluidised bed dried 
ibuprofen pellets containing 80%w/w drug. 
Microcrystalline cellulose contributes to the bonding mechanism and is 
largely responsible for the maintenance of pellet integrity due to its 
adhesive properties. 
Pellets are largely held together by the formation of solid bridges 
formed with binder hardening and to a limited extent with a poorly water 
soluble drug, crystallised solute molecules. Hence with increasing 
binder concentration, it is not unreasonable to expect increasing 
particle density and diametral strength (Figure 6.6) and a corresponding 
reduction in the sample specific volume and the particle elasticity 
(Figure 6.7). 
Figures 2.9 and 2.10 show the effect of the aqueous solubility of 
the main component on the skeletal properties of uncoated pellets. 
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Where the ma1n excipient 1S freely water soluble ( lactose ) , the degree of 
crystalline bond formation due to the presence of solute molecules during 
the pelletization process is much greater than where the main component 
exhibits poor aqueous solubility and therefore little tendency towards 
crystalline bond formation (ibuprofen). The mechanism of solid bridge 
formation is responsible for the fundamental bonding forces determining 
the strength of the formulation. These figures demonstrate admirably the 
effect of aqueous solubility on the resultant particle density. An 
excipient which is freely soluble in the granulating fluid exhibits 
greater particle density and mechanical strength than a pellet containing 
a poorly soluble component. 
In spite of differences associated with laboratory and pilot scale 
pelletization processes, there appears to be little effect of the scale 
of processing on the skeletal properties of the resultant product 
(Figures 2.11 and 2.12). 
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Figure 2.9. Effect of excipient aqueous solubility on the skeletal 
density of uncoated pellets. 
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Figure 2.10. Effect of excipient aqueous solubility on the sample 
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Figure 2.11. Effect of processlng scale on the skeletal density of 
uncoated pellets containing 80%w/w ibuprofen. 
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Figure 2.12. Effect of processing scale on the sample specific volume of 
uncoated pellets containing 80%w/w ibuprofen. 
Figures 2.13 and 2.14 show the skeletal properties of drug-laden and 
drug-depleted uncoated pellets; before and after in-vitro dissolution 
testing. The shaded areas in these figures represent drug-laden and the 
non-shaded areas represent drug-depleted pellets. As might reasonably be 
expected, those particles from which the drug has been removed display 
similar skeletal properties irrespective of the initial drug loading. 
The effect of a film coating of Eudragit RS/RL30D (12% solids 
increase) on the skeletal density and sample specific volume of pellets 
containing 80%w/w drug is shown in Figures 2.15 and 2.16. As expected 
the presence of a film coat serves to enhance particle density and reduce 
the sample specific volume. 
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Figure 2.13. Comparative skeletal densities of drug-laden (shaded) and 
drug-depleted (non-shaded) pellets (uncoated). 
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Figure 2.14. Comparative sample specific volumes for drug-laden (shaded) 
and drug-depleted (non-shaded) pellets (uncoated). 
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Figure 2.15. Effect of film coating (Eudgragit 12%w/w) on the skeletal 
density of pellets containing 80%w/w drug. 
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Figure 2.16. Effect of film coating (Eudgragit 12%w/w) on sample 
specific volume for pellets containing 80%w/ w drug. 
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2.3.5. Consequence of drying method on the physical and release 
properties of pellets containing ibuprofen and lactose. 
The main differentiating factor between the two drying methods 1S 
the rate of water removal from the product. Those pellets dried by 
fluidised bed technique achieve the desired moisture content much more 
quickly due to the rapid evaporation of water as a result of the 
turbulent motion of the fluidised particles. Water removal from tray-
dried material is slow due to the static nature of the bed. 
The free movement of individual fluidised particles leads to rapid 
water removal and minimises the migration of solute particles within the 
spheres; the tray dried entities are more likely to exhibit solute 
migration during the lengthy drying process. For pellets in which the 
main excipient lactose, which is freely soluble in the granulating fluid. 
solute migration is inevitable and is exacerbated by the slow drying 
associated with static bed dryers. 
2.3.5.1. Effect of drying method on in-vitro drug release from uncoated 
pellets containing 80%w/w ibuprofen. 
Dissolution testing using the methodology described in Chapter 4, 
was performed on uncoated pellets containing 80%w/w ibuprofen which had 
been dried by fluidised bed drying and by tray drying in a hot air oven. 
Figure 2.17 shows the effect of the drying method on the in-vitro release 
profiles of uncoated ibuprofen pellets. 
It is apparent that drug release from tray dried pellets is slightly 
faster than from fluidised bed dried material. It is postulated that the 
slower water removal from the static bed associated with tray drying 
leads to a degree of solute migration. 
It would appear that drug in solution migrates to the pellet surface 
as the water is slowly driven off during the lengthy drying period of 24 
hours which is necessary with static bed drying. 
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Figure 2.17. Effect of drying method on the in-vitro drug release from 
uncoated pellets containing 80%w/w ibuprofen. 
Fluidised material however dries much more quickly and therefore this 
technique enables the use of a slightly higher drying temperature; the 
possibility of causing thermal damage to the product is reduced due to 
the continuous motion of fluidised particles. This factor together with 
rapid water removal enables a slightly higher drying temperature to be 
used for drying fluidised particles. Ibuprofen exhibits poor aqueous 
solubility and although one might expect little solvation of drug within 
the uncoated cores during pelletization, there is evidence of some 
dissolution of drug and solute migration. This phenomena is apparently 
minimised by the rapid drying of fluidised product (Figure 2.17). 
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2.3.5.2. Effect of drying method on pellet surface characteristics. 
The pore structure of pellets can affect the capillary action of the 
dissolved drug and consequently influence the rate of release of drugs 
from pellets (Ghebre-Sellassie, 1989). The pore structure and the pellet 
surface characteristics also affect film deposition and formation. 
Figures 2.18 and 2.19 show scannIng electron micrographs (SEMs) of the 
surfaces of the same batch of uncoated ibuprofen pellets dried using 
fluidised bed and static bed drying techniques. It is clear that there 
is a significant difference in the nature and quality of these pellets 
and that the slower water removal associated with the static bed drying 
appears to cause some solute migration during drying and impaired surface 
smoothness. 
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Figure 2.I8a. SEM of an uncoated pellet surface dried by fluidised bed 
methodology; magnification x400. 
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Figure 2.18b. SEM of an uncoated pellet surface dried by tray drying; 
magnification x400. 
Figure 2.19a. SEM of an uncoated pellet surface dried by fluidised bed 
methodology; magnification x800. 
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Figure 2.19b. SEM of an uncoated pellet surface dried by tray drying; 
magnification x800. 
2.3.5.3. Effect of drying method on the diametral strength and 
elasticity of uncoated pellets. 
Detailed consideration is given to the effect of the drying method 
on the tensile properties of uncoated pellets in section 6.3.2 of Chapter 
6; pellets containing highly water soluble and poorly water soluble 
components are discussed. In summary, pellets dried using static bed 
techniques exhibit greater diametral strength and are less elastic than 
their fluidised bed dried counterparts. 
2.4. Conclusions. 
This work has revealed that for a glven pellet formulation, the 
drying method employed has a significant effect on the mechanical 
strength of pellets prepared by extrusion-spheronisation. Pellets dried 
by tray drying exhibit greater diametral strength and skeletal density 
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and are less elastic than their fluidised bed dried counterparts. 
In-vitro drug release from tray dried pellets IS slightly enhanced 
when compared with the same batch of pellets dried by fluidised bed 
methodology. This IS a consequence of the lengthy drying time which IS 
associated with static bed drying. It is therefore postulated that it is 
the actual length of the drying process which is the primary cause of any 
solute migration and that the solubility of the pellet components in the 
granulating fluid influences the degree of solute migration occurring 
during drying. 
A further consequence of the effect of the drying method and 
therefore the rate of the drying process on uncoated ibuprofen pellets IS 
on the surface characteristics. Scanning electron micrographs have 
illustrated the effect of a lengthy drying process and solute migration 
on the quality of the surface smoothness of uncoated multiparticulates. 
This has ramifications in respect of the suitability of tray dried 
pellets for the subsequent application of a polymeric membrane or film 
coating. Particles prepared using this technique are well documented as 
possessing the ideal qualities necessary for the application of a release 
retarding membrane due to their uniform shape, particle size distribution 
and smooth surface characteristics. 
It should also be noted therefore in addition to the many processing 
variables which are capable of significantly influencing the nature and 
quality of the final product, that the drying technique employed as a 
pelletization process variable will therefore influence the surface 
characteristics of pellets which may have consequences in respect of the 
suitability of such material for film coat application. 
Figure 2.20 shows that the drug release from uncoated pellets is not 
sufficiently retarded to enable drug delivery over a 12 or 24 hour period 
and it was therefore considered necessary to apply a release controlling 
membrane to the uncoated pellets. 
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Figure 2.20. In-vitro drug release from uncoated pellets containing 
x %w/w ibuprofen with Avicel PH10l (see key). 
It was postulated that the effect of the presence of a film coating 
would not only influence the drug release characteristics from these 
multiparticulates but that it may also impart additional mechanical 
strength. This scenario was considered to be highly favourable since 
these particles were required to retain their integrity following 
compaction into tablets. 
Chapter 3 therefore is a study of polymer systems which were 
considered suitable for application to multiparticulates. The films are 
examined in terms of their effect on drug release from pellets containing 
ibuprofen (Chapter 4), the mechanical properties of free-films are 
studied in Chapter 5 and the effect of the presence of a film coating on 
the mechanical properties of pellets is studied in Chapter 6. 
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CHAPTER 3 
STUDY OF SOME AQUEOUS POLYMERIC FILM COATING DISPERSIONS 
FOR APPLICATION TO IBUPROFEN PELLETS 
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3.1. Introduction. 
Environmental pollution, flammability, explosion potential and the 
expense of flame-proofing equipment, are some of the disadvantages 
associated with the use of organic solvent systems for film coating. The 
possibility for solvent recovery exists, however the expense of 
installing such equipment is considerable; other problems include the 
purchase, quality control and storage of organic solvents. 
Perceived advantages associated with the use of organic film coating 
solutions include the very rapid processing times which are possible with 
these systems. In reality however there is little difference in the 
total processing times associated with organic and aqueous systems. One 
of the main problems associated with aqueous systems is the sheer volume 
of water which must be removed by evaporation and its high latent heat of 
vapourisation. It is vital that a compromise product temperature IS 
achieved during processing, such that the rate of heat energy input 
enables a steady product temperature to be maintained during water 
evaporation. Any increase in the outlet temperature during coating 
indicates either an excessive inlet temperature or an inadequate spray 
rate. This may result in premature drying of atomised droplets with 
resulting poor film quality. A decrease in the inlet temperature during 
processing indicates an excessive spray rate causing overwetting of the 
pellets, or alternatively a decrease in the inlet temperature. Due to 
the physical size of pellets any overwetting of the product due to 
excessive spraying or inadequate inlet temperature, IS rapidly 
illuminated in the form of pellet agglomeration. This leads to an uneven 
distribution of polymer on the pellet surface and product agglomeration 
resulting in poor fluidisation of individual particles. 
It was thought previously that the penetration of water into the 
core formulation during coating using aqueous systems would be a 
significant problem causing both physical damage to the dosage form and 
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chemical damage in the form of degradation of the active ingredient(s). 
This scenario however is avoidable by pre-warming the uncoated product 
prior to the application of the film coating dispersion. 
Higher processing temperatures are possible with aqueous systems 
with little risk of causing thermal damage to the product. since much of 
the heat energy in the drying air is used to supply the latent heat of 
evaporation of the water and not in causing an excessive bed temperature. 
Most water-insoluble polymers (including ethylcellulose and the 
polymethacrylates) may be presented in the form of a latex or pseudolatex 
dispersion in water. The need for organic solvents therefore is totally 
eliminated. Aqueous dispersions have low viscosities as compared to 
organic solutions with a comparable solids content and they are capable 
of containing a relatively high solids content. 
Film formation in an organic solvent coating system depends on the 
polymer molecules becoming entangled and in close proximity to each other 
as the solvent is evaporated. Film formation in a latex system however 
relies upon the evaporation of water causing the latex spheres to soften, 
come within close proximity of like particles and then coalesce and 
deform to form a continuous film by capillary force and the surface 
tension of the polymer (Bindschaedler et ale 1983). The heat energy 
within the inlet air provides the energy necessary to evaporate off the 
aqueous phase and it also facilitates the softening and coalescence of 
the latex particles. Due to the low affinity of these latex particles 
for water relatively low operating temperatures enable efficient water 
removal. The actual drying temperature in the coating system is critical 
in the process of latex softening and particle coalescence. A continuous 
film is produced only if the temperature of the bed exceeds the minimum 
film-forming temperature (MFT). Conversely, if the product temperature 
is too high, particularly for small particles (pellets or granules), 
there may be the generation of an electrostatic interaction and 
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agglomeration as a result of exceSSIve drying and softening of the latex 
film. The minimum film forming temperature should therefore be used as a 
guide for determining the air inlet temperature. 
The volume of the fluidising air must be carefully controlled to 
produce efficient bed fluidisation. The spray rate of the coating 
dispersion affects the degree of wetting and the size of the atomised 
droplets (Hogan, 1982). Increasing the spray rate at a given atomisation 
pressure results in larger droplet formation and enhanced possibility of 
overwetting. The atomisation pressure must remain constant throughout 
the coating process as this influences the spraying pattern and the size 
of the droplets (Mathur et al. 1984). Excessive atomisation may result 
In disturbance of the fluidised bed, with possible attrition or damage of 
the particles and the loss of coating excipients by film formation on the 
chamber wall of the fluidising column. Inadequate atomisation IS 
causative of overwetting of pellets and subsequent adhesion of pellets to 
themselves (agglomeration) and to the coating chamber wall. 
The dynamics of the coating process IS a carefully balanced 
equilibrium and is summarised in Table 3.1. 
A key to achieving a smooth uniform polymeric coating on small 
particles using aqueous dispersions is the choice of the processIng 
equipment and the conditions within the coating chamber. Equipment used 
for film coating may be classified into three basic groups; pans, 
perforated pans and fluid-bed processors (McGinity, 1989). 
Basic requirements of the coating apparatus are that the materials 
being coated are contained In an environment which will enable the 
coating to dry. It must also be in an environment in which all particles 
receive equal amounts of evenly applied coating material and the same 
exposure to the drying conditions. The coating material must be 
delivered in a controlled and reproducible manner. 
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PROCESS 
1. Formation of 
appropriate 
sized droplets 
2 . Contact and 
adhesion of droplets I--
to substrate 
3. Spreading and 
coalescence of 
polymer 
4. Solvent evaporation 
INFLUENCING FACTOR ADVERSE EFFECf 
too h' h1 bed disturbance Ig 
too high- particle 
attrition Atomisation I--
pressure I--
too low-
overwetting/ 
agglomeration 
too I ow-
particle 
adhesion 
Spray rate 
Inlet temp. 
Product temp. I--
Outlet temp. 
-
..---too low 
L...-- degree of 
fluidisation 
-
too hi gh,--------.l 
softening of 
too h igh polymer 
premature drying 
too low overwetting 
inefficient water 
removal 
core penetration 
incomplete film 
too hi gh-1 at t r i t i on I 
adhesion of particle 
to side of chamber 
Table 3.1. Factors affecting the film coating process. 
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The conventional coating pan IS used primarily for sugar coating. 
The perforated pan was developed to improve drying efficiency during the 
coating process by drawing air through the bed rather than supplying it 
to the bed surface only. These pans are not considered suitable for the 
application of sustained or controlled release coatings. 
Fluidised bed apparatus provides the technique of choice for the 
coating of small particles using aqueous polymeric dispersions. Coatings 
may be applied to fluidised material as a spray either from above the 
bed, below or tangentially. Top spraying is the preferred method for the 
application of Eudragit Aqueous Dispersions (personal communication Rahm 
Pharma, Weiterstadt, Germany) since an even coating may be achieved with 
easy nozzle access during the coating process should a blockage occur. 
The pellets are fluidised to the height of the nozzle which sprays 
countercurrently into the material. High particle velocity and efficient 
heat transfer allow aqueous coating of small particles with little or no 
agglomeration under optimised coating conditions. 
Bottom spray coating systems enable a quality product to be achieved 
although an inherent disadvantage of this system is the inability to 
access the nozzle during processing. Wurster systems use a controlled 
air flow pattern formed by a partition and orifice plate. This method 
enables the application of droplets to the substrate prior to any 
significant evaporation of the vehicle; the surface solvent is then 
rapidly removed prior to core penetration. This method is considered 
suitable for the application of aqueous dispersions. 
Mehta (1986) considered that the spray rate is probably the most 
important consideration in the aqueous film coating process. Film 
coating requires uniform application of the film and a controlled drying 
environment. Thi~ occurs simultaneously but independently during the 
coating process. The rate of heat transfer affects the rate of 
evaporation of the water and also for aqueous dispersions regulates the 
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rate and degree of coalescence of the polymeric material. In summary the 
ideal inlet air temperature enables an equilibrium to be established 
between the application of liquid and its subsequent evaporation. film 
formation and particle coalescence. If the product temperature. degree 
of fluidisation of the bed and the humidity of the inlet air are 
maintained constant, together with the dispersion spray rate, then the 
temperature and the humidity of the exhaust air will also remain 
constant. A state of equilibrium is achieved shortly after the 
commencement of film coating. In conclusion the critical coating process 
variables are listed below: 
spray rate 
atomisation pressure 
inlet air temperature 
degree of fluidisation of bed 
batch size 
outlet (exhaust) aIr temperature 
bed (product) temperature 
type of equipment 
method of spraying 
spray gun nozzle diameter 
delivery tubing diameter 
drying time 
3.1.1. polymethacrylates. 
3.1.1.1. Chemical Structure. 
The two products used in this study were Eudragit RS30D and RL30D 
(Rahm Pharma GMBH); both are methacrylic ester co-polymers and are 
insoluble in water, dilute acid, buffer solutions and digestive fluids. 
Table 3.2 gives an indication of the characteristics of the two 
forms of polymethacrylates being studied. (Source: McGinity, 1989). 
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Both Eudragit RS30D and RL30D commercial dispersions contain 30%w/w 
polymer with 0.25%w/w sorbic acid added as a preservative. The MFT of 
these dispersions is 40-50°C. Addition of 10-20%w/w plasticiser reduces 
the MFT to below 20°C. 
Commercial Marketed as: Behaviour In nl : n2 : n3 MW 
name digestive JUIce (see below) (Da) 
RL30D 30%w/w aqueous insoluble film 1:2:0.2 150.000 
dispersion high permeability 
RS30D 30%w/w aqueous insoluble film 1: 2: 0.1 150.000 
dispersion low permeability 
Table 3.2. Relative properties of Eudragit RL30D and RS30D. 
Scientific name poly(ethylacrylate, methylmethacrylate) trimethyl-
ammonioethyl methacrylate chloride 
Structural formula : 
H CH3 CH3 
I 
-CH2- C-
I 
-CH2- C 
I 
-CH2- C 
I 
C = 0 
I 
C = 0 
I 
C = 0 
I 
OC2Hs 
I OCH3 I OR 
3.1.1.2. Processing considerations. 
Prior to the application of the aqueous dispersion to the product it 
is necessary to pre-warm the bed to enable satisfactory film formation 
under the desired mild operating conditions. 
When the temperature of the product is approximately 10-20°C above 
the MFT and the drying capacity of the inlet air is sufficient to enable 
rapid drying, the first latex layer immediately forms a thin water-
insoluble film; this prevents penetration of the aqueous phase into the 
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core of the product. For an uncoated formulation which is highly 
water-sensitive it may be necessary to pre-coat the cores using an 
organic coating system. 
Table 3.3 shows the mInImum film-forming temperatures for Eudragit 
RL and RS as aqueous dispersions with added plasticiser. 
EUDRAGIT 
RL RS 
Quantity of plasticiser* 10% 20% 10% 20% 
No plasticiser 39 39 47 47 
Triethylcitrate 11 <0 20 5 
* plasticiser expressed as % weight dry polymer 
Table 3.3. Effect of plasticiser on the MFT for Eudragit aqueous 
dispersions. (Source: McGinity, 1989). 
The MFTs of the pure dispersions are approximately 40 and 50 G C 
respectively. As previously mentioned it IS necessary to add 10-20%w/w 
plasticiser to reduce the MFT to below 20 G C. The literature reports that 
one of the most effective plasticisers is triethylcitrate; this is the 
plasticiser most recommended for use in these systems by Rahm Pharma 
(personal communication). 
3.1.2. Ethylcellulose. 
Ethylcellulose in the form of Surelease, a commercial aqueous 
polymeric dispersion containing incorporated plasticiser, is studied. 
This product contains 17.5%w/w polymer (70% of the total solids content); 
the total solids content being 25%w/w (Ghebre-Sellassie et al. 1988). 
The plasticisers In this product are a combination of dibutyl sebacate 
and oleic acid such that the plasticiser molecules are incorporated 
within the dispersed polymer particles. The manufacturers claim that 
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this enables film coalescence during the coating process and IS discussed 
subsequently. 
Other excipients include the vehicle ammoniated water, which ser\'es 
to stabilise the dispersed polymer and fumed silica as an antiadherent. 
The latter facilitates the application of Surelease during the actual 
coating process. 
With this particular coating system, the manufacturers recommend 
that following the application of the release controlling membrane, it IS 
necessary to apply an overcoat formulation to the product in order to 
minimise interparticulate adherence. The overcoat formulation consists 
of a solution of Opadry Clear (YS-1-7006) in purified water BP. The 
component excipients the Opadry are HPMC, PEG 400 and PEG 6000. 
Although the overcoat formulation is extremely viscous this work has 
shown that it is an absolutely essential part of this coating system 
SInce there is a high tendency of pellets coated solely with the 
Surelease dispersion to agglomerate. Furthermore the overcoat 
formulation imparts free-flow characteristics to pellets coated in this 
manner. The manufacturers literature states that conditions within the 
coating chamber should be maintained such that the outlet temperature is 
within the range 24-30°C. Film formation is achieved during the coating 
process only if the drying conditions within the chamber are as indicated 
and the MFT is exceeded; this enables coalescence of polymeric particles 
to occur simultaneously with film coat application. A working 
equilibrium is rapidly established during the coating process and must be 
maintained throughout in order that complete film formation may be 
achieved. 
3.1.2.1. Chemical Structure. 
Ethylcellulose, empirical formula 
CI2H2306(CI2H220S)n-2CI2H230S 
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consists of the cellulose molecule as a chain of S-anhydroglucose units 
joined together by acetal linkages. Ethylcellulose is water insoluble. 
3.1.2.2. Processing considerations. 
Porter (1989) describes the heat generated by the coating process as 
important in facilitating the coalescence of the polymer particles on the 
surface of the dosage form. Porter also indicates that should the 
polymer coated product be exposed to elevated temperatures then some 
softening of the membrane may occur causing "clumping". Porter states 
that this problem is eliminated by the application of an aqueous overcoat 
formulation to the polymer coated product. This present work has 
confirmed that an overcoat formulation is necessary to prevent coated 
particles from adhering to each other and not only at elevated 
temperatures. Ibuprofen pellets coated with Surelease showed complete 
agglomeration following coating even after cooling to room temperature. 
This problem was successfully eliminated by the presence of the overcoat 
formulation, quantitative details of which are discussed In section 3.2. 
The type of polymer system applied to the surface of the pellets is 
a major factor influencing the drug release characteristics. The nature 
of the film coat is determined largely by the polymer used, but also the 
presence of other excipients within the coating dispersion. 
Ethylcellulose aqueous dispersions require the presence of plasticiser to 
enable complete film formation by facilitating polymeric particle 
coalescence. Colorcon have incorporated the appropriate level of 
plasticiser into their commercial preparation during the manufacturing 
process. 
The importance of plasticiser incorporated into ethylcellulose 
aqueous dispersions IS discussed by Goodhart et al. (1984). Since the 
latex forming process involves the fusion of individual polymer particles 
to form a continuous membrane, sufficient plasticiser must be present to 
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cause a lowering of the MFT, thus enabling polymer particle coalescence 
and deformation under the operating conditions of the coating chamber. 
The basis for film formation is therefore attributable to the capillary 
pressure exerted by the closely packed polymer particles as a result of 
water evaporation (Goodhart et al. 1984). Plasticisers enhance polymer 
pliability; In latex systems however they must also enable particle 
coalescence by reducing the glass transition temperature (Tg) or MFT. 
Assuming that polymer coalescence and film formation is complete, the 
drug release rate from a polymer coated product is a function of the 
plasticiser concentration in addition to the thickness of the polymeric 
membrane surrounding the individual particles. 
Ozturk et al. (1990) reported that plasticiser IS important with 
respect to forming a continuous film and that diffusion of drug through 
the plasticiser channels is unlikely to make a significant contribution 
to the overall drug release rate. The authors also indicate that for 
pellets coated with an ethylcellulose pseudolatex plasticised with 
dibutyl sebacate, lowering the amount of plasticiser increases the drug 
release rate dramatically. This relatively faster drug release observed 
at low plasticiser levels was shown by SEM studies to be attributable to 
major flaws in the film; thus indicating that there is a minimum level of 
plasticiser required for these ethylcellulose based systems necessary for 
continuous and complete film formation. 
Lippold et al. (1990) state that plasticised aqueous ethylcellulose 
dispersions show a decrease in the MFT from 87°C to approximately 30°C 
with 20% dibutyl sebacate in the resulting film. They also state that 
the plasticiser must completely penetrate the ethylcellulose particles 
prior to film formation In order that optimal film formation is achieved. 
The film formation of ethylcellulose from an aqueous polymeric 
dispersion is described by Porter et al. (1989). In the dispersion, the 
polymer is present as discrete particles in an aqueous vehicle. 
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Film formation requires that these polymeric particles come into close 
proximity with each other enabling polymer deformation and fusion in the 
from of coalescence. Simultaneously the aqueous vehicle is removed. The 
coalescence of these polymeric particles is facilitated by the capillary 
forces between them being generated as the water is driven off by 
evaporation. Porter also states that coalescence can only occur 
completely as a result of viscous flow, thus eliminating the boundaries 
between adjacent polymer particles. Therefore diffusion of polymer 
chains must occur across the boundaries; this process may be accounted 
for to some extent by the free volume theory which presumes that 
sufficient free volume or intermolecular space exists in the bulk polymer 
to accommodate the diffusion process. 
The glass transition temperature (Tg) of ethylcellulose is reported 
to be 135°C (Rowe et al. 1984). Since the Tg of ethylcellulose IS 
significantly greater than the temperature used during the coating 
process in the application of these aqueous dispersions, the system must 
be efficiently plasticised to enable complete coalescence of the latex 
particles and the formation of a continuous film. The authors also 
indicate that by lowering the glass transition temperature of the 
polymer, the toughness of the ethylcellulose film should be greatly 
improved, thus enabling the film coat to withstand stresses occurrIng 
during the coating process more easily and ultimately such that these 
polymer coated pellets may withstand compression with no impaired 
integrity of the film coat and hence the drug-laden multiparticulates. 
Ghebre-Sellassie et al. (1988) reported that the occurrence of 
complete film formation achieved during coating depends upon the 
manufacturing processes, the coating conditions and the formulation 
variables used; they also state that an additional curing step may be 
necessary. These authors comment that it is highly probable that the 
incorporation of plasticiser during the manufacturing process of 
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Surelease results in some interaction between the plasticiser and the 
polymer particles; this causes the polymer particles to swell and 
partially deform during the coating operation. Furthermore this 
interaction may not be great enough to provide the necessary degree of 
softening of these polymeric particles at temperatures of between 28°C 
and 40°C, thus ensuring complete coalescence. These authors conclude by 
saying that In order to ensure the stability of the coating during 
storage and handling over a range of temperatures, Surelease coated 
actives must be cured at elevated temperatures. 
To be effective a plasticiser molecule must interpose itself 
between the polymer chains and interact with the forces holding the 
chains together, thereby extending and softening the polymer matrix 
(Rowe, 1982). The mobility of a polymer chain influences the magnitude 
of the stresses due to shrinkage. Plasticisers increase the polymer 
chain mobility and therefore have a significant effect on those stresses 
and hence the incidence of film cracking; non-plasticised are therefore 
more brittle than plasticised films. 
In summary therefore, it is the shrinking of the water film around 
the latex particles which produces a surface tension high enough to drive 
the polymer particles close together. Film formation then occurs by 
coalescence as the boundaries between the latex particles disappear. 
Coalescence IS facilitated by the presence of incorporated plasticiser 
which is capable of diffusing itself into the latex pellets resulting in 
a softening effect. The reduction in the MFT enables continuous film 
formation under the operating conditions of the coating process. It may 
be necessary to complete the coalescence by means of a curing process 
following coating. 
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3.1.3. Silicone Elastomer. 
3.1.3.1. Chemical Structure. 
The Dow Corning X7-2837 Silicone Emulsion IS polymerised latex and 
IS a cross-linked product of hydroxyendblocked polydimethylsiloxane 
(PDMS). When this material is combined with colloidal silica particles 
and a water dispersible organic material, an aqueous latex dispersion 
results which may be used as a controlled release system for oral dosage 
forms. 
The chemical structure of polydimethysiloxane (PDMS) IS shown below: 
CH3 CH3 CH3 
I I I CH3--Si Si Si--CH3 
I I I CH3 CH3 CH3 
n 
The formulation for the controlled release system being studied IS 
composed of the silicone elastomer latex, colloidal silica and a 
plasticiser, polyethylene glycol; although Dow Corning do suggest that 
the incorporation of a plasticiser may not be necessary for the coating 
of small particles or pellets using this coating system (personal 
communication). The use of a plasticiser in silicone elastomer film 
formulations is discussed subsequently in section 3.2.3. 
The silicone latex X7-2837 has a mean particle SIze of 200nm, a pH 
of 8.2 and a total solids content of 53.0%w/w. The colloidal silica is a 
silica sol with a mean particle size of 4nm, a pH of 10.7 and a solids 
content of 17.0%w/w. 
3.1.3.2. Processing considerations. 
Li and Peck (1989) have studied controlled release tablets coated 
with a silicone elastomer membrane. The suitability of this system for 
controlled release coating is primarily dependent upon the permeability 
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of the coating to various drug molecules. Polydimethylsiloxane is 
hydrophobic in nature and therefore the silicone elastomer membrane IS 
relatively impermeable to hydrophilic and ionic compounds. Incorporation 
of water soluble components within the hydrophobic silicone elastomer 
formulation in the form of the polyethylene glycols has been shown to 
enhance the drug release from dosage forms coated with this system (Li 
and Peck, 1989). 
The fundamental film properties are determined largely by the nature 
and quantity of the excipients from which they are composed. Li and Peck 
(1989) have studied free-films derived from silicone elastomer aqueous 
dispersions with particular reference to the level and type of 
plasticiser and to the ratio of silicone to colloidal silica forming the 
latex. They have generated information relating to the elasticity and 
mechanical strength of free-films, including tensile strength and 
elongation at break; both factors of which are of considerable importance 
in the design of a coating system which will withstand compression and 
enable the coated pellets to retain their integrity. 
Li and Peck speculated that the presence of polyethylene glycol 
(PEG) in the silicone elastomer film facilitates the formation of a 
porous film structure in an aqueous medium, through which the hydrophilic 
and ionic species pass as they are leached from the core of the dosage 
form. Furthermore, that the presence of different molecular weight PEGs 
may be an effective formulation variable and a means of controlling the 
rate of drug release. Personal communication with Dow Corning however 
suggests that for small particles, the use of a plasticiser may not be 
necessary. Data presented by these authors indicates that with 
increasing silicone to silica ratio, there is a reduction in the elastic 
modulus and a marked increase in the percentage elongation for free 
films. with increasing silica content however the film becomes 
correspondingly more brittle. 
60 
The work of these authors supports the idea that at low loading 
levels the incorporation of PEG as a plasticiser in silicone elastomer 
mixed films, leads to reduced brittleness and a corresponding ductility 
associated with the silica filled silicone elastomer. This plasticising 
effect it is suggested may be attributed to the polar interaction between 
the polymer and the silica. At high plasticiser levels however, the 
plasticising effect of the PEG is prevented due to the presence of 
unbound PEG causing an apparent film brittleness. Li and Peck (1989) 
also indicated that complete leaching of PEG(s) from these silicone 
elastomer films and extensive film hydration In water, causes these 
silicone elastomer films to exhibit a highly porous structure which may 
provide water filled diffusion channels for the leaching out of polar or 
ionic molecules. 
In addition Li and Peck (1989) studied drug release from potassium 
chloride tablets coated with silicone elastomer controlled release 
coatings. Significant formulation variables were found to include the 
loading level and the molecular weight of PEG and the ratio of silicone 
to silica in the coating dispersion. Other variables were shown to alter 
the drug release rate from coated tablets, including drying temperature, 
pH of the dissolution medium and aging. Furthermore these authors showed 
that the PEG molecular weight has a greater effect on the drug release 
rate than the ratio of silicone to silica. Tablets coated with a low 
silicone to silica ratio released potassium chloride at a faster rate 
than those with a higher silicone content. An increased silicone to 
silica ratio it is reported, produces a more compact coating with a 
microporous tortuous structure than a film coating containing a lower 
level of silicone. 
A study is made In this present work of the effect of the silicone 
to silica ratio and the presence of PEG on the drug release from 
ibuprofen pellets and also of the elastic properties of free-films of 
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these silicone elastomer formulations. SEM studies have been performed 
on coated material and also on coated pellets from which drug has been 
removed by in-vitro dissolution testing. 
3.2. Materials and Methods. 
Three polymeric aqueous dispersion coating systems were studied and 
are discussed accordingly. The use of the different systems was designed 
to enable evaluation of the three polymers with respect to their effect 
on drug release, their relative mechanical strengths and elasticities and 
ultimately the ability of the coated pellets to retain their integrity 
following compression into tablets with an inert diluent formulation. 
The information appearing in Table 3.4 relates to the excipients 
used in the manufacture of the film coating dispersions and the source 
from which they were obtained. 
3.2.1. Polymethacrylate (Eudragit) aqueous polymeric dispersions. 
3.2.1.1. Formulation. 
Eudragit RS30D and Eudragit RL30D were used in combination such that 
the resulting polymeric membrane was the factor controlling the drug 
release rate rather than the quantity of plasticiser incorporated within 
the film coat. The RS30D exhibits low permeability but when in 
combination with the highly permeable RL30D, a satisfactory release 
profile is obtained. To this end 20%w/w triethylcitrate (Citroflex 2) 
was included as an integral part of the formulation. This level of 
plasticiser is documented as reducing the MFT to SoC, thus ensuring 
complete film formation during the coating process (McGinity, 1989). 
For the purpose of calculation plasticiser IS expressed as per cent 
weight of dry polymer (see Table 3.3, section 3.1.1.2). 
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Excipient 
Eudragit RS30D & RL30D 
Citroflex 2 
(triethylcitrate) 
Syloid Silica 244FP 
Sure lease Dispersion 
Opadry (YS-1-7006) 
Silicone Emulsion 
Colloidal Silica 
PEG 6000 BP 
Supplier 
Rohm Pharma GMBH 
Weiterstadt, Germany 
Pfizer Ltd., Chemicals 
Div., Sandwich, Kent 
Grace GMBH, Postfach 
449, Worms, Germany 
Colorcon Ltd., Murray 
Road, St. Pauls Cray, 
Orpington, Kent 
Colorcon Ltd. 
Dow Corning Company 
France 
Dow Corning Co. 
Boots Pharmaceuticals 
Table 3.4. Excipients used In film coating studies and their suppliers. 
Syloid Silica 244FP is included in the formulation to aid the 
coating process as an anti-adherent or anti-tack agent. It has an 
average particle size of 3~m and a specific surface area of 310m2 g-l and 
is therefore an ideal excipient offering an efficient means of minimising 
the tendency for agglomeration or sticking of particles within the 
coating chamber, assuming of course that the processing variables are 
optimised as previously discussed. Table 3.5 gives quantitative formulae 
for the Eudragit aqueous polymeric dispersions; the coating formulation 
contains 13.35%w/w polymer solids. 
It is an aim of this work to study the effect of polymer level on 
the drug release rate, paYIng particular regard to the mechanical and 
physical properties of coated pellets, rather than a study of the 
film coating composition about which much has been published and is 
discussed in section 3.1. 
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Excipient %w/w g polymer 
Eudragit RS30D 35.5 10.65 
Eudragit RL30D 9.0 2.7 
Citroflex 2 2.67 -
Syloid Silica 244FP 4.0 -
Purified water BP 48.83 -
100.00 13.35 
Table 3.5. Quantitative particulars of the polymethacrylate aqueous 
dispersion used in film coating studies. 
3.2.1.2. Method of manufacture. 
Citroflex and Syloid were added to the purified water and mixed at 
low shear for S minutes. In a separate container the Eudragit RS30D was 
added to the Eudragit RL30D with stirring. The aqueous solution was then 
added to the polymeric dispersion and mixed with low shear for a further 
S minutes. Agitation in the form of low shear mixing was maintained 
throughout the coating process; excessive agitation causes frothing and 
increases the risk of dispersion coagulation. 
Uncoated pellets (SOOg) were placed in a 1kg Aeromatic Fluidised Bed 
Dryer (Strea 1) with top spray attachment. It was found necessary to use 
a stainless steel chamber for coating of small particles since generation 
of static during product pre-warming rendered satisfactory fluidisation 
of pellets impossible within a perspex chamber. 
The spray gun had a liquid nozzle diameter of 1.10mm and the film 
coating dispersion was applied by means of a peristaltic pump and 2mm 
bore diameter silicone tubing. Rahm Pharma suggested that the use of 
tubing of diameter in excess of 2mm leads to sedimentation of the solid 
components forming the dispersion during transit from the bulk container 
to the nozzle of the spray gun attachment. 
Pellets were fluidised to nozzle height and pre-warmed to a product 
temperature (represented by the outlet temperature) of 28-32·C and a 
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inlet temperature of sooe. The product temperature did not exceed 40 0 e 
during the coating process; temperatures in excess of this cause polymer 
softening and as a consequence, sticking and agglomeration of the product 
both to itself and to the coating chamber during the coating process. 
A spray rate of approximately 109 min- 1 kg- 1 product and an 
atomisation pressure of 2 bar was found to be optimum and maintained 
throughout. The film coating dispersion was applied by weight and the 
coating application spraying times recorded to ensure a constant spray 
rate. Accordingly visual observation of the product within the coating 
chamber and the outlet temperature gives an accurate indication of the 
success of the coating procedure during processing. 
SOOg batches of uncoated ibuprofen pellets were coated with 
progressively increasing polymer loadings and are expressed as percentage 
increase in weight of product. Plasticiser is expressed as per cent 
weight dry polymer for the purpose of calculation of solids content of 
the dispersion, therefore the formulation in Table 3.S contains 20%w/w 
solids. Eudragit RS30D and RL30D both contain 30%w/w polymer and the 
aqueous dispersion contains 13.3S%w/w polymer. 
For each given uncoated pellet formulation, small samples of coated 
product were removed from the batch during the coating process. Just 
prior to sample removal, the batch was subjected to an interim 10 minute 
drying period under the drying conditions already established within the 
system. For all batches of coated pellets, the following procedures were 
adhered to: 
i) pre-warming of the bed to approximately 30 0 e 
ii) atomising pressure of 2 bar 
iii) uncoated batch size of SOOg 
iv) post-coating drying for 30 minutes under existing drying 
conditions 
v) post-coating drying for 24 hours at 40 0 e In a hot air oven. 
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In order to ensure that the formation of a complete film was 
produced during processing, coated pellets were subjected to a period of 
24 hours tray drying at 40°C. A control sample was also taken (a sample 
of pellets which were not subjected to this "curing" process). The 
in-vitro release profiles obtained for the aforementioned samples yielded 
information relating to the success of the plasticiser in reducing the 
MFT to below that temperature existing In the coating chamber, such that 
polymer particle coalescence and complete film formation was ensured 
during processing. 
Table 3.6 is a summary of ibuprofen pellet formulations coated with 
the polymethacrylate aqueous dispersion. 
% ibuprofen % weight spray rate 
In cores Increase (g min- l kg-I) 
80 12.0 8.36 
80 4.5 12.16 
70 9.2 9.12 
70 5.3 11. 32 
60 5.6 8.84 
Table 3.6. Summary of uncoated ibuprofen pellet formulations coated 
with the Eudragit aqueous film coating dispersion. 
A study of the in-vitro release profiles (Chapter 4) enabled the 
selection of a suitable polymer loading. This study highlighted that it 
is possible with such coating systems to apply an accurate polymer 
loading to multiparticulates such that a specific in-vitro release 
profile is obtained; the greater the potency of the uncoated pellets, the 
greater the quantity of polymer was necessary to retard drug release. 
It is interesting that the 10% weight increase recommended by Rahm Pharma 
was far in excess of that necessary to produce the sustained drug release 
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of ibuprofen pellets over 24 hours. Details relating to in-vitro 
dissolution methodology and the drug release profiles of both uncoated 
and coated ibuprofen pellets appear subsequently in Chapter 4. 
3.2.2. Ethylcellulose (Surelease) aqueous polymeric dispersions. 
3.2.2.1. Formulation. 
Commercially available Surelease Dispersion contains 25%w/w solids; 
the manufacturers recommend that the product be diluted to 15%w/w solids 
for application as an aqueous polymeric dispersion of ethylcellulose to 
oral dosage forms. It is necessary with this product to apply an 
overcoat formulation to product coated with the polymeric dispersion, In 
order to minimise and ideally eliminate sticking and adherence of 
particles to themselves and to the coating chamber walls and spray gun 
attachment. A weight gain of 1%w/w is sufficient the manufacturers 
claim, to impart free-flow characteristics to the polymer coated product. 
The film coating dispersion and overcoat formulation compositions being 
studied therefore are as follows: 
Surelease Dispersion (15%w/w solids) %w/w 
Surelease Dispersion (25%w/w solids) 60.0 
Purified water BP 40.0 
Overcoat Formulation %w/w 
Opadry Clear (YS-1-7006) 10.0 
Purified water BP 90.0 
3.2.2.2. Method of manufacture. 
The Purified water BP was added to the Surelease dispersion with low 
shear mixing and gentle agitation for approximately 15 minutes and then 
throughout the coating process; vigorous mIxing resulted in excessive 
foaming. With the overcoat formulation, Opadry was rapidly added to the 
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vortex of Purified water BP, again under the conditions of low shear 
mixing. This mixing process was continued for not less than 45 minutes: 
the minimum time necessary for complete hydration and dissolution of the 
Opadry. The resultant product was that of a highly viscous gel-like 
solution which was also agitated gently throughout the coating process. 
The apparatus and coating procedure are as described In 3.2.1.2. 
As previously discussed, uncoated pellets were pre-warmed to a bed 
temperature of 28-32°C. 
Colorcon recommended a weight increase of 10%w/w; for the coating of 
small multiparticulates this polymer loading was again found to be 
excessive. Table 3.7 summarises those batches of pellets coated with 
ethylcellulose and the product weight increase associated with the film 
coating. 
% ibuprofen % weight spray rate 
In cores Increase (g min- l kg-l) 
80 10 11.10 
70 10 12.10 
70 7.5 12.82 
60 10 13.60 
60 5 12.38 
Table 3.7. Summary of uncoated ibuprofen pellet formulations coated with 
Surelease. 
In-vitro dissolution profiles (Chapter 4) indicated that a 10% 
weight increase delayed drug release to too great an extent for uncoated 
pellet cores containing 60% and 70% ibuprofen. Therefore additional 
batches of pellets were coated with 5% and 7.5% solids weight increases. 
It is necessary with this product to apply an overcoat formulation 
to prevent sticking and particle agglomeration. An overcoat formulation 
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was therefore applied to each batch such that a further weight increase 
of 1%w/w was achieved. The resultant pellets were free-flowing ~ith a 
smooth esthetically pleasing glossy outer coat. The coating level IS 
expressed as %w/w solids applied to the uncoated material and is 
expressed as a percentage of the initial batch size. 
A post-coating tray drying process (the so-called "curing" stage) 
was performed on pellets coated with Surelease Dispersion; 24 hours tray 
drying at 40°C. Again a control sample w~s taken and the in-vitro drug 
release profiles obtained. The effect of this "curing" stage on the 
quality of the films and in-vitro release profiles are illustrated and 
discussed in Chapter 4. 
3.2.3. 
3.2.3.1. 
Aqueous polymeric dispersions containing Silicone Elastomer. 
Formulation. 
The Silicone Elastomer Emulsion is composed of a silicone elastomer 
latex and colloidal silica. It is optional whether plasticiser is 
incorporated within the product; this is discussed later. No work has 
been published to date regarding the use of this aqueous formulation of 
silicone elastomer and the film coating of pellets; the composition of 
the final emulsion with respect to the ratio of silicone to silica and 
the presence or otherwise of plasticiser, are obviously factors which 
require investigation. 
Formulations containing silicone to silica ratios of 2:1, 4:1 and 
6:1 were prepared and applied to ibuprofen pellets as aqueous polymeric 
film coating emulsions. Further work included a study of the effect of 
PEG 6000 10%w/w (polyethylene glycol 6000 BP) on the quality of the film 
coating; the effect of PEG on the coating process and drug release from 
ibuprofen pellets coated with these products. Although it was possible 
to coat pellets with an emulsion containing PEG 10%w/w (ratio 2:1) 
problems were experienced with interparticulate adhesion; it was found 
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necessary to increase the volumetric flow rate of the fluidising aIr In 
order that product fluidisation was maintained during coating. 
Incorporation of PEG in the 4:1 formulation however was unsuccessful. It 
was not possible to achieve a bed temperature which was low enough to 
prevent the waxy nature of this plasticiser from causing sticking and yet 
high enough to enable water evaporation during the coating process. 
Li and Peck (1989) reported that film coating dispersions containing 
up to 40% PEG were feasible for the film coating of tablets. It must be 
assumed that these workers did not experience similar problems of 
adherence of particles to each other and to the walls of the coating 
chamber seen with pellets. It is assumed that this is due to differences 
In the physical characteristics and dimensions of tablets and pellets. 
This work has shown that an increase in the silicone to silica ratio 
and the incorporation of PEG within the emulsion, increases the tendency 
for sticking and reduces the ease with which fluidisation is achieved and 
maintained throughout the coating process. These findings support 
similar observations made by the manufacturers in the literature provided 
with the product. The large surface area associated with 
multiparticulates appears to negate the need for incorporation of 
plasticiser within the polymeric film, since favourable release profiles 
are obtained in its absence. 
In-vitro dissolution profiles (section 4.3.2, Chapter 4) illustrate 
the effect of the silicone to silica ratio and the presence of 
plasticiser on drug release from pellets containing ibuprofen. 
Table 3.8 summarises those elastomer formulations studied and 
briefly highlights the success or otherwise of the film coating process. 
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Excipients %w/w % w/w Silicone: Comments 
I solids Silica 
ratio 
Silicone Emulsion 21. 88 11.60 2:1 No PEG; 
Colloidal Silica 34.10 5.80 coating process 
Purified water BP 44.02 - satisfactory 
Silicone Emulsion 43.77 23.20 4: 1 No PEG; 
Colloidal Silica 34.12 5.80 coating process 
Purified water BP 22.11 - satisfactory 
Silicone Emulsion 32.83 17.40 6: 1 No PEG: 
Colloidal Silica 17.06 2.90 coating process 
Purified water BP 50.11 - satisfactory 
Silicone Emulsion 43.77 23.20 8: 1 No PEG; 
Colloidal Silica 17.06 2.90 some tendency 
Purified water BP 39.17 - for sticking 
Silicone Emulsion 21. 88 11.60 2: 1 10% PEG; 
Colloidal Silica 34.10 5.80 coating process 
PEG 6000 BP 10.00 10.00 satisfactory 
Purified water BP 34.02 -
Silicone Emulsion 21. 88 11.60 4: 1 10% PEG; 
Colloidal Silica 17.06 2.90 severe pellet 
PEG 6000 BP 5.00 5.00 adhesion during 
Purified water BP 56.06 - coating 
Silicone Emulsion 32.83 17.40 6: 1 10% PEG; 
Colloidal Silica 17.06 2.90 total product 
PEG 6000 BP 5.00 5.00 agglomeration 
Purified water BP 45.11 - during coating 
Table 3.8. Silicone Elastomer coating formulations studied. 
3.2.3.2. Method of manufacture. 
Colloidal Silica X7-2837(B) was added to the Silicone Emulsion 
X7-2837(A) and agitated with low shear mixing. Where present plasticiser 
was dispersed in the purified water and added to the emulsion, again with 
low shear mixing. Addition of the remaining water to the formulation 
again with stirring, completed the process. Gentle agitation was 
maintained throughout the coating process. The apparatus and coating 
procedure is described in 3.2.1. A weight increase of 10% was applied to 
pellets calculated based on the % solids within each coating dispersion. 
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For those batches in which plasticiser IS present, PEG IS considered 
to be contributing to the solids content of the dispersion. Hence for 
pellets coated with aqueous formulations containing plasticiser, there IS 
a reduction In the level of polymer applied by virtue of the fact that 
plasticiser IS displacing polymer in respect of the solids present within 
the dispersion (for example SOg of solids applied to SOOg of uncoated 
pellets is equivalent to a weight increase of 10%w/w). In summary, SOg 
of solids were applied to the uncoated material irrespective of the 
presence of plasticiser in the dispersion. As with the polymethacrylate 
and ethylcellulose coated preparations, the polymer applied to pellets is 
expressed as the weight of coating solids applied as a percentage of the 
batch size of uncoated pellets. 
Table 3.9 shows the quantities of silicone elastomer film coating 
dispersion applied to SOOg batches of uncoated ibuprofen pellets. The 
uncoated pellet formulation used in this particular study contained 
80%w/w ibuprofen. 
ratio % w/w weight spray rate 
silicone:silica solids sprayed g min- 1 kg- 1 
2:1 17.50 286g 12.88 
4:1 20.30 246g 11.08 
6:1 29.00 172g 10.48 
6:1 (+ 10% PEG) 27.40 183g 10.48 
Table 3.9. Summary of the coating variables for batches of ibuprofen 
pellets coated with Silicone Elastomer aqueous dispersions. 
3.3. Results and Discussion. 
Uncoated pellet cores containing 60%, 70% and 80%w/w ibuprofen were 
coated with aqueous polymeric dispersions of the polymethacrylates, 
ethylcellulose and silicone elastomer. For each coating study a single 
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batch of uncoated pellets was used throughout, a l t hough in- vitro release 
profiles shown in section 2.3 confirm reproducibi li t y of the 
manufacturing process used in uncoated pellet manufacture. The success 
of the film coating procedure and the quality of the resulting film have 
been assessed qualitatively by microphotography and scanning electron 
microscopy and quantitatively by in-vitro dissolution testing. 
Microphotographs of uncoated pellets and pellets coated with the three 
polymer systems described previously, demonstrate the uniform smooth 
surface appearance exhibited by these multiparticulates (Figures 3.1 to 
3 . 3 ) . 
Scanning electron micrographs of the surface of pellets coated with 
polymethacrylate, ethylcellulose and Silicone Elastomer polymers are 
presented in Chapter 4 (Figures 4.2~ to 4.30). All qualitative evidence 
presented illustrates the smooth surface characteristics exhibited by 
these coated multiparticulates. 
Figure 3.1. Microphotograph of uncoated pellets containing ibuprofen 
70%w/w in Avicel PHlOl (magnification x40). 
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Figure 3.2. Microphotograph of ibuprofen pellets coated with the 
polymethacrylate dispersion (magnification x40). 
Figure 3.3. Microphotograph of ibuprofen pellets coated with Surelease 
(magnification x40). 
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Comparison of the in-vitro release profiles of coated pellets 
subjected to the post-coating "curing" stage with the control samples 
described In section 3.2, confirms that polymer coalescence and complete 
film formation is achieved whilst the pellets are in the stainless steel 
coating chamber. This is apparent as a consequence of the negligible 
difference in the release profiles of the control samples and pellets 
subjected to a post-coating drying stage, consisting of 24 hours storage 
at 40°C In a hot air oven (Figures 4.f, 4.10 , 4.11, 4.1~, 4.1~, 4.1) and 
4.1b}. 
A study of the tensile properties of polymeric films as free-films 
IS made subsequently in Chapter 5 and consideration is given to the 
effect of the formulation variables on the quality of the resulting film. 
Chapter 3 is a precursor to Chapters 4 and 5 which consider the 
in-vitro drug release from uncoated and polymer coated pellets and the 
tensile properties of free-films and respectively. Both of these 
chapters involve a study of the three polymer systems, with the aim of 
ascertaining that polymeric film formulation which is best able to 
sustain the effect of the applied load associated with the compaction of 
coated pellets into tablets. A study is made of the tensile properties 
of polymeric films including elasticity, elastic compliance and Newtonian 
Viscosity and of the effect of polymer loading on the in-vitro release 
rates and the mechanism controlling drug release. 
3.4. Conclusions. 
The film coating of multiparticulates USing aqueous polymeric 
dispersions requires uniform application of polymer in a closely 
controlled drying environment. An equilibrium must be established 
between the rate of application of liquid to the fluidised bed and its 
subsequent evaporation, polymer coalescence and complete film formation. 
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A major role of plasticiser in aqueous polymeric dispersion film 
coating operations is one of facilitating a reduction in the minimum film 
forming temperature (MFT) of the polymer to below the equilibrium 
temperature of the coating chamber. This is in addition to its influence 
on the elasticity and permeability of the resultant film. 
The success of the film coating operation may be qualitatively 
assessed by microphotography and scanning electron microscopy and 
quantitatively assessed by in-vitro dissolution testing. It is important 
with the application of any aqueous polymeric dispersion to ensure that 
polymer coalescence and complete film formation is achieved during the 
coating process. This may be confirmed by there being negligible 
difference in the in-vitro release profiles of coated pellets subjected 
to a post-coating drying operation or so-called "curing" stage and those 
which are not. 
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CHAPTER 4 
IN-VITRO DRUG RELEASE STUDIES FROM UNCOATED AND COATED 
PELLETS CONTAINING IBUPROFEN 
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4.1. Introduction. 
Dissolution is defined as the process in which a solid substance 
enters into the solvent phase yielding a solution; fundamentally it IS 
controlled by the relative affinity of the solute molecules between the 
solid and the solvent. On oral administration pharmaceutical dosage 
forms undergo dissolution in biological media, followed by absorption of 
the drug into the systemic circulation. In determining the dissolution 
rate of drugs from solid dosage forms under standardised conditions, it 
is necessary to consider several physicochemical processes in addition to 
the processes involved in the dissolution of pure chemical substances. 
Factors which may influence the dissolution characteristics of drugs 
include the physical characteristics of the dosage form, the wettability 
of the dosage unit, the penetration ability of the dissolution medium and 
any swelling, disintegration or deaggregation of the dosage form. 
For drug-containing pellets which are surrounded by a release-
retarding polymeric membrane, the process of dissolution may broadly be 
illustrated by Figure 4.1. 
4.1.1. Theory of Dissolution. 
For dissolution of a solid to occur, solute molecules must first 
escape from the surface of the solid and then undergo some form of 
transport process away from the surface into the bulk solution. 
Depending upon the relative significance of these two processes and the 
means by which the transport is effected, it is possible to set up 
physical models to account for the resulting dissolution behaviour. For 
the dissolution of pure substances, three models have been proposed, 
either individually or in combination to describe dissolution-rate 
mechanisms (Swarbrick, 1992). 
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polymer coated pellets 
wetting of the dosage form 
penetration of dissolution medium 
into the core formulation 
diffusion across the 
polymeric membrane 
penetration through aqueous 
pores or channels 
dissolution of drug In the pellet core 
diffusion of solute molecules 
into the bulk solvent 
drug In solution 
Figure 4.1. Schematic illustration of the process of in-vitro 
dissolution of drug from non-eroding pellets of spherical 
geometry surrounded by an aqueous insoluble polymeric 
membrane. 
4.1.1.1. Diffusion Layer Model. 
Probably initially proposed by Nernst and Brunner in 1904, this 
model assumes a static liquid film exists adjacent to the solid surface 
of thickness 1, a negative velocity component in the direction 
perpendicular to the surface. The reaction at the solid-liquid film 
interface is assumed to be rapid. Once the molecules pass the liquid 
film-bulk film interface, rapid mixing occurs and the concentration 
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gradient is destroyed. The rate of the solute movement and therefore the 
dissolution rate are determined entirely by Brownian motion diffusion of 
the molecules in the liquid film (Figure 4.2). 
/ <- Film boundary 
/ Cs 
Particle / 
Surface / 
/ C C 
/ 
/ 
/ Bulk solution 
1 
< > 
Stagnant layer 
Figure 4.2. Schematic illustration of the diffusion layer model. 
4.1.1.2. Interfacial Barrier Model. 
This model assumes that the reaction at the solid surface and 
therefore the diffusion across the interface is not significantly slower 
than diffusion across the liquid film. As a consequence solid-solution 
equilibrium may not be assumed; this must be accounted for In the model. 
The process at the solid-liquid interface IS rate limiting In respect of 
the transport process. This model is illustrated in Figure 4.3 where the 
relatively rapid transport process now occurs by diffusion through a 
static liquid film. 
/ <- Film boundary 
/ Cs 
Particle / 
Surface / 
/ 
/ 
/ C 
/ Bulk solution 
1 
< > 
Stagnant layer 
Figure 4.3. Schematic illustration of the interfacial layer model. 
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4.1.1.3. Danckwert's Model. 
This model (Figure 4.4) assumes that transport of solute away from 
the solid surface is achieved by macroscopic packets of solvent reaching 
the solid-liquid interface by eddy diffusion 1n a random fashion. These 
solvent packets attach themselves to the surface. During their residence 
at the interface, these packets are able to absorb solute and are then 
replaced by diffusional motion, by fresh packets of solvent. Assuming 
that the solid surface reaction 1S instantaneous, this surface renewal 
process may then be related to the solute transport rate and hence 
dissolution. 
Particle 
Surface 
Figure 4.4. Schematic illustration of Danckwert's model. 
4.1.2. Film Theory of Dissolution. 
The film theory of dissolution is based on the assumption that the 
surface of the dosage form in contact with the dissolution medium does 
not change during the process of dissolution and that the dissolution 
medium is stagnant. 
Under these simplified conditions Noyes and Whitney describe the 
quantitative kinetics of dissolution of a substance from an even surface 
by the movement of molecules at the solid-liquid interface and diffusion 
of dissolved molecules in the dissolution medium. Equation 4.1 describes 
this theory: 
de 
= K (Cs - C) Equation 4.1. 
dt 
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where de/dt is the change in concentration as a function of time. K IS 
the dissolution rate constant, Cs is the solubility or saturation 
concentration and C is the solution concentration at time t. 
As a consequence of the motionless nature of the liquid, a saturated 
solution is formed at the solid-liquid interface and the concentration 
decreases with growing distance from the interface reaching a finite 
concentration C' in the surrounding liquid. The layer of saturated 
solution functions as the diffusion barrier layer. Consequently 
according to Fick's Law of Diffusion, the dissolution rate constant K, is 
directly proportional to the coefficient of diffusion D. Hence K = D/Vi 
where V is the solution volume and i is the thickness of the diffusion 
layer. 
Since the rate of diffusion is proportional to the surface area of 
the dissolving substance S, employing the assumption of Noyes and 
Whitney, Nernst and Brunner, modified Equation 4.1 to incorporate the 
diffusion coefficient and the surface area of the dissolving substance: 
de DS 
= 
dt Vi 
, 
. 
(Cs - C) Equation 4.2. 
The dissolved substance moves according to differences in the 
concentration gradient between the layer that is in direct contact with 
the solid surface and the other layers of the medium, provided that there 
is now accelerated movement of the medium. If the liquid surrounding the 
dissolving substance is set In motion by either laminar or turbulent 
flow, the dissolved molecules will move more quickly into the ambient 
liquid. In such instances the resultant solution is homogeneously mixed 
at all times. In the case of sparingly soluble substances, C' is very 
low in the surrounding medium and Equation 4.2 simplifies to the 
following: 
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dc 
= KSCs Equation 4.3. 
dt 
Nernst proposed this film theory in 1904 and it demonstrates some of the 
basic principles concerning the dissolution of single particulate 
systems. When a solid particle is immersed In an agitated liquid and 
allowed to dissolve, the bulk liquid will continuously be exposed to the 
solid surface with a certain velocity. At any given instant during the 
process of solubilisation or dissolution, a stagnant layer or film 
surrounds the particle. This stagnant layer of thickness 1 and termed 
the Nernst-Brunner thickness layer, is not necessarily hydrodynamically 
stagnant although it behaves as such and a concentration gradient exists 
within it (Figure 4.2). Cs represents the concentration at the surface 
or the saturation concentration and C is concentration at the boundary 
between the bulk solution and the film. It is assumed that the thickness 
of this boundary layer is independent of the particle size. Assuming 
steady state exists, Fick's first law of diffusion may be employed: 
oC 
J = - D -- Equation 4.4. 
ox 
where the previous notation applies. oC/ox IS the concentration gradient 
and may be considered constant by virtue of it being the slope of the 
line (Figure 4.2). 
4.1.3. The importance of sink conditions. 
In the design of a reliable in-vitro dissolution test model which IS 
allegedly capable of mimicking the dissolution process in-vivo, it IS 
essential that the model simulates as far as possible, prevailing 
conditions within the biological system. One such condition is the 
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maintenance of nearly perfect sink conditions during in-vitro dissolution 
rate determinations. The drug concentration within the dissolution 
medium must not exceed 10 to 20% of its solubility (Swarbrick, 1992). 
This condition IS essential since during a dissolution-rate absorption 
process, there IS no significant drug concentration build-up in the 
gastro-intestinal fluids; they act as an infinite sink. 
4.1.4. Forced convection dissolution devices. 
The systems widely used for in-vitro dissolution testing with the 
provision of such conditions are fixed fluid volume, multiple phase and 
continuous fluid flow devices. 
4.1.4.1. Fixed fluid volume. 
Dissolution studies are undertaken as the phrase suggests, under 
conditions of fixed and finite aqueous dissolution fluid volume. The 
volume is such that the solute drug concentration is less than 10 to 20% 
of the drug solubility throughout the entire test. This test method IS 
unsuitable for both sparingly soluble or exceptionally high dose drugs, 
due to the practical limitations associated with the large fluid volume 
which would be necessary for the maintenance of sink conditions. 
4.1.4.2. Multiple phase systems. 
Here drug is dissoluted in an aqueous medium, but it is then either 
partitioned off into a water-immiscible organic phase or adsorbed onto a 
solid. Sink conditions are provided by the removal of solute molecules 
throughout testing. 
4.1.4.3. Continuous fluid flow. 
This method provides a relatively simple and convenient system and 
it is suitable for the determination of dissolution rates for all drugs 
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irrespective of their solubility and potency. Sink conditions are 
maintained by the constant removal of the dissolved drug from the 
dissolution medium. This is achieved by the continuous elimination of 
the filtered dissolution medium from the dissolution chamber and the 
simultaneous addition of fresh solvent to the vessel. 
4.1.5. Membrane-controlled drug release. 
The drug release mechanism from a membrane modified drug delivery 
system, in which the membrane ultimately controls the drug release 
characteristics of the dosage form, is essentially based on the 
principles of diffusion. Solid drug in the core of a membrane coated 
pellet must undergo dissolution within the core prior to delivery of 
solute molecules into the donor compartment. This process is facilitated 
largely by diffusional transport of solute molecules across the polymeric 
membrane. 
According to Fickian diffusion principles, the rate of drug release 
dO/dt at steady state is given by 
dO C".J- Cmr KdCd - KrCr 
= DA = DA Equation 4.5. 
dt 1 1 
~ CM.d ~J ~,.... ~ ~ ...v-.k-'V-b.'A-..Q. d .. ~ (u-.CQ.."\k 7-.-h u-J 
eJ- f1--..Q k',~ A.,,-J f'Q. CR-t) h-r s.clQ.. te J t'~ (h~L':J iIr- c.l 
where D is the coefficient of diffusion through the membrane, A is the 
membrane area, Cd the drug concentration in the delivery compartment, Cr 
the drug concentration in the receptor compartment, and Kd and Kr 
represent the partition coefficients between the membrane of drug in 
delivery and receptor solutions respectively. 
Under sink conditions Cr « Cd in the delivery compartment therefore 
dO DAKd PACd 
- -- Cd = Equation 4.6. 
dt 1 1 
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where P = KdD, which represents the permeability behaviour of the drug 
from such a system. 
The drug in the delivery compartment is in the form of a suspension. 
Therefore, the concentration of the resulting solution has a constant 
value, since the amount of drug lost due to permeation into the receiving 
compartment is replaced by drug from the core in solid form, thus 
yielding drug release which may be described by zero order kinetics. 
Equation 4.7 describes such behaviour; the right hand side of the 
equation remains constant 
dQ PACs 
= Equa t ion 4. 7 . 
dt 1 
Cs represents the drug solubility In the delivery compartment solution. 
According to Fick's law, the rate of drug release dQ/dt, depends on 
the coefficient of diffusion of drug through the coating Dm, coating 
area A and the thickness of the coat 1; partition coefficient of the 
coating/water ~; and the concentration of the saturated solution Cs. 
These parameters are expressed collectively in Equation 4.8: 
Equation 4.8. 
dt 1 
Under sink conditions and integrating, Equation 4.8 becomes 
PACs 
Q = KACs t = t Equation 4.9. 
1 
where K and P represent the diffusion rate and penetration rate constants 
respectively. 
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Lippold et ale (1990) however reports that drug release from coated 
tablets is more complex than this. Lipid coating is practically 
impermeable to hydrophilic molecules and weakly permeable to water but 
permeable only to undissociated lipophilic molecules. This inhibits the 
formation of a saturated drug solution within the core formulation. 
These are porous membranes permeable to both hydrophilic/lipophilic 
molecules and water. 
4.1.6. Interpretation of dissolution data. 
The in-vitro dissolution data obtained for modified-release dosage 
forms may be expressed in many ways but expression of cumulative amount 
of drug released Q expressed as a function of time, is as an informative 
method as any In the elucidation of the drug release mechanism. These 
functions can further be expressed graphically, and fall into four basic 
categories (Figure 4.5). 
For a dosage form in which the amount of drug permeating to the 
solution is constant for each time interval, Q = kt can express this 
process. Figure 4.5a represents dissolution displaying zero-order 
kinetics. This type of drug release is characteristic of sustained- or 
controlled-release dosage forms. 
Figure 4.5b illustrates dissolution kinetics from a dosage form 
exhibiting first-order kinetics, explained by the equation Q = 1 - kt. 
Most conventional dosage forms exhibit this dissolution mechanism, 
including some modified-release preparations. Some specialised dosage 
forms contain many drug particles of the same size and shape or their 
agglomerates that dissolve evenly. In such cases the dissolution process 
can be explained by the cube-root law, where Q = 1 - (1 - kt)3 (Figure 
4. 5c) . 
For a matrix drug delivery system where drug dissolves from the 
matrix, by dissolving in the matrix-forming substance, the process is 
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controlled by diffusion. The diffusion-controlled dissolution process 
can be expressed by the square-root equation, where Q = kit; this process 
is expressed by Figure 4.sd. 
% 
dissolved 
% 
dissolved 
(a) 
(c) 
t 
t 
% 
dissolved 
% 
dissolved 
(b) t 
(d) t 
Figure 4.S. Graphical interpretation of dissolution profiles in terms of 
cumulative % drug dissolved, as a function of time: 
(a) zero-order process; (b) first-order process; 
(c) dissolution adhering to cube-root law; (d) dissolution 
adhering to square-root Equation. 
It is important to emphasise that the dissolution kinetics of a 
given dosage form may not unequivocally fit into one of the above 
categories. Complex dissolution profiles may result, feasibly 
representing a combination of two or more of the release mechanisms 
discussed. 
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4.2. Methodology. 
4.2.1. Apparatus. 
In-vitro dissolution testing was performed in standard USP XXII, 
type II (paddle) apparatus containing 900ml of pH 6.8 phosphate buffer 
(BP formula), maintained at 37°C with a paddle rotation speed of 100rpm. 
Samples were analysed In one of the following ways; testing was performed 
using both systems to ensure that the two methods gave reproducible 
results. Sink conditions were maintained throughout in-vitro testing. 
The first system consisted of a six station flow-through dissolution 
apparatus attached to a CECIL CE595 Double Beam Digital u.v. 
spectrophotometer. Matched 10mm flow-through cells were used and samples 
were analysed for ibuprofen at 264nm. The concentration of ibuprofen 
present in a given sample is expressed as a percentage of the initial 
strength of the dosage form (following calibration with a blank and 100% 
standard). Each dissolution test was performed using six vessels and the 
mean per cent of drug released at anyone time was computed. Results are 
expressed graphically in most cases excepting those situations where 
greater clarity is achieved when data is tabulated. 
The second apparatus consisted of three six station dissolution 
tanks and a Hewlett Packard 8450A Diode Array spectrophotometer. Samples 
were removed at specified time intervals and lost-volume due to sample 
removal was compensated for by calculation, as shown subsequently. 
This system measures spectra over a specified wavelength range; it is 
claimed that greater accuracy IS achieved with this multiwavelength 
method. In this work a range of 245-300nm was used and measured spectra 
were compared to a measured standard, details of which were retained In 
the memory of the software. As assayed samples were not returned to the 
dissolution vessels after measurement, the volume remaining in each 
vessel was reduced by the 6ml sample volume after each sample was 
removed. A correction routine was used which allowed for this reduction 
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In the dissolution volume and also the amount of solute dissolved In the 
removed sample. The correction formula is as follows: 
where 
Dc = D [V - (n-1) Vs]/V + (Ds)n-l 
Dc = % dissolved corrected for lost volume 
D = % dissolved computed from absorbance value 
V = initial volume of dissolution medium 
Vs = sample volume 
n = total number of samples taken including the current 
sample 
(Ds)n-l = amount of dissolved solute lost In all previous 
samples 
The amount of dissolved solute lost In all samples including the current 
one IS 
(D)n = (Ds)(n-l) + D(Vs/V) 
(D)n becomes the (Ds)(n-l) for the next sample. The initial volume 
is 900ml and the sample volume Vs = 6.0ml. 
4.2.2. Compliance of ibuprofen with the Beer-Lambert Equation. 
The u.v. and visible spectra of organic compounds are associated 
with transitions between electronic energy levels. Excitation of 
electrons above 200nm from p- and d-orbitals, and x-orbitals and 
x-conjugated systems, gives rise to informative spectra which is easily 
measured. 
The energy of electronic excitation IS related to wavelength by the 
following: 
E (kJ/mol) = 1.19 x 105 / A (nm). 
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Therefore at 264nm ( A max. ibuprofen) the energy of electronic 
excitation is 451kJ. 
Two empirical laws have been formulated about the absorption 
intensity. Lambert's Law states that the fraction of incident light 
absorbed is independent of the intensity of the source. Beer's Law 
states that the absorption is proportional to the number of absorbing 
molecules. 
The Beer-Lambert Equation 1S therefore as follows: 
loglo (10/1) = Eel = A 
where 10 and I are the intensities of the incident and transmitted light, 
E is the molar extinction coefficient (dm3 mol- l cm-l), c is the 
concentration (mol dm- 3 ), and 1 is the length of the light path or path 
length and A 1S the absorbance. The factor log (10/1) is therefore 
proportional to the amount of absorbing material present in the sample, 
providing the amount of absorbing material present in the sample is not 
modified by a molecular reaction. The excitation energy at 264nm is 
sufficient to initiate such a reaction should the sample be left in the 
u.v. beam for longer than is necessary. 
The absorbance, also known as the optical density 1S related to 
transmittance (T) as follows: 
A = l/T = Eel 
Since E and 1 are constant, a linear relationship between absorbance and 
concentration of drug, indicates compliance of that compound with the 
Beer-Lambert Law. 
Figure 4.6 is a Beer-Lambert plot for ibuprofen in pH 6.8 phosphate 
buffer at 264nm. Readings were made in triplicate and the mean values 
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are as plotted. In order to ascertain the wavelength at which the 
excitation of molecules was maximum, a scan was performed over a 
wavelength range of 300-220nm. The A max. was determined to be 264nm. 
This is in accordance with the BP value for ibuprofen. 
4.2.3. Interference of inactive excipients. 
In order to ascertain the effect of the presence of excipients other 
than ibuprofen, on the absorption spectra of this compound in pH 6.8 
phosphate buffer and at 264nm, standard solutions were prepared 
equivalent to 800mg/900ml (888mg/1000ml) ibuprofen. 
It was necessary for each film coating formulation to consider the 
effect of the film coating excipients on the absorption spectra. By 
crushing coated pellets and sonicating for one hour in the buffer 
solution, the drug dissolves and a simple filtration process enables the 
sample to be spectrophotometrically assayed. 
The following standards were prepared, each In pH 6.8 phosphate 
buffer: 
i) 888mg/1000ml ibuprofen pure drug 
ii) equivalent of 888mg/1000ml ibuprofen presented as crushed pellets 
coated with Surelease dispersion; (uncoated pellets containing 
80%w/w drug, expressed as per cent weight dry solids). 
iii) equivalent of 888mg/1000ml ibuprofen presented as crushed pellets 
coated with Silicone Elastomer; (uncoated pellets containing 
80%w/w drug, expressed as per cent weight dry solids). 
iv) equivalent of 888mg/1000ml ibuprofen presented as crushed pellets 
coated with Eudragit RS/RL30D; (uncoated pellets containing 
80%w/w drug, expressed as per cent weight dry solids). 
Using a pestle and mortar, coated pellets were ground to powder; the 
required quantity was weighed into an analytical weighing boat using a 
five figure Mettler analytical balance. 
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Figure 4.6. Beer-Lambert plot for ibuprofen in pH 6.8 phosphate 
buffer BP at 264nm. 
The powder was transferred to a volumetric flask, the washings added and 
the standard made to volume with buffer. Each standard was sonicated for 
a period of one hour such that the ibuprofen was completely In solution. 
Samples were withdrawn from each flask, filtered to remove the insoluble 
component and scanned over a wavelength range of 300-220nm using a 
calibrated Perkin Elmer 554 spectrophotometer. 
For each test sample, the peak height and the peak wavelength were 
identical to that of the standard solution containing 888mg ibuprofen in 
lOOOml of buffer. Also for each sample, a replicate scan was performed 
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and the resulting traces indicated no interference by other excipients, 
with the spectra of ibuprofen within this wavelength range. It was 
concluded therefore that u.v. spectroscopy at 264nm was a suitable 
analytical technique for monitoring the in-vitro release of ibuprofen. 
4.3. Results and Discussion. 
Three uncoated pellet formulations containing ibuprofen 60%w/w, 
70%w/w and 80%w/w with Avicel PH101 were coated with aqueous polymeric 
release retarding membranes. For each coating study, one batch of 
uncoated pellets was used throughout, although release profiles shown 
previously indicate favourable reproducibility of drug release by 
replicating the manufacturing process for uncoated product. 
4.3.1. Drug release from uncoated pellets. 
The incorporation of ibuprofen in a pellet formulation containing 
microcrystalline cellulose (Avicel PHlOl), results in the formation of 
multiparticulates which are essentially spherical solid matrices. Drug 
removal from these uncoated entities by in-vitro dissolution of pellets 
containing ibuprofen and Avicel PHlOl, yields visibly intact spheres from 
which the drug has been leached; microcrystalline cellulose as a 
consequence of being water insoluble and present in quantities as low as 
20%w/w dry solids, is able to maintain the spherical shape of these 
pellets following drug removal by in-vitro dissolution testing. 
Dissolution kinetics from uncoated pellets comprising drug mixed with an 
insoluble excipient, in this case microcrystalline cellulose, may be 
considered as drug release from homogeneous matrices. 
It is possible to consider drug release from an homogeneous matrix 
from a simple planar surface involving unidirectional leaching and 
extraction, corresponding closely to the release process from an 
insoluble matrix, either in the form of a tablet or as uncoated pellets. 
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The mechanisms of release from these systems can be treated in two 
ways, firstly by extraction of the drug by a simple diffusional process 
through the homogeneous matrix and secondly leaching of drug by the 
solvent phase, which is able to enter the drug-matrix phase through 
pores, cracks and intragranular spaces. In the former case, drug 
presumably partitions from the crystal surfaces into the uniform matrix 
and out into the bathing solvent, which acts as a perfect sink. In the 
latter case however, drug dissolves slowly in the permeating fluid phase 
and diffuses from the system along the cracks and capillary channels 
filled with the extracting dissolution medium. Swarbrick (1992) comments 
that in most cases it is accepted that intragranular diffusion is 
minimal. 
Complication of the above theories arIses as a consequence of the 
occurrence of one or more of the following situations arising; (a) 
partial dissolution of matrix substances; (b) simultaneous breakup of the 
matrix; (c) drug on the surface of the matrix being released more rapidly 
than drug in the matrix and (d) one fraction of the dose being in a 
different, non-matrix, readily available form. 
4.3.1.1. Drug release from a homogeneous matrix of planar geometry. 
Assuming that the matrix does not dissolve and that the drug is uniformly 
distributed in it, drug release from this matrix surface under perfect 
sink conditions is described by 
Q = [DtCS(2W - CS)}1/2 Equation 4.10. 
where Q is the amount of drug released after time t per unit exposed 
area; D is the coefficient of diffusion of the drug In the homogeneous 
matrix media; W is the total amount of drug present in the matrix per 
unit volume and Cs is the solubility of the drug in the matrix substance. 
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In summary, Equation 4.10 may be rewritten as 
Q = [(It) Equation 4.11. 
indicating that drug release is dependent on the square root of time. 
This equation is known as the It Equation. 
4.3.1.2. Drug release from a granular matrix of planar geometry. 
The dissolution and release of drug from a granular matrix system 
under perfect sink conditions, for the leaching type of release mechanism 
occurring through diffusion movement within intergranular openings, can 
be expressed as 
DE 1/2 
Q = [- (2 W - CCs ) Cs t ] 
r 
Equation 4.12. 
where r is the tortuosity factor of the capillary system and E is the 
porosity of the matrix (Swarbrick, 1992). This expression is based on 
the existence of a pseudo-steady-state condition during the release 
process and on the assumption that the drug particles are quite small 
relative to the average distance of diffusion and are uniformly 
distributed in the matrix. Providing W > Cs or ECs by a factor of 3 to 
4, then Equation 4.12 can satisfactorily define the release of drug from 
such a system. If the situation were apparent that W < Cs or ECs, then a 
different expression would apply since drug would no longer be present as 
a solid. 
As drug is released, the porosity of the matrix increases in 
accordance with the volume of the drug. This difference in porosity 
would correspond directly to the volume of free space previously occupied 
by the extracted component(s). 
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Hence 
E = Eo + VW Equation 4.13. 
where Eo and E represent initial and final porosities respectively, of 
the matrix. If the amount of drug per unit volume of matrix is W, then 
the specific volume of the drug v, will be inversely proportional to the 
density of the drug, since V = l/density. When the initial porosity Eo 
IS very small or when the drug has a large volume compared with the 
volume of the matrix, the porosity at any subsequent time E, approximates 
the product of VandW. Hence Equation 4.12 may be modified: 
DV 1/2 
T (2 - VCs) Cs t ] Equation 4.14. 
This equation implies that the fraction of drug released at any given 
time IS essentially independent of the total amount of drug in the 
matrix, W. 
4.3.2. Drug release from polymer coated pellets. 
Ozturk et ale (1990) reported that drug release from pellets coated 
with ethylcellulose may occur by several mechanisms, including solute 
diffusion through the continuous polymeric membrane, through plasticiser 
channels and/or through aqueous pores; the solute molecules being driven 
by the difference in osmotic pressure between solute within the core of a 
pellet and that in the dissolution medium. Ozturk also considered the 
effect of the presence of cracks within the film coat on drug release. 
The author confirms the presence of plasticiser being of paramount 
importance in forming a continuous film, however that diffusion of drug 
through plasticiser channels is unlikely to make a significant 
contribution to the overall drug release rate. Ozturk concluded that 
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drug release from pellets coated with an ethylcellulose pseudolatex is 
attributable to both diffusion of solute molecules and also as a function 
of the relative osmotic pressure of the medium. 
Ozturk et ale (1990) and Zhang et ale (1991) both indicate that the 
mechanism controlling drug release is influenced by the thickness of the 
applied coating. Figures 4.7, 4.9, 4.11, 4.14 and 4.15 all show that 
drug release is retarded simultaneously with increasing polymer loading, 
indicating that the film is controlling the release process. Zhang et 
al. define the critical coating level (eeL) as being that coating level 
at which the drug release mechanism becomes completely barrier 
controlled. These authors found that the drug release rate and the drug 
release mechanisms were dependent upon the coating level. At low coating 
levels the pore control mechanism predominates, while at higher coating 
levels drug release is mainly membrane or barrier controlled. This is 
supported by Figures 4.7, 4.9 and 4.11, in that at zero or low polymer 
loading, the drug release rate cannot be described as being time 
independent; it is very much time dependent. However at higher coating 
levels corresponding to an increasing membrane thickness (above the 
so-called eeL), the drug release profile is exhibiting zero order 
kinetics (the rate of drug release is independent of time); the 
release profile of cumulative per cent ibuprofen released against time IS 
linear. 
At lower coating levels the membrane is relatively more porous and 
the drug takes the route of least resistance for release from the core of 
the individual multiparticulates. 
Wouessidjewe et al. (1991) consider the effect of multiple film 
coverage in sustained release pellets. As the film is applied to 
individual pellets, a continuous membrane is formed by the building up of 
overlapping segments. Above the eeL, it may be concluded that all of the 
"holes" are covered and that a continuous and complete membrane is 
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enveloping each individual pellet. As a consequence of building a 
continuous film by spraying atomised dispersion one might expect that 
imperfections within the film coat are present. This is discussed in 
Chapter 5 in the study of free films, which are inherently less likely to 
contain imperfections than the membrane surrounding film coated pellets. 
Wouessidjewe concludes that sprayed polymeric membranes leads to the 
formation of discrete films overlapping each other. Once the CCL IS 
exceeded, it may be assumed that complete membrane formation has 
occurred. 
As the coating thickness increases, fewer pores are available for 
drug transport thus retarding drug release. It is more likely that drug 
release is now occurrIng by diffusion across the polymeric membrane 
rather than by diffusion through pores or channels or imperfections 
within the film coat. 
All coated and uncoated pellets studied remained intact during drug 
removal by in-vitro dissolution testing. 
Figures 4.7, 4.9 and 4.11 show in-vitro release profiles for pellets 
coated with increasing levels of polymethacrylate containing aqueous 
dispersions; formulation details of which are given in Chapter 3. 
On the strength of preliminary feasibility coating studies, a desired 
polymer level was selected for each batch being studied, representing 
pellets containing 60%w/w, 70%w/w and 80%w/w ibuprofen (expressed as 
percentage dry solids present in the uncoated pellet formulation). 
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Figure 4.7. In-vitro drug release from 800mg of ibuprofen pellets 
containing 80%w/w ibuprofen (expressed as % weight dry 
solids in uncoated formulation) coated with an x% weight 
increase (see key), applied as an aqueous polymeric 
dispersion containing Eudragit RS/RL30D. 
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Figure 4.8. In-vitro drug release from 800mg of ibuprofen pellets 
containing 80%w/w ibuprofen (expressed as % weight dry 
solids in uncoated formulation) coated with a 4.5% weight 
increase, applied as an aqueous polymeric dispersion 
containing Eudragit RS/RL30D; (a) pellets subjected to a 
post-coating "curing" stage; (b) pellets not subjected to a 
post-coating "curing" stage. 
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Figure 4.9. In-vitro drug release from 800mg of ibuprofen pellets 
containing 70%w/w ibuprofen (expressed as % weight dry 
solids in uncoated formulation) coated with an x% weight 
increase (see key), applied as an aqueous polymeric 
dispersion containing Eudragit RS/RL30D. 
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Figure 4.10. In-vitro drug release from 800mg of ibuprofen pellets 
containing 70%w/w ibuprofen (expressed as % weight dry 
solids in uncoated formulation) coated with a 5.3% weight 
increase, applied as an aqueous polymeric dispersion 
containing Eudragit RS/RL30D; (a) pellets subjected to a 
post-coating "curing" stage; (b) pellets not subjected to a 
post-coating "curing" stage. 
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Figure 4.11. In-vitro drug release from 800mg of ibuprofen pellets 
containing 60%w/w ibuprofen (expressed as % weight dry 
solids in uncoated formulation) coated with an x% weight 
increase (see key), applied as an aqueous polymeric 
dispersion containing Eudragit RS/RL30D. 
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Figure 4.12. In-vitro drug release from 800mg of ibuprofen pellets 
containing 60%w/w ibuprofen (expressed as % weight dry 
solids in uncoated formulation) coated with a 5.6% weight 
increase, applied as an aqueous polymeric dispersion 
containing Eudragit RS/RL30D; (a) pellets subjected to a 
post-coating "curing" stage; (b) pellets not subjected to a 
post-coating "curing" stage. 
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Figure 4.13. In-vitro drug release from 800mg of ibuprofen pellets 
containing 80%w/w ibuprofen (expressed as % weight dry 
solids in uncoated formulation), coated with a 10% weight 
increase applied as an aqueous polymeric dispersion 
containing Surelease; (a) pellets subjected to a 
post-coating "curing" stage; (b) pellets not subjected to 
a post-coating "curing" stage. 
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Figure 4.13. In-vitro drug release from 800mg of ibuprofen pellets 
containing 80%w/w ibuprofen (expressed as % weight dry 
solids in uncoated formulation), coated with a 10% weight 
increase applied as an aqueous polymeric dispersion 
containing Surelease; (a) pellets subjected to a 
post-coating "curing" stage; (b) pellets not subjected to 
a post-coating "curing" stage. 
106 
100 
>jffo0OOO 90 
% 80 
70 ~ 0% r v 
e 60 + 10% (a) I 50 B-e 10% (b) 
a 40 
8 
e 30 
d 20 
10 
0 
0 4 8 12 16 20 24 
Time (Hours) 
Figure 4.13. In-vitro drug release from 800mg of ibuprofen pellets 
containing 80%w/w ibuprofen (expressed as % weight dry 
solids in uncoated formulation), coated with a 10% weight 
increase applied as an aqueous polymeric dispersion 
containing Surelease; (a) pellets subjected to a 
post-coating "curing" stage; (b) pellets not subjected to 
a post-coating "curing" stage. 
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Figure 4.13. In-vitro drug release from BOOmg of ibuprofen pellets 
containing BO%w/w ibuprofen (expressed as % weight dry 
solids in uncoated formulation), coated with a 10% weight 
increase applied as an aqueous polymeric dispersion 
containing Surelease; (a) pellets subjected to a 
post-coating "curing" stage; (b) pellets not subjected to 
a post-coating "curing" stage. 
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Figure 4.13. In-vitro drug release from 800mg of ibuprofen pellets 
containing 80%w/w ibuprofen (expressed as % weight dry 
solids in uncoated formulation), coated with a 10% weight 
increase applied as an aqueous polymeric dispersion 
containing Surelease; (a) pellets subjected to a 
post-coating "curing" stage; (b) pellets not subjected to 
a post-coating "curing" stage. 
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Figure 4.13. In-vitro drug release from 800mg of ibuprofen pellets 
containing 80%w/w ibuprofen (expressed as % weight dry 
solids in uncoated formulation), coated with a 10% weight 
increase applied as an aqueous polymeric dispersion 
containing Surelease; (a) pellets subjected to a 
post-coating "curing" stage; (b) pellets not subjected to 
a post-coating "curing" stage. 
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Figure 4.14. In-vitro drug release from 800mg of ibuprofen pellets 
containing 70%w/w ibuprofen (expressed as % weight dry 
solids in uncoated formulation), coated with 7.5% and 10% 
weight increases, applied as an aqueous polymeric 
dispersion containing Surelease; (a) pellets subjected to a 
post-coating "curing" stage; (b) pellets not subjected to a 
post-coating "curing" stage. 
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Figure 4.15. In-vitro drug release from 800mg of ibuprofen pellets 
containing 60%w/w ibuprofen (expressed as % weight dry 
solids in uncoated formulation), coated with 5% and 10% 
weight increases, applied as an aqueous polymeric 
dispersion containing Surelease; (a) pellets subjected to a 
post-coating "curing" stage; (b) pellets not subjected to a 
post-coating "curing" stage. 
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Figure 4.16. In-vitro drug release from 800mg of ibuprofen pellets 
containing 80%w/w ibuprofen (expressed as % weight dry 
solids in uncoated formulation) coated with a 10% weight 
lncrease, applied as an aqueous polymeric dispersion 
containing Silicone Elastomer; (a) pellets subjected to a 
pos t -coat i ng "cur ing" stage; (b) pe 11 et s not subj ected to 
a post-coating "curing" stage. The ratio of Silicone 
Emulsion:Colloidal Silica in the coating formulation is 
given in the key; one of the coating formulations contains 
PEG 6000 BP (polyethylene glycol) 10%w/w, as a plasticiser. 
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As discussed in some detail In section 3.1 it IS essential that 
polymer coalescence and complete film formation IS achieved during the 
film coating process with these aqueous polymeric dispersions. Coated 
pellets were therefore subjected to an additional "curing" stage of 24 
hours in a hot air oven at 40°C. All profiles shown represent drug 
release from pellets which have been subjected to this "curing" 
procedure. As a control, samples of coated pellets from each batch were 
not exposed to this additional "curing" stage. Those in-vitro release 
profiles for which the additional "curing" stage was not part of the 
manufacturing process are given the nomenclature of profile (b), (Figures 
4.8, 4.10, 4.12, 4.13, 4.14, 4.15, 4.16). It IS evident from those 
figures showing the in-vitro release profiles for coated pellets not 
subjected to the "curing" process, that complete film formation and 
polymer coalescence is occurring during the coating process under the 
drying conditions of the coating chamber. This may be concluded as a 
consequence of the negligible difference in the in-vitro drug release 
profiles obtained from both tray dried and control samples within this 
study. 
In-vitro drug release from uncoated pellets containing 80%w/w 
ibuprofen and coated with silicone elastomer is shown in Figure 4.16. 
Again by exposing these pellets to an additional "curing" stage, it is 
apparent that complete polymer coalescence occurs during the coating 
process; this supports the claim by Dow Corning in their product 
literature that this is the case. 
Comparison of the in-vitro release of ibuprofen from those pellets 
coated with a Silicone Elastomer dispersion containing a ratio of 
silicone emulsion:colloidal silica of 2:1, with and without the 
incorporation of plasticiser, polyethylene glycol (PEG 6000) 10%w/w, 
results as anticipated, in an enhanced rate of drug release. It is 
therefore apparent, that a consequence of incorporating plasticiser In 
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such a polymeric membrane surrounding multiparticulates ~hich are 
essentially homogeneous matrices in their uncoated form, is an enhanced 
rate of drug release. This enables postulation that diffusion of solute 
drug molecules through plasticiser channels created as a consequence of 
the pore-forming properties of an incorporated plasticiser within the 
otherwise impermeable membrane, is at the very least, contributing to the 
mechanism of drug release from such a system. 
The effect of increasing the ratio of silicone to silica leads to a 
corresponding reduction in the rate of drug release (Figure 4.16). 
Increasing the silicone content of the dispersion with a corresponding 
decrease in the content of the colloidal silica, enhances release 
retarding capacity of the membrane. 
In summary, the presence of plasticiser or a reduction in the ratio 
of silicone to silica, will have the effect of increasing the rate of 
drug release by increasing the permeability of the polymeric membrane. 
A further consequence of incorporating polyethylene glycol 6000 in 
the coating formulation and/or of increasing the silicone content, is a 
degree of sticking and pellet agglomeration during the coating process 
under the equilibrium conditions within the coating chamber. As a 
consequence of this it was not possible to successfully coat pellets 
with a dispersion containing a ratio of silicone:silica greater than 6:1, 
nor with a dispersion containing PEG 6000 in any formulation with a 
higher ratio of silicone:silica than 2:1. 
In short, the presence of plasticiser or an increase in the silicone 
content within the coating formulation, leads to sticking and a real 
danger of pellet agglomeration during the coating process. The waxy 
nature of polyethylene glycol under the drying conditions within the 
coating chamber is particularly highlighted in the coating of small 
particles. As a result of the physical size and density of these 
pellets, any tendency for sticking is immediately evident in the form of 
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agglomeration. Once this has occurred within the coating chamber it is 
necessary to discard the batch, since uneven application of film coating 
dispersion is the primary consequence of poor, inadequate or incomplete 
fluidisation of the chamber contents. 
Within the scope of this work both uncoated and coated pellets 
containing ibuprofen and pellets post in-vitro dissolution testing, have 
been examined by scanning electron microscopy (SEM), in an attempt to 
understand more fully the drug release mechanism(s) from uncoated and 
coated pellets. 
4.3.3. Qualitative evaluation of pellet and film coat appearance using 
scanning electron microscopy (SEM). 
Uncoated and coated pellets containing ibuprofen have been examined 
by scanning electron microscopy in terms of pellet surface and pellet 
cross-sectional characteristics. In an attempt to elucidate the 
mechanism(s) controlling drug release from pellets, which in the uncoated 
form are essentially homogeneous matrix multiparticulates, pellets, both 
uncoated and coated and pre and post in-vitro dissolution testing, have 
been examined closely in respect of these two parameters. 
4.3.3.1. Effect of uncoated pellet potency on the surface 
characteristics of ibuprofen pellets prior to and following 
drug removal by in-vitro dissolution. 
Figures 4.17 to 4.20 inclusive show scanning electron micrographs 
(SEMs) of the surface appearance of uncoated pellets containing 
ibuprofen, both before and after drug removal by in-vitro dissolution 
testing. Two pellet potencies have been examined within this section, 
namely pellets containing 80%w/w and those containing 60%w/w drug with 
Avicel PHIOl (expressed as per cent weight dry solids). 
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Figure 4.17a. SEM of uncoated pellet surface containing 80% ibuprofen 
(pre-dissolution); x400. 
Figure 4.17b. SEM of uncoated pellet surface containing 80% ibuprofen 
(pre-dissolution); x800. 
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Figure 4.18a. SEM of uncoated pellet surface containing 80% ibuprofen 
(post-dissolution); x400. 
Figure 4.18b. SEM of uncoated pellet surface containing 80% ibuprofen 
(post-dissolution); x800. 
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Figure 4.19a. SEM of uncoated pellet surface containing 60% ibuprofen 
(pre-dissolution); x400. 
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Figure 4.19b. SEM of uncoated pellet surface containing 60% ibuprofen 
(pre-dissolution); x800. 
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Figure 4.20a. SEM of uncoated pellet surface containing 60% ibuprofen 
(post-dissolution); x400. 
Figure 4.20b. SEM of uncoated pellet surface containing 60% ibuprofen 
(post-dissolution); xBOO. 
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Comparison of the surface characteristics of the two uncoated pellet 
formulations (Figures 4.17 and 4.19) prior to dissolution testing. 
indicates very little visible difference. The spheronisation processing 
variables used in the preparation of these two uncoated pellet 
formulations were similar and one might therefore anticipate that the 
resultant surface characteristics, in spite of different drug loading. 
would be similar. This is evidently the case. 
In-vitro dissolution testing of uncoated pellets (even those 
containing only 20%w/w microcrystalline cellulose) yields visibly intact 
entities; pellets were removed from the dissolution vessels following 
removal of the drug, allowed to dry under ambient conditions on a Whatman 
filter paper and subsequently examined by scanning electron microscopy. 
Figures 4.18 and 4.20 admirably illustrate the structural skeletal matrix 
network of the spheronisation enhancer, microcrystalline cellulose. The 
voids created in the pellet surface by drug removal from those pellets 
initially containing 80%w/w ibuprofen, are more profuse; this is as a 
consequence of the product initially housing a greater drug loading. The 
resultant uncoated pellet surfaces are sponge-like in appearance. It IS 
worthy of mention that the distribution of this inert component is 
extremely regular; one might therefore postulate that the distribution of 
ibuprofen within the pellets initially was also favourable. The voids 
created as a consequence of drug removal in the pellet surfaces, are not 
only evenly distributed but are also of regular size for any given drug 
loading. 
4.3.3.2. Effect of uncoated pellet potency on the cross-sectional 
characteristics of ibuprofen pellets prior to and following 
drug removal by in-vitro dissolution. 
Figures 4.21 to 4.24 inclusive show SEMs of the cross-sections of 
uncoated ibuprofen pellets both prior to and after drug removal. 
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Figure 4.21a. SEM of uncoated pellet cross-section containing 80% 
ibuprofen (pre-dissolution); x80. 
Figure 4.21b. SEM of uncoated pellet cross-section containing 80% 
ibuprofen (pre-dissolution); x400. 
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Figure 4.22a. SEM of uncoated pellet cross-section containing 80% 
ibuprofen (post-dissolution); x80. 
Figure 4.22b. SEM of uncoated pellet cross-section containing 80% 
ibuprofen (post-dissolution); x400. 
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Figure 4.23a. SEM of uncoated pellet cross-section containing 60% 
ibuprofen (pre-dissolution); x80. 
Figure 4.23b. SEM of uncoated pellet cross-section containing 60% 
ibuprofen (pre-dissolution); x400. 
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Figure 4.24a. SEM of uncoated pellet cross-section containing 60% 
ibuprofen (post-dissolution); x80. 
Figure 4.24b. SEM of uncoated pellet cross-section containing 60% 
ibuprofen (post-dissolution); x400. 
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As shown previously two pellet potencies are illustrated containing 
BO%w/w and 60%w/w drug. As with the uncoated pellet surface appearance 
prior to drug removal at the two drug loadings, it is not possible using 
this technique to differentiate between those pellets containing BO~/R/W 
and those containing 60%w/w ibuprofen, by examining the cross-sectional 
appearance of these pellets (c.f. Figures 4.21 and 4.23). Comparison of 
the cross-sectional appearance of these drug depleted skeletal entities 
following dissolution testing (in terms of the initial drug loading), 
indicates again that the drug was fairly evenly distributed throughout 
the pellet matrix. Dissolution testing facilitated the creation of a 
pore network as a consequence of solvent penetration and the diffusion of 
solute molecules from the matrix. It is noteworthy that drug release 
from uncoated pellets containing ibuprofen is surprisingly retarded even 
from those pellets containing only 20%w/w microcrystalline cellulose 
(Table 4.1). Pellets containing 60%w/w drug exhibit a T90 value of just 
under 9 hours for example. It is postulated that whichever drug release 
mechanism predominates for coated pellets, drug release from uncoated 
pellets is diffusion controlled and exhibits first order kinetics (c.f. 
uncoated pellet release profiles in Figures 4.7 and 4.11). 
Drug Loading Tso T90 
BO%w/w ibuprofen 69 mlns. 315 minso 
60%w/w ibuprofen 111 minso 532 mins. 
T bl 4 1 Summary of in-vitro drug release from uncoated pellets a e 0 0 
containing ibuprofen in pH 6.B phosphate buffer BP. 
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4.3.3.3. Effect of polymer type on quality and surface characteristics 
of film coating applied to pellets containing ibuprofen. 
Figures 4.25 to 4.30 inclusive are SEMs which show the quality and 
surface characteristics of pellets coated with the aqueous dispersions. 
details of which are described in Chapter 3. Pellets coated with aqueous 
dispersion formulations of either Eudragit (polymethacrylate) or 
Surelease (ethylcellulose), exhibit satisfactory uniform smooth surface 
characteristics (Figures 4.25 and 4.26). 
Figures 4.27 to 4.30 illustrate interesting differences in the 
surface characteristics of pellets coated with the aqueous Silicone 
Elastomer emulsion formulations; again specific formulation details and 
the film coating processing technique and variables are described in 
Chapter 3. A ratio of silicone to silica in the preparation of the 
emulsion of 2:1 without plasticiser (Figure 4.27) and with plasticiser 
(Figure 4.30), yields films of uniform, smooth surface characteristics, 
which at this stage of the investigation may be considered satisfactory. 
For ratios of silicone to silica of 4:1 and 6:1, it is evident that many 
surface irregularities are a feature of the resultant films. Reasons for 
this may be many fold and attributable to many factors. Possible 
explanations include poor coating processing variables, which mayor may 
not be a causative factor. It is felt however that this is unlikely 
since satisfactory film quality appears to have been achieved with the 
2:1 ratio. It has been concluded previously that an lncrease in the 
ratio of silicone to silica in the emulsion formulation has the effect of 
increasing the tendency of product sticking and agglomeration during 
coating. Although the capacity of the fluidising air within the coating 
chamber appeared to be sufficient to prevent pellet sticking and/or 
agglomeration during processing, it is possible that the nature of the 
excipients of the emulsion rendered the equilibrium conditions within the 
coating chamber unsuitable for these aqueous systems in some other way. 
123 
Figure 4.25. SEM of pellet surface coated with Eudragit RS/RL30D 
(pre-dissolution); x400. 
Figure 4.26. SEM of pellet surface coated with Surelease dispersion 
(pre-dissolution); x400. 
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Figure 4.27. SEM of pellet surface coated with Silicone Elastomer 2:1 
(pre-dissolution); xBOO. 
Figure 4.2B. SEM of pellet surface coated with Silicone Elastomer 4:1 
(pre-dissolution); xBOO. 
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Figure 4.29. SEM of pellet surface coated with Silicone Elastomer 6:1 
(pre-dissolution); x800. 
Figure 4.30. SEM of pellet surface coated with Silicone Elastomer 6:1 
with 10%w/w PEG (pre-dissolution); x800. 
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It is possible that the rate of water removal was not necessarily 
optimised under these circumstances and that the quality of the film 
coating of those pellets illustrated in Figures 4.28 and 4.29 is somewhat 
impaired when compared with the 2:1 ratio (with and without incorporated 
plasticiser). A further effect of incorporated plasticiser, in addition 
to enhancing the elasticity of the film, is to enhance the rate of drug 
release (Figure 4.16). This is attributable to the creation of 
hydrophilic pores or channels within the otherwise hydrophobic polymeric 
membrane as a consequence of the affinity of the plasticiser for the 
penetrating aqueous solvent during dissolution testing. 
The process involving dissolution of the plasticiser within the 
polymeric membrane leading to the creation of aqueous pores or channels, 
mayor may not playa significant role in the drug release from polymer 
coated pellets containing ibuprofen. Figure 4.16 enables confirmation of 
the drug release enhancing properties of incorporated plasticiser and 
illustrates that these pores or channels do have a role in facilitating 
diffusion of solute molecules from the pellet core into the bulk 
solution. The drug release mechanism from those pellets coated with the 
silicone emulsion formulation without incorporated plasticiser IS 
membrane controlled as a consequence of the hydrophobic nature of this 
film. It is possible that at least part of the rate controlling 
mechanism may be attributable to the relative osmotic pressures, In 
respect of difference in the osmotic pressure caused by the presence of 
solute molecules within the pellet core and solute concentration within 
the bulk solvent. 
Figure 4.16 indicates that drug release from those coated pellets 
without incorporated plasticiser exhibits first order kinetics. The 
creation of plasticiser pores within the membrane for those pellets 
coated with silicone emulsion 2:1 with the addition of polyethylene 
glycol, appears initially to display first order kinetics, but the rate 
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controlling mechanism appears to become zero order as the latter 25% of 
drug IS leached from the pellet core. 
It may be concluded that the presence of hydrophilic pores within an 
otherwise hydrophobic membrane, does contribute to drug release from 
pellets. It would appear however that the major release controlling 
mechanism IS not due to the presence of plasticiser pores, but largely by 
the diffusional transport of solute molecules across the polymeric 
membrane and possibly the relative osmotic pressure within the pellet 
core and the bulk dissolution medium. 
4.3.3.4. Effect of polymer type on the surface characteristics of film 
coating applied to pellets containing ibuprofen, following drug 
removal. 
Figures 4.31 to 4.36 are SEMs which show the surface characteristics 
of pellets which have been coated with the various polymers after drug 
removal. 
The polymethacrylate film contained the plasticiser triethylcitrate. 
This was necessary to reduce the glass transition temperature of the 
polymer thus ensuring polymer coalescence and complete film formation 
during the coating process; it also improves the elastic properties of 
the film. Thus a water soluble component is incorporated into an 
otherwise aqueous insoluble polymeric membrane. It is not unreasonable 
to expect the plasticiser to dissolve in the aqueous phase resulting In 
the creation of pores within the film coat. Figures 4.31a and 4.31b 
demonstrate this phenomena exceptionally well. The integrity of the film 
has been compromised by the removal of plasticiser from the membrane into 
the bulk solution. This has the consequence of at least contributing to 
drug release from the pellet core; these figures show the exposed core of 
the pellet where the integrity of the polymeric film has been compromised 
as a consequence of plasticiser removal by dissolution testing. 
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Figure 4.31a. SEM of pellet surface coated with Eudragit RS/RL30D 
(post-dissolution); x400. 
Figure 4.31b. SEM of pellet surface coated with Eudragit RS/RL30D 
(post-dissolution); x800. 
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Figure 4.32a. SEM of pellet surface coated with Surelease dispersion 
(post-dissolution); x80. 
Figure 4.32b. SEM of pellet surface coated with Surelease dispersion 
(post-dissolution); x400. 
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Figure 4.33a. SEM of pellet surface coated with Silicone Elastomer 2:1 
(post-dissolution); x400. 
Figure 4.33b. SEM of pellet surface coated with Silicone Elastomer 2:1 
(post-dissolution); x800. 
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Figure 4.34a. SEM of pellet surface coated with Silicone Elastomer 4:1 
(post-dissolution); x400. 
Figure 4.34b. SEM of pellet surface coated with Silicone Elastomer 4:1 
(post-dissolution); x800. 
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Figure 4.35a. SEM of pellet surface coated with Silicone Elastomer 6:1 
(post-dissolution); x400. 
Figure 4.35b. SEM of pellet surface coated with Silicone Elastomer 6:1 
(post-dissolution); x800. 
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Figure 4.36a. SEM of pellet surface coated with Silicone Elastomer 2:1 
with 10%w/w PEG (post-dissolution); x400. 
Figure 4.36b. SEM of pellet surface coated with Silicone Elastomer 2:1 
with 10%w/w PEG (post-dissolution); x800. 
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The skeletal network of drug depleted cores containing only microcryst-
alline cellulose are exposed; the core formulation in this case initially 
contained 30% microcrystalline cellulose and 70%w/w ibuprofen. The 
incorporation of plasticiser into aqueous dispersions containing the 
polymethacrylates was necessary for film formation. It was therefore not 
possible to prepare coated pellets using the same formulation without 
plasticiser. There are therefore no comparative release profiles 
available for pellets coated with the polymethacrylate dispersion without 
added plasticiser, as there are for the silicone coated particles. It is 
postulated that although solute transport through aqueous pores within 
the otherwise hydrophobic membrane contributes to drug release, it is not 
necessarily the main mechanism of drug removal from the pellet core. 
Figures 4.32a and 4.32b show the surface of a drug depleted pellet 
coated with a commercial ethylcellulose formulation {Surelease} 
containing plasticiser; details relating to the formulation of the 
Surelease formulation have been given previously {section 3.2.2}. Figure 
4.32a illustrates how the film coat envelopes the pellet which initially 
contained 80%w/w ibuprofen; some pellet shrinkage is apparent. This may 
be attributable to core shrinkage as a consequence of drug removal and 
the drying out of the pellet after dissolution testing. As previously 
mentioned, pellets were dried under ambient conditions of humidity and 
temperature in order to try and minimise core shrinkage due to drug 
removal and increased voidage within pellet cores. 
Alternatively, it is possible that the relative osmotic pressures 
between the solute concentration in the coated pellet core and in the 
bulk solution during in-vitro testing, caused a degree of swelling of the 
pellet with a resultant "expanding" or "stretching" of the film coat, 
which was unrecoverable after drug removal and subsequent drying of the 
coated pellet. This effect has not been seen with the other coating 
systems studied. 
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Figure 4.32b shows the creation of pores within the film coat as a 
result of in-vitro testing. Again the pellet core is exposed and it is 
postulated that the leaching of drug from the core through these pores or 
cracks only plays a contributory part in the release of drug and that it 
IS not the predominating mechanism; this is on account of the frequency 
of these craters. 
Figures 4.33 to 4.36 inclusive illustrate the nature of the polymeric 
film following drug removal by dissolution testing. It is apparent that 
breach of the film resulting in exposed core for those pellets coated 
with an unplasticised Silicone Elastomer membrane, is not occurring to 
anywhere near the extent of those plasticised films discussed previously 
(Figures 4.33, 4.34 and 4.35 inclusive). The proposed mechanism of drug 
release from these entities is by diffusion of solute molecules across 
the polymeric membrane, with a possibility of the process of osmosis 
contributing the release mechanism. Even under a magnification of x800 
exposed core is not evident following complete drug removal. This IS as 
expected since these films are exceptionally hydrophobic and there IS no 
incorporated plasticiser ensuring the creation of pores within the film. 
Figure 4.36 shows that the presence of plasticiser within a silicone 
elastomer membrane (as a result of contact with an aqueous solvent), will 
cause the formation of aqueous pores as the hydrophilic plasticiser is 
leached from the otherwise hydrophobic film by the penetrating aqueous 
phase. The extent of this process is obviously totally dependent upon 
the concentration of plasticiser within the aqueous silicone emulsion. 
~ 
This factor may not be used as means of controlling drug release from 
~ 
this polymer however, since increasing polyethylene glycol content leads 
to product sticking and agglomeration during the film coating process. 
It is anticipated that the presence of plasticiser does not have a major 
effect on the drug release mechanism from pellets coated with these 
silicone formulations. 
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4.3.3.5. Effect of polymer type on the cross-sectional characteristics 
of film coated pellets containing ibuprofen following drug 
removal. 
Figures 4.37 to 4.42 inclusive show sectioned drug depleted pellets. 
It is possible to differentiate between the skeletal structure of the 
microcrystalline cellulose core remaining after drug removal by in-vitro 
dissolution and the polymeric membrane surrounding the core In each of 
the pellets illustrated at the relatively low magnification of x80. 
Figures 4.39a, 4.40a, 4.41a and 4.42a clearly show that at silicone to 
silica ratios of 4:1 and 6:1 in particular, there appears to be poor 
adhesion/cohesion between the pellet core and the film coat. It appears 
with these formulations that the film coat has a tendency to become 
detached from the pellet core. At a ratio of silicone to silica of 2:1 
(Figure 4.39a) film detachment 1S evident. However incorporation of 
polyethylene glycol into the film formulation appears at worst, to reduce 
this poor adhesion between these two components. 
All pellets illustrated which are coated with the Silicone Elastomer 
formulations contained 80%w/w ibuprofen in the core formulation prior to 
in-vitro dissolution testing. 
Poor adhesion of the Silicone Elastomer films to pellet cores is not 
the only problem associated with the use of this product as a means of 
achieving a release retarding film coating for multiparticulates. 
Already discussed in detail is the tendency for product sticking and 
agglomeration during the coating process with these systems. Discussed 
subsequently in Chapter 7, is the fact that it was not possible to 
compact pellets coated with silicone formulations into tablets, due to 
these pellets exhibiting instant recovery on removal of the applied load 
associated with the compression process; it was not physically possible 
to form a tablet containing Silicone Elastomer coated pellets. 
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Figure 4.37a. SEM of pellet cross-section coated with Eudragit RS/RL30D 
(post-dissolution); 80% drug; x80. 
Figure 4.37b. SEM of pellet cross-section coated with Eudragit RS/ RL30D 
(post-dissolution); 80% drug; x400. 
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Figure 4.38a. SEM of pellet cross-section coated with Surelease 
dispersion (post-dissolution); 80% drug; x80. 
Figure 4.38b. SEM of pellet cross-section coated with Surelease 
dispersion (post-dissolution); 80% drug; x400. 
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Figure 4.39a. SEM of pellet cross-section coated with Silicone Elastomer 
2:1 (post-dissolution); x80. 
Figure 4.39b. SEM of pellet cross-section coated with Silicone Elastomer 
2:1 (post-dissolution); x400. 
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Figure 4.40a. SEM of pellet cross-section coated with Silicone Elastomer 
4:1 (post-dissolution); x80. 
Figure 4.40b. SEM of pellet cross-section coated with Silicone Elastomer 
4:1 (post-dissolution); x400. 
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Figure 4.41a. SEM of pellet cross-section coated with Silicone Elastomer 
6:1 (post-dissolution); x80. 
Figure 4.41b. SEM of pellet cross-section coated with Silicone Elastomer 
6:1 (post-dissolution); x400. 
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Figure 4.42a. 
Figure 4.42b. 
SEM of pellet cross-section coated with Silicone Elastomer 
2:1 + 10% PEG (post-dissolution); x80. 
SEM of pellet cross-section coated with Silicone Elastomer 
2:1 + 10% PEG (post-dissolution); x400. 
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The mechanical properties of free-films of Silicone Elastomer are 
discussed in detail in Chapter S. It was considered necessary to be able 
to quantify the fundamental tensile properties of the free-films in order 
to demonstrate the relative abilities of the polymer systems to withstand 
applied load in the form of pellet compaction. 
4.4. Conclusions. 
The incorporation of ibuprofen into an uncoated pellet formulation 
with microcrystalline cellulose (Avicel PHlOl), results in the formation 
of multiparticulates which are essentially spherical porous matrices. 
Drug removal by in-vitro dissolution from pellet cores containing as 
much as 80%w/w drug and therefore only 20%w/w microcrystalline cellulose. 
yields visibly intact spheres. 
Using the technique of scanning electron microscopy under high 
magnification to examIne pellet surface and cross-sectional 
characteristics, it is apparent that drug has been leached from the 
pellet cores resulting in a fine tortuous skeletal network of 
microcrystalline cellulose. 
Drug release from uncoated pellets containing ibuprofen appears to 
exhibit first-order kinetics and is remarkably sustained even when the 
initial drug loading is as high as 80%w/w. 
The application of a polymeric membrane In the form of an aqueous 
dispersion to spherical multiparticulates, has the effect of retarding 
the rate of drug release. There appears to be a critical coating level, 
below which core coverage by the polymer is incomplete and drug release 
is diffusion controlled and first-order kinetics are observed. Above 
this critical coating level, drug release appears to become membrane 
controlled and zero order kinetics are observed; the drug release rate 
becomes time independent after a minimum polymer level has been achieved. 
The presence of plasticiser within the coating formulation. not only 
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influences the glass transition temperature of the polymer and the 
elasticity of the film, but it imparts a hydrophilic component to an 
otherwise extremely hydrophobic membrane. As a consequence of the 
in-vitro dissolution of plasticised polymer coated pellets, penetration 
of aqueous solvent molecules into and drug release from the pellet core, 
is enhanced by the creation of hydrophilic pores which are formed in the 
polymeric membrane by the leaching of the plasticiser into the 
dissolution medium. 
Polymeric membranes derived from aqueous dispersions and applied to 
pellets using the methodology described in detail in Chapter 3, enables 
polymer coalescence and complete film formation under the operating 
conditions of the coating chamber. This is characterised by the in-vitro 
drug release profiles for coated pellets containing ibuprofen, which were 
subjected to an additional "curing" stage involving 24 hours storage at 
40°C following coating. There is negligible difference between the 
release of ibuprofen from those pellets exposed to this additional 
"curing" stage and those which were not. It may be concluded therefore 
that complete film formation and polymer coalescence was facilitated by 
the equilibrium conditions within the coating chamber for the three 
polymer systems studied. 
The incorporation of plasticiser into the Silicone Elastomer aqueous 
emulsion leads to an enhanced rate of drug release and also appears to 
enhance the cohesion between the uncoated pellet surface and the 
polymeric membrane. Increasing the ratio of silicone to silica in the 
emulsion formulation, leads to a decrease In the rate of drug release and 
this appears to be reflected in the quality of the film coat. The 
presence of polyethylene glycol in emulsion formulations containing 
silicone to silica ratios in excess of 2:1, results in sticking and 
product agglomeration during the coating process. 
It is evident on drug removal from pellet cores, that for this drug 
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and using the massing, extrusion and spheronisation techniques described 
in Chapter 2, that drug is evenly distributed throughout the cores. which 
even following drug removal are able to retain their physical shape and 
integrity. The interparticulate voidage exhibited by drug depleted 
pellets initially loaded with a high percentage of drug, is greater than 
that voidage created by the removal of drug from pellets initially 
containing a lower drug content. 
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CHAPTER 5 
STUDY OF THE TENSILE PROPERTIES OF SOME FREE POLYMERIC 
FILMS PREPARED FROM AQUEOUS DISP~RSIO~S 
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5.1. Introduction. 
It is proposed that a consideration of the tensile properties of the 
aqueous polymeric dispersions used to form the release-retarding 
membranes applied to the ibuprofen pellets in this study, will give an 
indication of the ability of the coating to withstand the compression 
process in the formation of the tablet. 
A study of the indentation hardness and tensile properties of free 
films is made in this work. By quantifying the physical properties of 
the film coating it is possible to gain insight into any damage that may 
occur during compression. In-vitro release studies (Chapter 7) have 
indicated that some damage 1S occurring to the polymeric membrane as a 
result of pellet compression; it was the aim of this work to establish 
and quantify where possible, the effect of compression as the causative 
factor of film splitting, cracking or peeling from the substrate. 
In any pharmaceutical film coating operation in which a polymer film 
is applied to a substrate surface, cohesive forces exist between the film 
forming polymer molecules and adhesive forces exist between the film and 
the substrate. The term cohesion has been defined by Banker (1966) as 
the ability of the contiguous surfaces of the same material at a 
molecular level, to form a strong bond which prevents or resists 
separation at the point of contact. Complete film formation from an 
aqueous dispersion of a water-insoluble polymer requires the coalescence 
of the polymer particles and consequential disappearance of the boundary 
layers between adjacent polymer molecular layers or surfaces. This is 
facilitated by the diffusion of individual macromolecules or segments of 
macromolecules between and within film layers. 
5.1.1. Film preparation. 
Kanig and Goodman (1962) described methods of preparing and studying 
free polymeric films and compared the properties of free films prepared 
148 
by casting and by conventional spraying techniques. A major 
differentiating factor between sprayed and cast films is that the 
mechanism of sprayed film formation involves the build up of contiguous 
layers of polymer on the substrate. It is proposed that at least some of 
the particles of the spray-dried polymer and air may become entrapped 
leading to imperfections in the structure of the film. Free-film 
preparation by the pouring of an aqueous polymeric dispersion can lead to 
an enhanced susceptibility of the dispersed particles to segregate. This 
IS a consequence of the lengthy drying times necessary with such systems 
and may result in films consisting of multiple dissimilar layers. This 
separation does not occur in the film coating of tablets by conventional 
spray techniques (Allen et al. 1972). 
Aulton (1982) argued that free-films prepared by spraying provide a 
more realistic model of the coating on a tablet substrate whilst films 
prepared by pouring are easier to prepare to the desired thickness with 
freedom from bubbles and defects. This author states that casting IS a 
more accurate method for achieving data on the fundamental properties of 
the polymer and the polymer formulation. Kanig and Goodman (1962) 
discussed the benefits of studying the properties of free-films without 
introducing the variables associated with the casting technique. 
Zaro and Smith (1972) described a technique to enable study of the 
effect of casting and spraying films onto similar tablet substrates. 
This consisted of a Teflon-coated plate with holes to accommodate the 
tablets, such that a single tablet surface was exposed to the coating 
formulation. 
It may be concluded from the literature that poured or cast films 
offer a means of studying the fundamental properties of polymers, whilst 
sprayed films more accurately simulate a polymeric membrane applied to 
the surface of a tablet substrate by commercial spraying techniques. 
Lindholm et al. (1987) studied the properties of free ethyl 
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cellulose films containing surfactant and particulate matter. Free films 
were prepared by casting and spraying an organic solution of ethyl 
cellulose. The results based on release curves and micrographs indicated 
that differences in structure and permeability between cast and sprayed 
films were small. These authors showed that for sprayed films, the 
effect of film thickness on elongation was minimal but that breaking 
strength increased with increasing film thickness. Lindholm et al. also 
showed that with this system thin poured films were mechanically stronger 
than sprayed films. 
Devereux (1988) studied techniques for preparlng free films from 
aqueous polymeric dispersions by pouring them onto various substrate 
surfaces. Parameters studied included the tendency of the film to adhere 
to the substrate surface and the ability of the dispersion to spread 
uniformly on the substrate surface. Substrates studied were glass, 
silicone coated glass, PTFE coated glass, perspex, foil and PTFE 
sheeting. PTFE sheeting was most favourable for this laboratory test in 
that adherence of the film to the substrate surface was minimal, although 
dispersion spreading was considered to be poor. Consequently Devereux 
described a technique for the casting of free-films from aqueous 
polymeric dispersions onto the inner surface of a rotating PTFE cylinder. 
This technique and the apparatus used in this study are described 
subsequently in section 5.2. 
5.1.2. Viscoelastic materials. 
The effect of stress a on an ideal viscous liquid and on an ideal 
elastic solid may be predicted from Newton's Law (Equation 5.1) and from 
Hooke's Law (Equation 5.2) respectively. Newton's Law states that shear 
stress a (Pa) is proportional to the rate of strain (d€/dt), where n is 
the viscosity (Pa s): 
a = n (d€/dt) Equation 5.1. 
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Hooke's Law states that shear stress a IS directly proportional to 
strain E 
a = G E Equation 5.2. 
where G is the modulus of elasticity (Pa). A spring with a modulus of 
G and a dashpot containing liquid with a viscosity n, have been used as 
models for Hookean elastic solids and Newtonian liquids respectively. 
In these models the spring stores energy in a reversible process and the 
dashpot dissipates energy as heat in an irreversible process. Figure 5.1 
IS a stress-strain curve for a typical elastomer; the straight dashed 
line indicates Hookean behaviour as described in Equation 5.2. It is 
evident that the elastomer behaviour is not Hookean. 
Stress 
a 
/ 
/ 
/ 
/ 
/ 
Strain E 
Figure 5.1. Stress-strain curve for a typical elastomer. The dashed 
line indicates Hookean behaviour. 
Elastomers and synthetic polymers exhibiting both viscous flow and 
elasticity are termed viscoelastic. The work done in deforming a Hookean 
solid is recovered completely 
shape. However the work done 
when the body is restored to its original 
~~~ 
in deformingAexnibiting Newtonian flow is 
used to maintain flow and is converted completely into heat by the 
friction between the molecules or particles in the liquid. It is this 
internal friction which is responsible for viscosity. When a 
viscoelastic material is stressed some of the work done is stored 
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elastically and can be recovered and the rest 1S dissipated as heat In 
maintaining flow. 
For most plastic materials, as an approximation, elasticity 
predominates at low stresses and viscous flow at high stresses; the two 
types of behaviour being separated by the yield stress. With all 
viscoelastic materials, elasticity and flow occur simultaneously. 
Rheological models describing the behaviour of viscoelastic materials 
contain springs and dashpots and which may be connected in series (Figure 
5.2) or in parallel (Figure 5.3). 
A viscoelastic liquid in which the slightest stress causes a 
permanent deformation in the form of viscous flow is represented by the 
Maxwell model (Figure 5.2). 
o 
o 
Figure 5.2. Maxwell model for viscoelastic behaviour. 
If the spring is considered to be strong, this model explains the 
elasticity of fluids such as liquids and gases. If the dashpot is 
considered to contain an extremely viscous oil, the model represents the 
slow creep of an elastic solid, including elastomers below their elastic 
limit (Wallwork and Grant, 1978). 
A viscoelastic solid will eventually return to its original shape 
after a small deforming stress has been applied and removed. The 
simplest rheological model for this behaviour consists of a spring and 
dashpot in parallel and is known as a Voigt body (Figure 5.3). 
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o 
o 
Figure 5.3. Voigt model for viscoelastic behaviour. 
The elastic property predominates if applied stress is slowly increased 
or decreased and the body behaves like a solid. When the body is 
subjected to rapidly changing stress, the elastic deformation and 
recovery are retarded by the viscous property of the material. Therefore 
if the body is subjected to an oscillating stress of high frequency and 
the VlSCOUS property predominates, the work of deformation is absorbed 
and the body behaves like a liquid. It is therefore apparent that the 
Voigt body and the Maxwell body show opposite time-dependent behaviour. 
The magnitude of the elastic modulus (or "stiffness") of a polymer 
film is a function of intermolecular forces and additives within that 
film. For elastomers in which there is little cross-linking of polymer 
chains, the chains are able to move relative to each other and the 
material flows visibly under conditions of applied stress. Considerable 
cross-linking hampers movement of polymer chains thus preventing flow, 
reducing the elasticity and causlng a hardening of the material. The 
amplitudes of the molecular motions and vibrations depends to a large 
extent on the temperature. For a given polymer the glass transition 
temperature (Tg) is the temperature above which the polymer is ductile 
due to the macromolecules possessing a certain freedom of motion. Below 
the Tg the polymer is relatively hard, brittle and glass-like as a 
consequence of the attractive forces between the macromolecules causing 
an apparent fixing of their positions. 
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The Maxwell model may be expressed mathematically as follows: 
dEldt + Gin = 0 
G = Go e-t(G/n) 
Equation 5.3. 
Equation 5.4. 
where Go is equal to the initial stress before the stretched specimen 1S 
allowed to relax exponentially with time t. When t = nlG, the a 1S 
reduced to l/e (l/e = 1/2.7 = 0.37) times the original value. The 
relaxation time is equal to niG. When a Maxwell model is subjected to an 
applied stress it first deforms instantaneously and then undergoes 
irreversible flow. 
A viscoelastic solid will eventually return to its original shape 
after a small deforming stress has been applied and removed. The 
rheological model proposed by Voigt (Figure 5.3) in which the spr1ng and 
dashpot are in parallel, the applied stress is shared and each element 1S 
deformed equally. Thus the total stress G is equal to the sum of the 
viscous stress n(dEldt) plus the elastic stress GE: 
Total stress G = n(dEldtj + GE Equation 5.5. 
On integration Equation 5.5 becomes 
E = GIG (1 - e-tG/nj Equation 5.6. 
where the retardation time nlG is equal to the time for the stress to 
decrease to (1 - l/e) of the original value (1 - l/e = 1/2.7 = 0.63). 
Viscoelasticity is time-dependent since strain is not only a 
function of the magnitude of the stress at any given time, as is the case 
for an elastic solid (Hookean body), but is also a function of the rate 
of change of stress at any given time, as is the case for viscous or 
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Newtonian flow. Several Maxwell units arranged In parallel may be used 
to represent rheological behaviour, and several Voigt units arranged in 
series may be used to represent creep. It is not possible to accurately 
represent polymer behaviour with simple Maxwell or Voigt models. although 
they are able to mimic the type and relative importance of certain 
general types of behaviour on a molecular scale. 
In a more practical way, Carswell and Nason have classified polymers 
on the basis of modulus into five categories, as shown in Figure 5.4: (a) 
soft and weak, (b) hard and brittle, (c) soft and tough (low modulus and 
high elongation), (d) hard and strong and (e) hard and tough. 
It is important to note that the behaviour of polymers below the 
yield point is Hookean and essentially reversible in the short term. 
Thus the range, which is associated with the stretching and bending of 
covalent bonds, is called the elastic range. The area under the 
stress-strain curve is a measure of the toughness of the polymer. 
Stress Stress Stress 
(a) Strain (b) Strain (c) Strain 
Stress Stress Elongation at yield point 
--Elongation at break 
strength 
(d) Strain (e) Strain 
Figure 5.4. Typical stress-strain curves. 
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5.1.3. Indentation hardness. 
Indentation testing involves measuring the penetration of an 
indenter tip under known load into a film coat, either in-situ or 
presented as a free-film mounted onto a fixed platen. The indenter tip 
will penetrate the film to a distance which is dependent upon the applied 
load and the rheological properties of the membrane itself. The indenter 
will travel a greater distance into a soft, elastic material as compared 
with a harder more brittle film. Indentation testing yields information 
relating to the resistance to deformation and the elasticity of the 
polymeric material. 
This work involved a study of the effect of the nature of the 
polymer and the presence of other excipients forming the film, on the 
elastic modulus, the Newtonian viscosity, instantaneous and 
time-dependent elastic creep compliance. 
Aulton (1982) discusses definitions of hardness and indicates 
probably the most accurate to be that of Braun (1958); "hardness is the 
quasistatic resistance to local non-homologous deformation caused by 
point or line shaped force centres". The British Glossary of Paint Terms 
described hardness of paint film coatings as the ability of the coating, 
as distinct from its substrate, to resist indentation of penetration by a 
hard object. Aulton discusses the relevance of this to pharmaceutical 
systems in which films are applied to pharmaceutical dosage forms, with 
particular reference to tablets, and the fact that the indentation load 
must be carefully selected such that the depth of indentation by any 
given load does not exceed 1/6 of the thickness of the film under test. 
Hardness is quantified in terms of the load applied to indenter 
divided by the area beneath the indenter tip supporting that load. It 
therefore has units of pressure (Pa or Nm- 2 ). For a spherical indenter 
tip, hardness data such as Brinell and Meyer's have been used in respect 
of pharmaceuticals. 
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Brinell Hardness is defined as the ratio of applied load to the curved 
area of indentation: 
load 
Brinell Hardness = Equation 5.7. 
curved area of indentation 
2F 
= Equation 5.8. 
F 
= Equation 5.9. 
1tDh 
where F is the applied load, D is the diameter of the indenter tip, h is 
the depth of penetration and d IS the diameter of the indentation in the 
plane of the surface (Figure 5.5). 
F 
--t 
--------------- i 
<-d-> 
Figure 5.5. Geometry of sphere indentation. 
Meyer's Hardness is defined as a ratio of the applied load to the 
projected area of indentation: 
load 
Meyer's Hardness = Equation 5.10. 
projected area of indentation 
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= Equation 5.11. 
An advantage of Meyer's definition is that it more closely approximates 
the mean pressure beneath the indenter. 
However due to the time-dependent deformation of films under applied 
load, even quoting hardness values calculated by measuring film 
penetration by the indenting load at a given time, does not necessarily 
guarantee that all polymers will have similar deformation characteristics 
as a result of a given penetration time (Aulton, 1982). 
Aulton (1982) discusses possible solutions to this problem. A 
mathematical alternative involves the derivation of some time-dependent 
viscoelastic parameters by the generation of creep compliance curves. 
5.1.4. Creep compliance. 
Creep is the name of the phenomenon in which strain deformation 
Increases with time, when a constant stress is applied to a viscoelastic 
material. When the stress is removed, the deformation will usually 
decrease, a process which is termed recovery. During recovery the strain 
falls to an equilibrium value which is usually higher than the initial 
value before deformation, as a consequence of viscous flow. Aulton 
(1982) describes the following equation originally presented by Lee and 
Radok (1960): 
Jc(t) = 
16/R 
3F 
[h(t)3/2] Equation 5.12. 
where Jc(t) is strain/stress or creep compliance at time t (MPa)-l, R is 
the radius of the indenting sphere. F is the indentation load and h(t) IS 
the depth of indentation at time t. Equation 5.11 enables calculation of 
creep compliance at time t and the results may be plotted as shown in 
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Figure 5.6. This presentation of viscoelastic behaviour enables polymer 
definition in terms of the Maxwell and Voigt spring and dashpot models 
described previously. The instantaneous elasticity (AB) and the 
instantaneous recovery (CD), are attributed to the spring in the Maxwell 
model (Figure 5.6). The delayed or retarded elasticity (BC) and the 
delayed or retarded recovery (DE) are due to the Voigt model. The 
dashpot in the Maxwell model explains the viscous deformation IN 
remaining after recovery. 
The ratio of the strain (due to creep) at a given time to the 
constant stress is termed the creep compliance (N- I m2 or Pa- I ) at that 
time. 
Creep I 
(at constant stress) 
Stress p~~---> 
Jc(t) 
B --------------------------
Jo 
A 
C 
D 
Recovery (after stress 
reduced to zero) 
Jo 
----------~------------~ 
Permanent 
deformation 
Time (t) 
Figure 5.6. Idealised creep compliance versus time profile for a 
viscoelastic material. 
Figure 5.7 illustrates how the Maxwell and Voigt models may be 
combined to define a polymer coat (Aulton, 1982). Jo to J3 are the 
compliance of the elastic elements and nl to nN are the effective 
viscosities of the dashpots. 
Indentation rheology of polymeric materials reveals that the elastic 
ent of such materials is attributable to multiple components. compon 
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The 
instantaneous elastic or Hookean component is associated with the bending 
or stretching of valency bonds. Films displaying these characteristics 
alone will be brittle and exhibit a small elongation at break. 
Secondly, a retarded elastic component which is time-dependent and 
IS represented by the Voigt model occurs as a result of uncoiling 
disentanglement and partial alignment of the molecular chains: In this 
situation the modulus is much lower. It IS also possible that the chains 
of the polymer molecules may also slip over each other, resulting in 
VISCOUS deformation only; this may be represented by the dashpot model 
alone. The total deformation which is the sum of the above three types 
of deformation exhibit time-dependent properties. 
Figure 5.7. 
o 
Jo 
nl 
n2 
J2 
o 
Diagram showing combination of Maxwell and Voigt models 
illustrating viscoelastic properties of polymer films. 
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5.2. Methods. 
5.2.1. Aqueous polymeric dispersion preparation. 
It was the aIm of this part of the study to quantify the mechanical 
properties and thus determine the ability of polymeric films prepared 
from aqueous dispersions to retain their integrity as a consequence of 
pellet compression. 
Aqueous polymeric dispersions were prepared using the methodology 
described in section 3.2. 
5.2.2. Free-film preparation. 
A film casting substrate must facilitate uniform spreading of the 
film causing minimal adherence of the film to its surface. The resultant 
film must be of uniform thickness, of smooth surface and free from aIr 
bubbles. The film must be free from any particulate contamination and 
was therefore cast onto a grease free surface, by prior treatment with 
industrial methylated spirit. Film casting by pouring resulted in the 
tendency of the aqueous dispersions to form "islands" when in contact 
with the hydrophobic surface of grease-free Teflon or glass surfaces. 
Also the relatively low viscosities of these aqueous dispersions as a 
consequence of being composed of solid polymer dispersed in an aqueous 
phase, rendered the formation of uniform films prepared by pouring onto a 
substrate surface, both glass and Teflon, impossible. This is in stark 
contrast to film casting by pouring for organic or indeed aqueous 
solutions of many water-soluble polymers, which are inherently of greater 
viscosity and therefore not susceptible to incomplete spreading and 
"island" formation when in contact with a hydrophobic grease-free Teflon 
or glass substrate. 
Any film adhering with a high affinity to a substrate surface, even 
if it were possible to be separated from that surface, is susceptible to 
damage as a consequence of being detached from the casting surface. Any 
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induced strain or stress or elongation as a consequence of this process, 
inherently has an adverse effect on the properties of that pol}~eric 
membrane. In the course of this work, aqueous dispersions were poured 
onto Teflon, glass and perspex Petri dishes, both directly and by means 
of a TLC applicator, and dried at room temperature (RT). typically 
I8-20°C, under ambient conditions and in also a hot air oven for 24 hours 
at 30, 45 and 60°C. No satisfactory films were prepared by this method: 
films were either of uneven surface characteristics due to the presence 
of air bubbles, were non-detachable from the substrate surface, or of too 
great a thickness to be of value for quantitative evaluation. Details of 
unsuccessful techniques are summarised subsequently (Table 5.1). 
Initial studies for evaluating a suitable technique for the 
preparation of free films composed of aqueous polymeric dispersions were 
made using a dispersion containing Eudragit RS30D 35.5%w/w, Eudragit 
RL30D 9.05w/w, plasticised with triethylcitrate (Citroflex 2) 2.67%w/w 
and containing Syloid 244FP 4.0%w/w. Syloid 244FP is a colloidal grade 
of silicon dioxide and was used in aqueous coating dispersions containing 
polymethacrylate to prevent pellet agglomeration and adherence under the 
operating temperatures of the film coating chamber. 
The virtues of free-film preparation by pouring and spraying 
techniques have been discussed in section 5.1. The importance of the 
operating conditions necessary for complete film formation and polymer 
coalescence of films prepared from aqueous dispersions have been 
documented previously in Chapter 3. 
In an attempt to reproduce those conditions created within the 
coating chamber during the coating of pellets, it was attempted to 
prepare free films by spraying an atomised dispersion in a warm-air 
environment (40-45°C) by means of a fan heater, created within a fume 
cupboard. It was not possible to control the air temperature adequately 
or to create conditions conducive for film formation and polymer 
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Substrate Method of Drying 
surface application conditions 
glass TLC applicator RT 
30°C 
45°C 
60°C 
spraying 40-4S o C 
Teflon TLC applicator RT 
30°C 
45°C 
60°C 
spraying 40-4S o C 
pouring RT 
30°C 
45°C 
60°C 
Perspex pouring RT 
(Petri. dish) 40°C 
Table 5.1. Summary of unsuccessful film casting techniques. 
coalescence uSIng this procedure. All that was achieved was a dried film 
of previously dispersed particles with a high affinity to both glass and 
Teflon. 
The technique of Devereux (1988) was adapted to facilitate the 
formation of uniform smooth surface films, free from air bubbles. These 
were prepared from aqueous polymeric dispersions by casting onto the 
inner surface of a hollow lipped rotating cylinder made of poly tetra-
fluoroethylene (PTFE). The cylinder had detachable lips lined with 
polythene, of internal diameter slightly smaller than that of the main 
body of the cylinder (see Figure 5.8). The cylinder was placed on ball 
mill rollers rotating at 20 rpm. Hot air was directed onto the outer 
surface of the rotating cylinder from a fan heater through an opening In 
a perspex environmental box; the environmental box completely encased the 
cylinder (Figure 5.9). A contact thermometer was used to maintain 
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thermal equilibrium throughout the film-forming process and was 
positioned inside the cylinder along the horizontal axis and parallel to 
the walls of the film-forming surface. The contact thermometer was set 
to maintain a working temperature of 43°C. The temperature of the 
circulating air surrounding the rotating cylinder was monitored during 
film formation and throughout the 24 hour drying period (Table 5.2). 
The apparatus was allowed to achieve thermal equilibrium by running 
for a two hour period prior to film casting. The required quantity 
(typically 60g) of aqueous film coating dispersion was then poured into 
the rotating PTFE cylinder by means of a glass funnel attached to a 
length of silicone tubing. Immediately after pouring the dispersion into 
the cylinder, the lid of the surrounding box was closed in order to 
minimise the tendency for temperature fluctuation and a deleterious 
effect on the thermal equilibrium established during the warm-up period. 
Cylinder rotation speed 20 rpm 
Contact thermometer setting 
Fan Heater Setting 1 kW 
Environmental box temperature 
a) Tl (opposite heat source) 
b) T2 (extreme end of box) 
Pre-warming time 2 hours 
Drying time 24 hours 
Weight of dispersion 60 g 
Table 5.2. Operating Variables of the Film Casting Technique using a 
Rotating PTFE Cylinder. 
During evaporation of the aqueous phase of the polymeric dispersion 
(which took approximately 2 hours), the heat energy supplied by the 
circulating warm air is used to facilitate mass transfer; thermal 
equilibrium was maintained by the contact thermometer. 
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Screw securing cylinder lip to the 
PTFE cylinder body 
60mIn :::> 
Rubber O-ring to improve 
friction between the cylinder 
and ball mill rollers 
-----t---- Main cylinder body (PTFE) 
(88mm Internal diameter) 
------------140mm -----------
Detachable perspex 
lip lined internally 
Figure 5.8. Diagram showing the PTFE rotating cylinder construction 
used in the film casting of aqueous polymeric dispersions. 
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Environmental Box (Perspex) 
Fan Heater 
lkW /2kW 
I 
Hot air 
~ 
Film casting 
PTFE cylinder 
Contact thermometer placed 
along horizontal axis of the 
rotating cylinder (420 C ± 20 C) 
Motorised Roller 
Free Rotating Roller 
Figure 5.9. Schematic aerial diagram of the free-film casting apparatus. 
Following evaporation of the aqueous phase, the temperature within 
the surrounding environmental box was seen to rise slightly. This is 
attributable to the fact that during water evaporation heat energy IS 
absorbed as a consequence of mass transfer, whereas after water removal 
all energy is available for maintaining the temperature of the 
circulating air. Heat loss during the drying stage rather than the film 
forming stage occurs only as a result of conduction and convection: it is 
not required for mass transfer. 
Films were carefully removed from the Inner surface of the PTFE 
166 
cylinder, wrapped In aluminium foil and stored in airtight containers. 
The absorption of atmospheric moisture by the films was prevented by 
storing the foil wrapped films with a 250g silica gel sachet (Sorbsil 
Chemicals) in each airtight container. This was to enable assessment of 
the rheological properties of films without the influence of any sorbed 
moisture. Formulations of free polymeric films studied are detailed in 
Table 5.3: 
Excipient % w/w 
Eudragit RS30D 35.5 35.5 35.5 35.5 35.5 35.5 
Eudragit RL30D 9.0 9.0 9.0 9.0 9.0 9.0 
Citroflex 2 2.67 2.67 3.0 2.67 3.0 1. 34 
Syloid 244FP 4.0 2.0 4.0 
Purified water BP to 100.0 100.0 100.0 100.0 100.0 100.0 
a). Polymethacrylate Film Compositions 
Excipient %w/w 
Surelease Dispersion (25% solids) 60.0 
Purified water BP to 40.0 
b). Ethylcellulose Film Composition 
Ratio Silicone:Silica 2: 1 4:1 6: 1 
Excipient %w/w 
Silicone Emulsion X7-2837(A) 21.88 43.77 32.83 
colloidal Silica X7-2837(B) 34.10 34.12 17.06 
Purified water BP to 100.00 100.0 100.0 
c). Silicone Elastomer Film Compositions 
Table 5.3. Aqueous Polymeric Film Formulations Prepared by Film Casting. 
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5.2.3. Indentation hardness of free-films. 
5.2.3.1. Apparatus. 
The apparatus employed 1n the determination of the rheological 
properties of films prepared from aqueous polymeric dispersions was the 
ICI Micro-Indenter (Figure 5.10). The apparatus consists of a steel 
triangular main chassis, supported on a base plate by means of three 
adjustable legs. Coarse and fine adjustments of the raising or lowering 
of the platform or for zeroing of the instrument are facilitated by means 
of two of the three mounting legs. The coarse adjustment has a single 
screw thread of 20 threads per inch (20tpi). The fine adjustment has a 
differential thread of 26tpi and 28tpi, such that one revolution of the 
adjustment wheel gives a vertical movement of 20 micrometers at the 
position where the test sample is mounted. This wheel is graduated 1n 
divisions of 0.5 micrometers and is used to calibrate the instrument. 
Figure 5.10. Photograph showing the ICI Micro-Indenter. 
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~~ 
A beam mounted on brass crossed flexure bearings has adjustable 
A 
counterbalance weight at one end. At the other end of the beam is an 
adjustable weight for setting the neutral stability or balancing the 
~ 
beam, an oil-filled dashpot damper and an indenter needle, a saphire 
A 
sphere of 1.550mm diameter. 
The original apparatus was modified such that a steel armature 
sub-miniature linear variable differential transformer (LVDT) core, 
(model 222-00005, RDP Electronics, Wolverhampton) was fitted. In place 
of the original pneumatic amplifier (Houghton, 1990). The depth 4f 
penetration of the steel armature into the body of the LVDT was energised 
by the output of the LVDT, and was accurate to ± O.l~m. 
The test specimen was mounted on a rigid platform situated just 
below the indenting sphere of the indenter needle. The indenting load 
was pneumatically lowered onto the beam by means of a bellows system, 
immediately above the indenter needle. As the sample was indented, the 
vertical movement of the indenter sphere and therefore the depth of 
indentation was gauged by a change in output from the LVDT. An amplifier 
(model 2027A) and a stabilised power supply (model 2031, both of RDP 
Electronics, Wolverhampton) energised the primary coil of the LVDT and 
demodulated the output of the secondary coils, giving a signal between OV 
and 10 V d.c. at full scale displacement of the transducer. The 
amplifier gain was adjusted to give an output which was converted to a 
digital signal by means of an analogue-to-digital converter (ADC). This 
facilitated data logging and manipulation using a BBC Model B 
Microcomputer (Houghton, PhD Thesis, 1990). 
In order to minimise the generation of erroneous results due to 
environmental conditions, the apparatus was mounted on rubber dampers 
designed to absorb vibration and within an environmental box in attempt 
to minimise excessive disturbance of the surrounding air during testing, 
In particular whilst the specimen was under applied load. 
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5.2.3.2. Sample preparation. 
Samples of films of thickness approximately 100~m, cast uSIng the 
rotating PTFE cylinder technique discussed previously (section 5.2.2) by 
means of a thin film of paper glue, were mounted onto glass cover-slips 
and allowed to dry under the storage conditions described previously for 
one hour prior to testing. 
5.2.3.3. Indentation testing of prepared samples. 
Each test sample was rigidly clamped directly below the tip of the 
indenter needle, a sapphire sphere of 1.550mm diameter facilitating 
sample indentation at low load thus enabling the determination of creep 
compliance of the test samples. 
The indenting probe was gently lowered onto the surface of the 
sample until it just made contact with the film. The output of the LVDT 
at this point was zeroed electronically; this was recorded as zero 
penetration depth by the data logging system. The indenting load was 
lowered onto its stage above the indenter probe by means of a pneumatic 
bellows system. This facilitated uniform, reproducible and gentle load 
application to the sample. Data logging of time versus indentation depth 
commenced automatically on application of the load to the film causing a 
quantitatively determinable sample penetration. The voltage output of 
the LVDT during indentation was recorded as digital byte values; these 
values were then converted to displacement or depth of sample penetration 
values (~m). Logged data was stored on disc for subsequent retrieval, 
evaluation by discrete mechanical analysis and conversion into creep 
compliance curves by software specifically written for use with this 
apparatus (Houghton 1990). 
The indentation load applied to each sample was designed to enable 
sample penetration of between 0 and 6~m over the duration of the test; 
the optimum penetration depth with respect to instrument calibration and 
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to ensure an indentation of less than 1/6 of the thickness of the film. 
Indentation duration was sample specific and determined for each 
film formulation to ensure that a linear increase in creep compliance 
with time was established. 
Table 5.4 shows the test variables for each film sample studied: 
these were determined experimentally and are sample specific. The 
indentation load required for a sample penetration of between 0 and 6 
micrometers and also the indentation duration necessary for the 
establishment of linearity in respect of creep compliance is dependent 
upon the nature of the polymer forming the film, the quantity of 
plasticiser and the presence of other excipients. 
Excipient % w/w 
Eudragit RS30D 35.5 35.5 35.5 35.5 35.5 35.5 
Eudragit RL30D 9.0 9.0 9.0 9.0 9.0 9.0 
Citroflex 2 2.67 2.67 3.0 2.67 3.0 1. 34 
Syloid 244FP 4.0 2.0 4.0 - - -
Indentation load 3g 19 3g 19 19 3g 
a). Polymethacrylate Film 
Surelease Dispersion 
Indentation load 19 
b). Ethylcellulose Film 
Ratio Silicone:Silica 2:1 4: 1 6: 1 
Indentation load 19 0.5g O.5g 
c). Silicone Elastomer Films 
Table 5.4. Effect of free-film composition on the indentation load 
necessary to cause a film penetration of less than 6~. 
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5.3. Results and Discussion. 
5.3.1. Creep Compliance of Free-Films. 
Creep is the term given to a viscoelastic material in which strain 
deformation increases with time when a constant stress is applied. When 
the stress is removed the deformation will usually decrease. a process 
termed recovery. During recovery the strain falls to an equilibrium 
value which is usually higher than the initial value before deformation, 
as a consequence of viscous flow (Figure S.6). 
Briefly, the instantaneous elastic deformation (AB in the creep 
curve, Figure 5.6) and the instantaneous recovery (CD) are attributed to 
the spring in the Maxwell model. The delayed or retarded elasticity (BC) 
and the delayed or retarded recovery (DE) are due to the Voigt model. 
The dashpot in the Maxwell model explains the viscous deformation (E) 
remaining after recovery. In practice AB and BC may form a continuous 
curve, as may CD and DE, since elasticity and recovery are rarely 
instantaneous. 
The compliance Jo, for the regIon of instantaneous elastic recovery 
(AB), IS obtained by dividing the shear strain e(t) measured at the 
onset of applied shear stress (at t = 0), by the shear stress 0. 
Jo = e(t)/o = 1/Go Equation 5.13. 
where Go is the shear elastic modulus. 
The retarded elastic region, characterised by the region BC, has a 
compliance of JR (Equation 5.14). 
Equation 5.14. 
where ER(t) is the strain In this region. 
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The linear regIon of non-recoverable (Newtonian viscous) compliance Js IS 
given by 
IN = (t/no) = (EN(t)/a) Equation 5.15. 
where no is the apparent Newtonian viscosity of VISCOUS flow and EN (t) 
is the strain. Bonds may actually rupture in this region and as a 
consequence the time required for them to reform is greater than the test 
period and the entities flow past each other. 
On removal of the applied stress, there is some strain recovery. 
The region CD in Figure 5.6 represents the regIon of instantaneous 
elastic recovery and is the same magnitude as the initial elastic 
deformation (AB). This is followed by a retarded elastic recovery (DE) 
which is equivalent to (BC), the delayed or retarded elasticity. The 
viscous region IN represents plastic deformation; this is permanent. 
Here bonds are irreversibly broken and the initial structure is 
not recoverable. 
The results of hardness testing are influenced by many factors; 
examples include environmental vibration during application of the load, 
the condition of the specimen surface, the homogeneity of the film, the 
presence of any entrapped air, the thickness of the material and the 
location of the indentation. Indentation testing too close to previous 
indentation is liable to generate poor results, since the process of 
applying load to a polymer film can have the effect of causing 
work-hardening and/or a weakening of the area. Several readings were 
therefore taken for each sample such that the mean value was more 
representative of a given sample. 
It is felt that the analysis of plastic deformation of polymer films 
by indentation testing provides a useful means of evaluating the 
mechanical properties of films and polymers themselves, particularly 
where films are directly subjected to applied stress, as in this work 
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during the compression of coated pellets. 
Tables 5.5 to 5.14 inclusive, show the experimentally determined 
mechanical properties of the polymeric film formulations studied. Of 
particular interest are the instantaneous and the time-dependent elastic 
compliance data for these polymers and also the elastic modulus values. 
The instantaneous elastic compliance Jo is obtained directly from the 
creep curve as time tends to zero. The elastic modulus Go IS calculated 
as the reciprocal of Jo. The apparent Newtonian viscosity no associated 
with the compliance of non-recoverable deformation is obtained from the 
slope of the late linear part of the creep compliance curve, since 
IN = t/no Equation 5.16. 
where the preVIOUS notation applies. The Newtonian viscosity therefore 
is inversely proportional at time t, to the non-recoverable viscous 
deformation IN(t). Hence a material exhibiting a large non-recoverable 
viscous deformation on the application of applied stress will have a 
correspondingly low apparent Newtonian viscosity; the converse is 
therefore also true. 
The instantaneous elastic compliance (Jo) is as previously stated 
the reciprocal of the elastic modulus. Those materials displaying a 
relatively high instantaneous elastic component will therefore exhibit a 
relatively low elastic modulus. 
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5.3.2. Tabulated creep compliance data. 
Free-Film Composition 
Excipient 
Eudragit RS30D 
Eudragit RL30D 
Citroflex 2 
Syloid 244FP 
Purified water BP to 
Intercept on Y Instantaneous 
JR + Jo Elastic 
Compliance Jo 
(x10- 8 Pa-I) (x10- 8 Pa-I) 
3.268 2.451 
3.559 2.403 
4.376 2.996 
6.403 4.597 
3.778 2.682 
6.201 4.804 
6.254 4.393 
7.053 5.754 
5.729 4.101 
3.601 2.207 
n 10 10 
x 5.022 3.639 
SD 1.439 1.240 
%RSD 28.66 34.09 
35.50 
9.00 
2.67 
4.00 
100.00 
Time-Dependent 
Elastic 
Compliance JR 
(x10- 8 Pa- I ) 
0.817 
1.156 
1.380 
1.806 
1. 096 
1.397 
1. 861 
1. 299 
1.628 
1.394 
10 
1.383 
0.321 
23.23 
% solids 
10.65 
2.70 
2.67 
4.00 
20.02 
Elastic Newtonian 
Modulus Viscosity 
Go no 
x107(Pa) x109 (Pa s) 
4.080 10.539 
4.162 16.559 
3.338 13.065 
2.175 9.937 
3.729 15.094 
2.082 14.044 
2.276 10.335 
1.738 15.054 
2.439 11.121 
4.532 16.479 
10 10 
3.055 13.223 
1.024 2.583 
33.51 19.53 
Table 5.5. Discrete Mechanical Analysis of a Polymethacrylate Film 
containing 2.67%w/w Plasticiser and 4.0%w/w Syloid. 
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Free-Film Composition 
Excipient %w/w % solids 
Eudragit RS30D 35.50 10.65 
Eudragit RL30D 9.00 2.70 
Citroflex 2 2.67 2.67 
Syloid 244FP 2.00 2.00 
Purified water BP to 100.00 
18.02 
Intercept on Y Instantaneous Time-dependent Elastic Newtonian 
JR + Jo Elastic Elastic Modulus Viscosity 
Compliance Jo Compl iance JR Go no 
(x10- 8 Pa-I) (x10- 8 Pa- I ) (x10- 8 Pa-I) x107(Pa) x10 9 (Pa s) 
20.166 11.612 8.554 0.861 1.568 
11.070 7.285 3.785 1.373 3.153 
10.820 6.420 4.400 1. 558 2.657 
13.566 8.222 5.344 1. 216 3.171 
13.784 9.279 4.505 1.078 2.190 
15.084 8.067 7.017 1.240 3.755 
15.497 9.253 6.244 1.081 1.415 
19.411 11.343 8.068 0.882 2.204 
13.927 7.596 6.331 1. 316 2.111 
n 9 9 9 9 9 
x 14.814 8.786 6.028 1.178 2.469 
SD 3.234 1. 771 1.663 0.228 0.779 
%RSD 21. 83 20.16 27.59 19.32 31. 53 
Table 5.6. Discrete Mechanical Analysis of a Polymethacrylate Film 
containing 2.67%w/w Plasticiser and 2.0% Syloid. 
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Free-Film Composition 
Excipient 
Eudragit RS30D 
Eudragit RL30D 
Citroflex 2 
Syloid 244FP 
Purified water BP to 
Intercept on Y Instantaneous 
JR + Jo Elastic 
Compliance Jo 
(x10- 8 Pa-I) (x10- 8 Pa-I) 
4.405 3.205 
7.370 5.093 
6.408 3.453 
5.652 4.452 
7.323 5.197 
7.696 5.859 
7.869 5.954 
5.517 3.946 
9.267 6.930 
5.191 3.622 
n 10 10 
x 6.670 4.768 
SD 1.487 1. 233 
%RSD 22.30 25.87 
35.50 
9.00 
3.00 
4.00 
100.00 
Time-dependent 
Elastic 
Compliance JR 
(x10- 8 Pa-I) 
1.200 
2.277 
2.955 
1.200 
2.126 
1. 837 
1. 915 
1. 571 
2.337 
1. 569 
10 
1.899 
0.548 
28.84 
% solids 
10.65 
2.70 
3.00 
4.00 
20.35 
Elastic Newtonian 
Modulus Viscosity 
Go no 
x107(Pa) x10 9 (Pa s) 
3.120 23.948 
1. 963 11. 658 
2.895 16.983 
2.246 27.047 
1. 924 12.327 
1.707 12.514 
1. 679 13.837 
2.534 19.458 
1.443 12.219 
2.761 20.748 
10 10 
2.227 17.074 
0.574 5.504 
25.80 32.23 
Table 5.7. Discrete Mechanical Analysis of a Polymethacrylate Film 
containing 3.0%w/w Plasticiser and 4.0%w/w Syloid. 
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Free-Film Composition 
Excipient %w/w % solids 
Eudragit RS30D 35.50 10.65 
Eudragit RL30D 9.00 2.70 
Citroflex 2 2.67 2.6: 
Syloid 244FP 
Purified water BP to 100.00 
16.02 
Intercept on Y Instantaneous Time-dependent Elastic Newtonian 
JR + Jo Elastic Elastic Modulus Viscosity 
Compliance Jo Compliance JR Go no 
(x10- B Pa- l ) (x10- B Pa-l) (x10- B Pa-l) xl07 (Pa) x10 9 (Pa s) 
9.628 4.339 5.289 2.305 2.774 
5.267 1.809 3.458 5.528 2.801 
14.847 4.548 10.299 2.199 0.779 
12.073 2.326 9.747 4.300 1.413 
6.671 2.095 4.576 4.773 2.679 
5.184 1.879 3.305 5.322 3.461 
6.207 1.858 4.349 5.383 2.399 
7.742 2.399 5.343 4.170 1. 980 
n 8 8 8 8 8 
x 8.452 2.657 5.796 4.248 2.286 
SD 3.483 1.125 2.715 1. 328 0.860 
%RSD 41. 21 42.35 46.85 31. 26 37.63 
Table 5.8. Discrete Mechanical Analysis of a Polymethacrylate Film 
containing 2.67%w/w Plasticiser. 
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Free-Film Composition 
Excipient 
Eudragit RS30D 
Eudragit RL30D 
Citroflex 2 
Syloid 244FP 
Purified water BP to 
Intercept on Y Instantaneous 
JR + Jo Elastic 
Compliance Jo 
(x10- 8 Pa-l) (x10- 8 Pa-l) 
14.761 4.577 
14.737 4.421 
22.703 7.967 
15.938 3.413 
11.221 2.459 
16.230 5.791 
13.038 2.733 
13.489 3.920 
n 8 8 
x 15.265 4.410 
SD 3.420 1.790 
%RSD 22.38 40.60 
35.50 
9.00 
3.00 
100.00 
Time-dependent 
Elastic 
Compliance JR 
(x10- 8 Pa-l) 
10.184 
10.316 
14.736 
12.525 
8.762 
10.439 
10.305 
9.569 
8 
10.855 
1.894 
17.45 
% solids 
10.65 
2.70 
3.00 
16.35 
Elastic Newtonian 
Modulus Viscosity 
Go no 
x107(Pa) x10 9 (Pa s) 
2.185 0.733 
2.262 0.960 
1. 255 0.593 
2.930 0.732 
4.067 0.872 
1. 727 0.689 
3.660 1. 318 
2.551 0.965 
8 8 
2.580 0.858 
0.944 0.228 
36.60 26.58 
Table 5.9. Discrete Mechanical Analysis of a Polymethacrylate Film 
containing 3.0%w/w Plasticiser. 
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Free-Fi 1m Composition 
Excipient %w/w % sol ids 
Eudragit RS30D 35.50 10.65 
Eudragit RL30D 9.00 2.70 
Citroflex 2 1. 34 1. 34 
Syloid 244FP 
Purified water BP to 100.00 
14.69 
Intercept on Y Instantaneous Time-dependent Elastic Newtonian 
JR + Jo Elastic Elastic Modulus Viscosity 
Compliance Jo Compliance JR Go no 
(x10- 8 Pa- 1 ) (x10- 8 Pa- 1 ) (x10- 8 Pa- 1 ) x107 (Pa) x109 {Pa s) 
2.660 1. 829 0.831 5.469 10.994 
3.418 2.451 0.967 4.080 16.935 
2.381 1. 471 0.910 6.799 15.298 
2.889 1. 852 1. 037 5.400 12.848 
3.190 2.263 0.927 4.419 16.558 
2.812 1.910 0.902 5.237 16.920 
2.305 1.430 0.875 6.992 14.997 
2.766 1. 654 1.112 6.045 14.216 
n 8 8 8 8 8 
x 2.803 1. 858 0.945 5.555 14.846 
SD 0.375 0.375 0.091 1.032 2.106 
%RSD 13.37 19.23 9.64 18.57 14.19 
Table 5.10. Discrete Mechanical Analysis of a Polymethacrylate Film 
containing 1.34%w/w Plasticiser. 
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Free-Film Composition 
Excipient 
Surelease Dispersion (25%w/w solids) 
Purified water BP to 
Intercept on Y Instantaneous Time-dependent 
JR + Jo Elastic Elastic 
Compliance Jo Compliance JR 
(x10- 8 Pa-I) (x10- 8 Pa- I ) (x10- 8 Pa-I) 
22.868 21. 361 1. 507 
26.090 23.596 2.494 
24.824 22.857 1. 967 
24.014 22.224 1.790 
18.928 17.210 1. 718 
21. 214 19.838 1. 376 
19.853 15.416 4.437 
23.069 20.197 2.872 
n 8 8 8 
x 22.608 20.338 2.270 
SD 2.460 2.824 1.008 
%RSD 10.88 13.89 44.41 
% solids 
60.0 
100.0 
Elastic 
Modulus 
Go 
x107(Pa) 
0.468 
0.424 
0.438 
0.450 
0.581 
0.504 
0.649 
0.495 
8 
0.501 
0.077 
15.45 
15.0 
15.0 
Newtonian 
Viscosity 
no 
x109 (Pa s) 
3.150 
2.416 
3.768 
4.098 
5.053 
2.856 
5.952 
4.250 
8 
3.943 
1.169 
29.64 
Table 5.11. Discrete Mechanical Analysis of an Ethylcellulose 
(Surelease) Film. 
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Free-Film Composition 
Excipient 
Silicone Emulsion X7-2837(A) 
Colloidal Silica X7-2837(B) 
Purified water BP to 
21. 88 
34.10 
100.00 
Intercept on Y Instantaneous Time-dependent 
JR + Jo Elastic Elastic 
Compliance Jo Compliance JR 
(x10- 8 Pa- I ) (x10- 8 Pa- I ) (x10- 8 Pa-I) 
18.937 17.242 1. 695 
12.931 11. 281 1.650 
17.552 16.406 1.146 
19.829 19.035 0.794 
13.135 12.032 1.103 
17.438 16.691 0.747 
15.089 13.838 1. 251 
19.188 15.218 3.970 
n 8 8 8 
x 16.762 15.218 1. 545 
SD 2.719 2.667 1.039 
%RSD 16.22 17.53 67.25 
% solids 
11.60 
5.80 
17.40 
Elastic Newtonian 
Modulus Viscosity 
Go no 
x10 7 (Pa) x109 (Pa s) 
0.580 16.170 
0.886 11. 089 
0.609 8.850 
0.525 14.240 
0.831 14.844 
0.599 9.158 
0.723 12.056 
0.657 17.484 
8 8 
0.676 12.986 
0.127 3.199 
18.81 24.63 
Table 5.12. Discrete Mechanical Analysis of a Silicone Elastomer Film 
containing Silicone Emulsion:Colloidal Silica 2:1. 
182 
Free-Film Composition 
Excipient 
Silicone Emulsion X7-2837(A) 
Colloidal Silica X7-2837(B) 
Purified water BP to 
43.77 
34.12 
100.00 
Intercept on Y Instantaneous Time-dependent 
JR + Jo Elastic Elastic 
Compliance Jo Compliance JR 
(x10- 8 Pa-I) (x10- 8 Pa-I) (x10- 8 Pa- I ) 
24.332 12.700 11. 632 
19.080 15.963 3.117 
24.305 16.292 8.013 
19.011 14.503 4.508 
17.641 13.852 3.789 
28.169 24.661 3.508 
22.227 18.119 4.108 
n 7 7 7 
x 22.109 16.584 5.525 
SD 3.769 3.978 3.147 
%RSD 17.05 23.99 56.95 
% solids 
23.20 
5.80 
29.00 
Elastic Newtonian 
Modulus Viscosi ty 
Go no 
x107(Pa) x109 (Pa s) 
0.787 4.452 
0.626 12.156 
0.614 4.872 
0.690 14.136 
0.722 15.012 
0.406 9.625 
0.552 16.150 
7 7 
0.628 10.920 
0.125 4.762 
19.85 43.61 
Table 5.13. Discrete Mechanical Analysis of a Silicone Elastomer Film 
containing Silicone Emulsion:Colloidal Silica 4:1. 
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Free-Film Composition 
Excipient 
Silicone Emulsion X7-2837(A) 
Colloidal Silica X7-2837(B) 
Purified water BP to 
32.83 
17.06 
100.00 
Intercept on Y Instantaneous Time-dependent 
JR + Jo Elastic Elastic 
Compliance Jo Compliance JR 
(x10- 8 Pa-I) (x10- 8 Pa- I ) (x10- 8 Pa-I) 
11.132 9.063 2.069 
11.464 10.526 0.938 
30.531 16.232 14.299 
19.687 11. 493 8.194 
40.076 35.427 4.649 
34.801 33.281 1. 520 
36.389 19.753 16.636 
11. 488 9.503 1.985 
11.956 11.218 0.738 
18.830 15.487 3.343 
n 10 10 10 
x 22.635 17.198 5.437 
SO 11. 654 9.658 5.749 
%RSD 51.49 56.16 105.7 
% solids 
17.40 
2.90 
20.30 
Elastic Newtonian 
Modulus Viscosity 
Go no 
x10 7 (Pa) x109 (Pa s) 
1.103 4.470 
0.950 6.833 
0.616 4.321 
0.870 12.939 
0.282 5.654 
0.300 5.323 
0.506 2.845 
1. 052 8.817 
0.891 7.744 
0.646 3.733 
10 10 
0.722 6.268 
0.297 2.980 
41. 08 47.55 
Table 5.14. Discrete Mechanical Analysis of a Silicone Elastomer Film 
containing Silicone Emulsion:Colloidal Silica 6:1. 
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5.3.3. Graphical presentation and interpretation of creep compliance 
data. 
The formulations of the free-films studied may be classified into 
four groups according to the polymer type and the presence of plasticiser 
and other excipients within the films. 
5.3.3.1. Effect of plasticiser concentration on the mechanical properties 
of films containing the polymethacrylates. 
Figures 5.11 to 5.14 inclusive show the effect of the plasticiser 
(triethylcitrate) concentration on the mechanical properties of films 
prepared from aqueous dispersions of Eudragit RS30D and RL30D. Figure 
5.11 clearly shows that an increase in the plasticiser concentration 
within such films results in an enhanced instantaneous elastic 
compliance. It is pertinent to note that concentrations of plasticiser 
in excess of 3%w/w resulted in films which were inherently sticky in 
nature and indeed even at this level, under the working temperature of 
the coating chamber, would cause problems of pellet agglomeration. For 
the purposes of studying the tensile properties of films as a consequence 
of plasticiser presence however, it was possible to prepare free-films 
containing 3%w/w triethylcitrate. A plasticiser concentration of 
1.34%w/w (expressed as percent weight dry solids) was sufficient to 
enable complete film formation at approximately 43°C; quantities less 
than this however lead to problems in respect of the film forming 
temperature (see Chapter 3). 
Polymethacrylate films of the same composition, as anticipated, also 
show an significant increase in the time-dependent elastic compliance 
with increasing percent plasticiser. The effect of plasticiser on the 
tensile properties of polymeric films is to increase the both the 
instantaneous and the time-dependent elastic component with a 
corresponding reduction in the brittleness of such films. 
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Since the elastic modulus Go is inversely proportional to the 
instantaneous elasticity Jo, it is not unreasonable to expect a reduction 
In Go with increased plasticiser concentration. One of the consequences 
of increasing the plasticiser concentration of a given polymer film is to 
enhance the elasticity of that film; this is reflected in a corresponding 
reduction in the elastic modulus Go. This is confirmed by Figure 5.13 
which shows that by increasing the proportion of triethylcitrate in the 
polymethacrylate film there is a corresponding reduction in the elastic 
modulus. 
The Newtonian viscosity no of a viscoelastic material is derived 
from the late linear region of time-dependent elastic region of the creep 
compliance profile for a material under constant applied stress. 
Equation 5.16 indicates that the apparent Newtonian viscosity is in fact 
inversely proportional to IN, the non-recoverable viscous deformation. 
Hence a relatively low Newtonian viscosity is indicative of a relatively 
high non-recoverable viscous component. Figure 5.14 shows that with 
increasing plasticiser concentration for films containing the Eudragits, 
there is a reduction in the apparent Newtonian viscosity, but more 
importantly an Increase in the non-recoverable elastic component of such 
films under applied stress. The viscous compliance IN represents plastic 
deformation and arises when bonds are irreversibly broken and the initial 
structure becomes non-recoverable; this plastic deformation is permanent. 
In summary, increasing the plasticiser component of such films enhances 
plastic, non-recoverable deformation under applied stress. 
5.3.3.2. Effect of Syloid concentration on the mechanical properties of 
polymethacrylate films with constant plasticiser concentration. 
Figures 5.15 to 5.18 inclusive [each at constant plasticiser 
concentration of 2.67w/w (expressed as percent weight dry solids)], show 
the effect of the presence of Syloid 244FP on the mechanical properties 
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of free-films prepared from aqueous polymeric dispersions of Eudragit 
RS30D and RL30D. As previously discussed, the presence of Syloid 
(silicon dioxide) was a necessity in these polymethacrylate formulations 
in order to prevent pellet agglomeration and adherence of spheres to the 
coating chamber wall during the application of the dispersion. There are 
however associated problems as highlighted by these results. Zero or 
inadequate levels of this excipient result in very sticky films, even at 
room temperature. At 40 to 45°C these films are exceptionally sticky and 
it was not possible to coat pellets with polymethacrylate aqueous 
dispersions without this excipient as a component of the aqueous 
dispersion formulation. 
Interestingly, Figure 5.15 shows that the relationship between the 
instantaneous elastic compliance and the concentration and presence of 
Syloid in the film is not linear. Films containing 0% and 4% w/w Syloid 
show a significantly lower instantaneous elastic component than those 
containing 2%w/w Syloid. For films displaying a high instantaneous 
elastic component, one might at this stage anticipate problems which may 
arise as a consequence of compression of pellets coated with these 
formulations, since on removal of the force provided by the compreSSIon 
process, one might postulate that the instantaneous elastic recovery may 
be so great as to prevent the formation of a tablet of sound mechanical 
properties, In particular friability and diametral crushing strength. 
The situation is slightly different when consideration is made of 
the time-dependent compliance JR (Figure 5.16). Those films containing 
the relatively high Syloid concentration of 4%w/w, exhibit a lower time 
dependent elastic component than those containing 0 and 2%w/w. 
The elastic modulus Go (being a reciprocal of the instantaneous 
elasticity Jo) of the film containing 4%w/w Syloid is higher than that 
containing 2% and lower than Go for films containing O%w/w silicon 
dioxide (Figure 5.17). For a series of polymethacrylate films containing 
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constant plasticiser content (Figure 5.17): with O%w/w silicon dioxide 
concentration the film was exceptionally sticky even under standard 
conditions of room temperature (reflected by the relatively high elastic 
modulus); with 2%w/w silicon dioxide the film displayed the greatest 
elasticity, both instantaneous and time-dependent and this is supported 
by a relatively low elastic modulus; at 4%w/w silicon dioxide the film 
exhibited a relatively low time-dependent elastic component (Figure 5.16) 
(again this is reflected in the elastic modulus value determined for this 
film). 
Of tremendous importance and interest are the apparent Newtonian 
viscosity values (Figure 5.18). The 4%w/w-Sylo-id containing film 
exhibits a significantly greater apparent Newtonian viscosity than the 
other two film formulations; this is indicative of a reduced 
non-recoverable elastic tendency on the application of load. 
For the three films formulations represented in these figures 
therefore, least permanent and non-recoverable damage is caused to that 
film containing 4%w/w Syloid than for those containing 2%w/w and O%w/w 
Syloid. At these latter Syloid concentrations there is greater tendency 
for permanent, non-recoverable, plastic deformation under applied stress. 
This parameter is of tremendous importance when selecting a suitable 
polymeric film composition, for application to pellets which are to be 
subjected to compression into tablets and for which film coat damage is 
to be prevented at best, or minimised at worst. 
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5.3.3.3. An overview of the effect of the presence and concentration of 
plasticiser and Syloid on the mechanical properties of 
free-films containing the polymethacrylates. 
Figures 5.19 to 5.22 summarise the effect of the presence and 
concentration of both triethylcitrate and Syloid 244FP in free-film 
Eudragit formulations prepared using the rotating PTFE cylinder technique 
described previously (section 5.2.2). 
Figure 5.19 illustrates that the effect of plasticiser concentration 
on the instantaneous elastic compliance is less significant than the 
presence and concentration of other excipients, notably in this 
situation, Syloid 244FP. A decrease in the Syloid concentration or an 
increase in the plasticiser concentration in films composed of the 
polymethacrylates has the effect of increasing the time-dependent elastic 
compliance of these free-films (Figure 5.20). 
Figure 5.21 illustrates the fact that the presence and concentration 
of adjuvents in polymeric film formulations has a significant influence 
on the elastic modulus Go of free-films. Indeed the presence of 
additional excipients within the composition of the film may make a major 
contribution to the mechanical properties, as well as to the processing 
conditions during film application, reasons for which these additional 
components were originally incorporated. Figure 5.22 shows that at high 
plasticiser concentration (3%w/w triethylcitrate) the apparent Newtonian 
viscosity is relatively high (17.074 X 109 Pa s) and it may therefore be 
concluded that there is a correspondingly low non-recoverable elastic 
deformation associated with these films under stress. Low or zero syloid 
concentrations result in films exhibiting low apparent Newtonian 
viscosities and a correspondingly relatively high tendency for plastic, 
permanent deformation under the application of stress. These films are 
however relatively less brittle (at constant plasticiser concentrations) 
than those films with a high Syloid content. 
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A film containing 0% Syloid and 2.67%w/w triethylcitrate exhibits a 
degree of tackiness and stickiness; this becomes less of a problem with a 
increasing Syloid concentration. At 4%w/w Syloid there IS no tackiness 
associated with either the free-film or that applied to pellets using the 
fluidised bed apparatus and technique described previously. 
5.3.3.4. Effect of the polymer on the mechanical properties of 
free-films. 
Figures 5.23 to 5.26 inclusive gIve an overview of the mechanical 
properties of those films applied as aqueous polymeric dispersions to 
ibuprofen pellets. 
Figure 5.23 shows that the Silicone Elastomer formulations and the 
Surelease (ethylcellulose) film exhibit an extremely high instantaneous 
elastic compliance. With increasing silicone to silica ratio in the 
Silicone Elastomer formulations there is a corresponding increase in the 
instantaneous elastic component; there are also problems with these films 
associated with the high instantaneous elastic recovery and thus a 
greater susceptibility of these films to environmental conditions. Any 
environmental vibrations, however small, have a deleterious effect on the 
quality of the data obtained; this is in fact illustrated by the large 
error bars associated with the data exposed graphically In Figures 5.23 
and 5.24. Also, in order to achieve a film penetration of less than 6 
micrometers, it was necessary to use'an indenting load of 0.5g for the 
elastomer films composed of silicone to silica ratios of greater than 
2:1. These formulations are exceptionally sensitive to applied stress; 
this is reflected in the instantaneous and the time-dependent elastic 
compliance data. The polymethacrylate formulation shown in these figures 
is that containing 2.67%w/w triethylcitrate and 4%w/w Syloid. This 
Eudragit formulation represents that film formulation which was applied 
to pellets which were subsequently compressed satisfactorily. 
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Consideration of Figures 5.23, 5.24 and 5.25 yields information 
relating to those film properties necessary to withstand applied stress 
associated with pellet compression. The integrity of both the polymeric 
membrane and the pellet cores must remain intact in spite of the 
compression process. 
Pellets coated with the Silicone Elastomer films were not 
compressible; reasons for this are discussed in detail in Chapter 7 
(section 7.3). Briefly, the Silicone Elastomer coated pellets achieved 
such an instantaneous elastic recovery following release from the punches 
and die that they collapsed immediately into a mass resembling that 
blend from which the tablets were intended to be composed. This scenario 
occurred even under extreme compaction pressures; details of which are 
given in section 7.2. Reasons for this appear to be attributable to the 
high instantaneous and time-dependent elastic components exhibited by 
these films. Initially, on selecting potential aqueous polymeric release 
retarding dispersions, it was postulated that those systems exhibiting a 
high degree of elasticity may be those affording the greatest protection 
to pellets on compression. These results however indicate that those 
polymers displaying relatively high elastic tendencies, have associated 
problems in respect of instantaneous recovery on removal of the applied 
stress. 
The Surelease (ethylcellulose) film, as illustrated by Figure 5.23, 
exhibits high instantaneous elastic deformation and recovery; this 
polymer actually displayed the greatest instantaneous elasticity of any 
formulation studied (20.34 x 10- 8 Pa- l ). Its time-dependent component, 
although greater than the polymethacrylate film and the Silicone 
Elastomer film (2:1), was considerably less than that exhibited by the 
4:1 and the 6:1 elastomer formulations. Unfortunately, Sure lease-coated 
pellets exhibited a tendency towards sticking during the coating process. 
although careful optimisation of the coating conditions facilitated a 
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satisfactory coating process. Disadvantages of the Surelease aqueous 
formulation however were further compounded by the fact that it was 
necessary to overcoat the polymer film with a film of Opadry (composed of 
HPMC, PEG 400 and PEG 6000). "The overcoat formulation is necessary to 
prevent the phenomenon of blocking (pellets loosely adhering to one 
another) after the coating process. The resulting clumps of pellets may 
cause inconsistent film thickness which could contribute to variable 
release rates" (Surelease product literature, Colorcon, 1985). 
In summary, Surelease films exhibit a high degree of elasticity, the 
greatest component being instantaneous rather than time-dependent, on the 
application of stress. Surelease films therefore have a lower elastic 
modulus (Figure 5.25) and they also exhibit the lowest Newtonian 
viscosity (Figure 5.26) of all the formulations studied. In line with 
this low Newtonian viscosity, as a consequence of the relationship 
between this parameter and non-recoverable plastic deformation, the 
Surelease film is therefore most susceptible to permanent non-recoverable 
damage under applied stress. 
5.4. Conclusions. 
Indentation hardness testing provides a valuable means of assessing 
the tensile properties of polymeric films. 
The analysis of elastic and plastic deformation of polymer films 
induced by an indenter tip is however influenced by a number of 
parameters. Films must be of uniform thickness, free from entrapped air, 
of uniform surface characteristics and samples must be large enough such 
that each indentation occurs on a fresh area of film. The effect of 
environmental conditions on the microindenter must also be carefully 
controlled. Any surface vibrations or air disturbance will have a 
considerable effect of the quality of the data obtained, in particular 
for those films which are extremely elastic and are therefore sensitive 
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to applied stress. All of these variables were carefully controlled 
during the quantitative evaluation of these films. 
It was considered that although such a technique IS influenced by a 
variety of factors, that indentation testing does provide a valuable 
means of evaluating the mechanical properties of polymers and the effect 
of the presence of other excipients within the polymeric film. This 
technique is of particular value within the scope of this work. whereby 
polymer coated pellets are subjected to applied stress by means of 
compression into tablets. 
Valuable parameters which may be quantified using this technique of 
particular interest and usefulness In respect of this work include the 
instantaneous and time-dependent elastic deformation and recovery, the 
elastic modulus and the Newtonian viscosity. 
The apparent Newtonian viscosity of a film gIves an insight into how 
the polymer behaves under applied stress and is associated with the 
compliance of non-recoverable deformation. It is obtained from the late 
linear region of the creep compliance curve (Figure 5.6). The Newtonian 
viscosity of a material is inversely proportional to the non-recoverable 
viscous deformation (Equation 5.16). Hence a film exhibiting a large 
non-recoverable viscous deformation on the application of stress, will 
have a correspondingly low apparent Newtonian viscosity. 
The instantaneous elastic compliance of a material is the reciprocal 
of the elastic modulus. Those materials displaying a relatively high 
instantaneous elastic component will therefore exhibit a relatively low 
elastic modulus. 
In a given polymeric film formation the effect of increasing the 
plasticiser content, is to enhance the instantaneous and the time-
dependent elastic components; there is a corresponding decrease in the 
elastic modulus and the apparent Newtonian viscosity. That is to say 
that the permanent non-recoverable plastic deformation associated with 
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applied stress, increases with increasing plasticiser concentration. 
The presence of other excipients within a polymeric film other than 
the polymer itself and the plasticiser may also exhibit a considerable 
influence on the mechanical properties of a given polymeric film 
formulation. In this work, the presence of silicon dioxide within the 
polymethacrylate film has a tremendous influence on the mechanical 
properties of such a system. These effects are product specific and it 
is not feasible to make generalisations regarding the influence of these 
additional components on the resultant mechanical properties of films 
containing such excipients. Suffice to state that a consequence of the 
addition of silicon dioxide to polymethacrylate films is a significant 
influence on the elastic parameters and that the effect is concentration 
dependent. 
It is evident from this study of the mechanical properties of 
polymeric films, in conjunction with the study discussed in Chapter 7 
regarding the effect of compression on tablet formulation and pellet core 
and film coat integrity, that polymeric films exhibiting a relatively 
high elastic compliance, both instantaneous and time-dependent (Silicone 
Elastomer films with a high silica to silicone ratio and also Surelease 
films) are unlikely to satisfy the requirements for favourable tablet 
preparation due to this associated elastic recovery occurring immediately 
on removal of the applied stress. 
It may also be concluded that those films exhibiting a relatively 
high elastic modulus (polymethacrylate films) and a relatively high 
apparent Newtonian viscosity (polymethacrylate films and Silicone 
Elastomer films containing a low silicone to silica ratio) provide 
greatest protection to the pellet core and to the film coat on pellet 
compression. 
Within the scope of this work, of those aqueous polymeric film 
coating systems evaluated, the polymethacrylate (EudrA~it) dispersion 
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appeared to form a more favourable film suitable for coating ibuprofen 
pellets, which must be able to withstand compression into tablets. 
The effect of the compression process on the ability of coated 
pellets to withstand applied stress and the effect on the integrity of 
the film coat and the pellet core is discussed in Chapter 7. 
It was considered necessary not only to evaluate and quantify the 
tensile properties of polymers as free-films but also to study the 
tensile properties of the pellet core and the polymeric membrane in-situ, 
since the process of pellet compaction involves the application of stress 
to polymer coated pellet cores. Chapter 6 IS a study of the mechanical 
properties of uncoated and coated pellets. Using a Single Particle 
Crushing Assembly (Figure 6.4) the force required to cause single pellet 
fracture and the particle displacement under applied load were 
quantified. Yielding this information facilitated calculation of the 
tensile stress, per cent strain and work done in causing pellet fracture 
for the various formulations. Calculation of the elastic modulus of 
these discrete units was therefore made possible having quantified these 
parameters. 
It was postulated that by gaInIng an insight into the tensile 
properties of these coated pellet formulations that it would be possible 
to design a compacted pellet tablet formulation in which the compreSSIon 
process had minimal effect on the integrity of pellet cores, the 
polymeric membrane and as a consequence, the drug release mechanism from 
these multiparticulates. 
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CHAPTER 6 
A STUDY OF THE MECHANICAL PROPERTIES OF UNCOATED 
AND COATED PELLETS 
20.+ 
6.1. Introduct ion. 
As tabletting excipients and processing variables affect the 
physical strength of granules and tablets, so these factors affect the 
mechanical strength and tensile properties of pellets. 
6.1.1. Mechanism of particle fracture. 
Particles must be stressed in order that fracture is produced. When 
stress (force per unit area) IS applied to a solid, the solid undergoes 
strain (ratio of change in a given dimension to its original value). An 
elastic material deforms under stress but returns to its original shape 
when the stress is removed. Hooke's Law states that stress is directly 
proportional to strain; the ratio of stress to strain gives the elastic 
modulus of that material. If a particle is stressed to too great an 
extent, failure occurs and the solid fractures at a stress known as the 
tensile strength. The behaviour of a plastic material is shown in 
Figure 6.1. 
Fracture strength 
Stress ~ Plastic deformation 
-------
\ 
Elastic deformation 
Strain 
Figure 6.1. Stress-strain curve for a plastic material. 
Initially within the elastic limit of the particle, the stress IS 
proportional to the strain according to Hooke's Law. As the stress is 
increased. the elastic limit of the material is exceeded and at the yield 
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point and permanent deformation occurs. With the application of further 
stress, within the region of irreversible plastic deformation. the 
stress-strain curve is non-linear. As the stress is yet further 
increased particle fracture occurs. 
When the application and release of stress causes permanent 
deformation, energy is expanded and cracks will be initiated in the 
solid. The furthest extension of a crack is the point of greatest 
stress. As real particles have irregular surfaces, the force is 
initially applied to the higher portions of the surface and consequently 
high stresses and temperatures exist locally. As fracture occurs, the 
points of application of force shift. Stress waves caused by the initial 
fracture release energy producing other regions of high stress from which 
new cracks or fracture may occur (Swarbrick and Boylan, 1990). 
A "perfect" particle is composed of planes of molecules or Ions 
which are separated by equal intermolecular attractive forces. When 
stress is applied, the intermolecular bonds may be stretched, but any 
molecule still has a balance of forces on it. However Figure 6.2 shows 
that movement away from the non-stressed equilibrium against attractive 
forces requires additional energy and the solid reaches equilibrium at a 
higher energy state (stored strain energy). The maximum attractive force 
that the solid can exert on the surface layer IS the inflection point of 
the potential energy curve (Figure 6.2). 
An external force in excess of this maxImum causes an imbalance of 
forces and acceleration of one plane of molecules away from another. 
The "perfect" particle would then disintegrate into individual units. A 
real particle however fractures under less force than a "perfect" 
particle into a few relatively large particles and a number of fine 
particles with relatively few particles of intermediate size. 
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Potential 
Energy 
Repulsion 
Attraction 
Inflection point 
Unstressed 
Separation Distance 
Figure 6.2. Diagrammatic illustration of the total potential energy 
against distance of separation. 
Crack 
No stress 
• stress concentrated at smallest 
radii of curvature 
Figure 6.3. Crack concept and effect of radius of curvature 
(Swarbrick and Boylan, 1990). 
It is postulated that the SIze of the large particles IS related to 
the mechanism causing pellet fracture and that the size of the finer 
particles is related to the structure of the components from which these 
particles are composed. The presence of flaws or cracks leads to areas 
of weakness; damage would occur at these areas under lower stress than 
for a "perfect" particle. Stress concentrates in the region with maximum 
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curvature or the smallest radius of curvature (Figure 6.3). The stress 
intensifies as the length of the crack is increased and the crack becomes 
narrower. The tensile strength of a particle is significantly affected 
by the presence of cracks and flaws, SInce as the crack progresses on the 
application of stress, extra energy becomes available to accelerate the 
crack tip, the system becomes unstable and the crack progresses at high 
velocity. 
The bulk stress does not have to be sufficient to break all the 
bonding forces "simultaneously" because only the bonds about the crack 
tip are breaking at any instant. The presence of many flaws close 
together will further reduce the tensile strength. 
Plastic materials deform due to the sliding of planes of the solid 
over one another caused by the movement of dislocations under stress. In 
plastic behaviour the intermolecular forces between planes are not all 
broken at once; only enough bonds are broken to enable the dislocations 
to move to another position. Bonds reform behind the dislocation. This 
process continues leading to the slip of one plane over another. When 
plastic yield has occurred, the plastic slip may cause part of the solid 
to act as a wedge, creating tensile forces which may then propagate 
brittle fracture. In addition, the movement of dislocations may 
accumulate dislocations at a grain boundary, leading to the formation of 
a small hole. 
Plastic materials are generally stronger than brittle materials; 
however once fracture is initiated the energy may decrease as the crack 
moves at high velocity in relation to the movement of dislocations and 
conferred plasticity. 
Brittle fracture IS essentially temperature independent, whereas 
plastic materials decrease in strength as the temperature is increased 
due to the greater mobility of dislocations. For a brittle material, a 
smaller particle has less of a probability of having a large flaw and 
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will be relatively stronger than a larger particle with more flaws. The 
rate of stress application IS more crucial with plastic materials than 
brittle materials, since a fast rate of stress will cause brittle 
fracture, whereas a slow rate of stress application may provide time for 
plastic behaviour. 
Bemrose and Bridgwater (1987) state that all particles contain 
weaknesses in the form of micro-cracks or cracks and that all normal 
particle structures will contain imperfections, dislocations and 
impurities. This, the authors claim, leads to non-uniform mechanical 
behaviour in the deformation or compression and subsequent fracture of 
particles. Bemrose and Bridgwater also state that the breakage strength 
of particles increases markedly as the diameter decreases since the size 
of the flaws and micro-cracks becomes smaller at smaller particle sizes. 
6.1.2. Review of particle crushing techniques. 
Techniques reported to date for measuring the mechanical strength of 
particles are varied and range from simply crushing granules with a 
spatula to more sophisticated apparatus. 
Harwood and Pilpel (1968) describe a simple technique involving 
measuring that weight of lead shot necessary to crush granules of 
Griseofulvin. They showed a linear relationship between breaking load 
and surface area of granules. These authors and others report a 
considerable degree of scatter in considering any relationship between 
granule strength and size, however expressed. Ganderton and Selkirk 
(1970) used a spatula to ascertain the crushing strength of granules 1n 
studying the effect of granule properties on the pore structure of 
tablets. 
Gold et al. (1971) described the use of an apparatus consisting of a 
motor-driven cam with a cantilever beam and strain gauges to determine 
the granule strength. A compressive load proportional to a millivolt 
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response was applied to the granule which was measured on a recorder. 
Ganderton and Hunter (1971) measured granule strength by determining 
resistance to fracture. This involved using a miniature press with a 
moving lower platen and a fixed upper platen to which a load cell was 
attached. They discussed the effect of preparing granules by pan 
granulation and by massing and screening which included a study of the 
effect of processing variables on the work done in crushing such 
particles. 
Erni and Ritschel (1977) describe a pIece of apparatus based on a 
vertical, modified disposable syrInge. Preliminary work involved 
determining the pressure resistance of granules by the addition of 
weights into the plunger part of the syringe container. Pressure 
resistance was measured by using a load less than that determined 
necessary by the pre-test to crush the particle, to which water is added 
from a burette into the syringe until fracture occurred. The load 
required to crush the granule was then calculated from the sum of the 
weights and the volume of water added to the system. 
Ahuja (1977) studied the critical stresses of brittle and ductile 
polymeric spheres. This author describes a single-particle crush 
apparatus utilising strain gauges. The strain indicator sends a signal 
on deflection of a metallic strip, which is expressed as an amplified 
voltage and fed to a chart recorder. A glass probe was inserted through 
the metallic strip which was sensitive to vertical and horizontal 
displacement. Even for chemically homogeneous small spheres it was 
anticipated that there would be a distribution of particle strengths as a 
result of the inherent morphological characteristics, micro-cracks or 
small voids. 
Krogh (1980) discussed a method based on drop weights as a technique 
for crushing particles. This author illustrated that particles of the 
same size do not possess the same tensile strength. 
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Kuno and Okada (1982) studied the compaction process and the 
deformability of granules. They summarised their work by claiming that 
crushing a particle is composed of two sequential stages; the first stage 
involving rearrangement and deformation of particles and second to this. 
the crushing stage. Properties of the granules including the porosity 
and elasticity, affect that stress which must be applied to cause 
particle fracture. These authors describe apparatus for measuring 
strength and deformability of single granules. Load IS applied to the 
granule by pouring water from a reservoir into a bucket hanging on a 
lever. Stress applied to the granule was detected by a transducer on 
which the granule was placed. A transformer detected any displacement of 
the diameter of the particle which was expressed as linear shrinkage by 
these authors. 
Jarosz and Parrott (1983) described a method for measuring the 
crushing strength of granules. This technique involved the use of glass 
syringes which were modified to act as a load cell to which mercury was 
added from a reservoir until the granule was crushed. 
Tanaka et al. (1985) described equipment used in the determination 
of crushing strength of ferrite particles. A Rockwell Hardness Tester 
was employed. Load was applied to the particles manually and the crush 
load monitored by a load cell underneath the lower anvil. The crushing 
force was read from a recorder from which crushing stresses were 
calculated. Results were expressed graphically as crushing stress (MPa) 
against particle size (micrometers). A great degree of scatter was 
evident. This scatter was explained as being attributive to crack 
initiation occurring in the vicinity of that part of the particle in 
contact with one of the anvils. The implication being that plastic 
surface penetration at the contact surface is the cause of the crack 
initiation. The authors in fact confirmed that the crushing stress of 
ferrite is related to the fundamental hardness of the material and is 
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independent of particle size. 
Wan and Jeyabalan (1986) described the use of a simple technique to 
measure the crushing strength of spherical granules involving water 
flowing slowly from a reservoir into a plastic container placed on a 
pellet. The weight of water required to cause pellet fracture was 
interpreted as the crushing strength of that particle. 
The aim of this present study involving the a determination of the 
crushing characteristics of both placebo and active pellets containing a 
high ibuprofen content was to acquire an insight into the physical 
strength and elasticity of such formulations. This information was 
required in order that a suitable pellet formulation may be designed, 
such that the integrity of the pellet cores and that of an applied film 
coating may be maintained even during compression of pellets with an 
inert diluent blend into tablets. 
The mechanical strength of a pellet is related to the nature of the 
excipients from which it is composed, the cross-sectional area, the 
quality of the geometry of the sphere and inherent physical parameters 
determined by the manufacturing process; these include massing, extrusion 
and spheronisation variables and the drying method employed. These 
parameters all contribute to the elastic, plastic and fragmentary 
properties of the pellets. Pellet porosity and density are also affected 
by these variables associated with the manufacturing technique. 
6.2. Methods. 
6.2.1. Single Particle Crushing Assembly. 
Determination of the tensile properties of pellets, active and 
placebo, uncoated and coated, was facilitated by determining the force 
required to cause pellet fracture using the Single Particle Crushing 
Assembly. The use of this technique yielded quantitative information 
relating to the crushing strength, pellet displacement under applied 
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stress , percent age s t ra in and the elastic modulus of pellets. These 
parameters were sought in orde r to s tudy those formulation factors 
influencing the tensile propert i es of uncoated pellets, the manufacturing 
technique and the effect of film coat ing of pe ll et s on the r esultant 
mechanical properties . 
Figure 6.4. Photographic illustration of the Single Particle Crushing 
Assembly. 
The Single Particle Crushing Assembly (Figure 6.4) consisted of a 
highly sensitive load cell (U-4000, Maywood Instruments Ltd. Basingstoke ) 
which was sensitive to a maximum load of SON and capable of a high 
dynamic response as a result of a low deflection under load. Th i s 
particular load cell used transducer strain gauges in a ful l br idge 
configuration bonded to a transduction element. A motor i sed un it to 
which an upper brass pointer was connected , was se t t o approach the 
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pellet mounted on a lower platen at a given rate. The load applied to 
the pellet was detected by the strain gauges, converted into a millivolt 
response and recorded on a calibrated X-V chart recorder. An excitation 
energy of 10 volts was maintained throughout. Figure 6.5 is a schematic 
representation of the Single Particle Crushing Assembly. 
The chart recorder was calibrated so that displacement of the pellet 
under applied load was reflected on the x-axis; a Imm diameter pellet 
displacement being equivalent to 100mm on the chart recorder. 
Similarly the load applied to each pellet was recorded on the 
y-axis; a force of SN was represented by a distance of 100mm on the chart 
recorder. Pellet diametral measurements were made in the X and the Y 
plane using a digital micrometer (Mitustoyo, Japan); the mean diameter of 
each randomly selected pellet was therefore determined. 
Determination of pellet dimensions together with quantitative 
information in respect of the applied load and as a consequence particle 
displacement, enabled calculation of pellet cross-sectional area, applied 
stress and strain, work done in causing particle fracture and the 
relative elasticity of those formulations under test. 
That force causing pellet fracture is represented on the X-V chart 
recording by a maximum peak just prior to fracture. For a pellet 
fracturing into many progeny units, the break will manifest itself as a 
sharp peak on the chart. For a pellet showing very little fragmentation 
after crushing, resulting in a fewer, larger particles, the peak 
representing the fracture may not necessarily be the highest point on the 
chart, since further application of force to the fractured material will 
result in further fragmentation of the progeny particles. 
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Figure 6.5. Schematic illustration of the Single Particle Crushing 
Assembly. 
6.2.2. Determination of the tensile properties of pellets as a 
consequence of fracture under applied load. 
On application of a force (F) to a particle of diameter (D), the 
particle will exhibit a degree of deformation or displacement (d), in the 
direction of that force. The work done (Nm) in causing particle fracture 
may therefore be defined as the product of that force (N) causing 
fracture and displacement (m) in the direction of the applied force 
(Equation 6.1): 
work done = force x displacement Equation 6.1. 
With this technique force IS being applied to a spherical particle and 
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therefore the work done in causing pellet fracture is represented by the 
area under the force-displacement peak on the X-Y chart recording. 
The force per unit area (FjA) producing the deformation of a solid 
particle is termed the tensile stress (0). For a spherical particle or 
pellet therefore, tensile stress may be defined as follows: 
force 4F 
stress = = Equation 6.2. 
maxImum cross-sectional area nD2 
The elastic deformation exhibited by a particle on the application 
of load is termed the strain, which may therefore be defined as the 
relative change in dimension in the direction of the force. 
The linear tensile strain (or relative elongation or displacement) 
E, exhibited by a sphere on the application of load is therefore defined 
as the change in diameter (or pellet displacement) in the direction of 
the applied force (Equation 6.3). 
displacement 
strain E = Equation 6.3. 
diameter 
The units of displacement and diameter are both units of length and 
strain is thus a dimensionless parameter. 
The elastic modulus of a material may be defined as the ratio of 
tensile stress to linear strain, since for elastic material there is a 
linear relationship between these two parameters 
o = E E Equation 6.4. 
where E is the elastic modulus. 
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Substituting Equation 6.2 into Equation 6.4 therefore 
F 
= 
A 
4F d 
=E-
D 
Equation 6.5. 
where d is the displacement exhibited by a pellet of diameter D. on the 
application of force. E IS the proportionality constant or the elastic 
modulus of the material. 
6.2.3. Composition of pellet formulations studied. 
Precise formulation and manufacturing details for those pellet 
formulations studied are gIven in Chapter 3. 
Briefly, uncoated pellets were manufactured USIng the technique of 
extrusion-spheronisation using either bench or pilot scale massing and 
spheronisation equipment, and an Alexanderwerk GA65 Extruder. Pellets 
were dried USIng Aeromatic fluidised bed apparatus (of IL or 10L 
capacity), or by tray drying in a hot air oven. The film coating of 
ibuprofen pellets using aqueous polymeric dispersions of different 
polymers is discussed previously in Chapter 3. Pellets were film coated 
using a IL Aeromatic fluidised bed apparatus with a stainless steel 
chamber and top spray attachment. 
A study of the tensile properties of placebo and ibuprofen-
containing pellets in respect of formulation factors, scale of the 
manufacturing equipment used, drying technique and the presence or 
otherwise of a film coat, was facilitated using the Single Particle 
Crushing Assembly described in this work. In addition to obvious reasons 
for studying the aforementioned variable parameters, determination of the 
tensile properties of pellets was necessary within the scope of this work 
involving a presentation of a monolithic drug delivery device composed of 
polymer coated multiparticulates, in order to ascertain the relative 
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mechanical properties of these units. Identification of those pellet and 
film coating formulations able to withstand the compression process was 
necessary in order to at least minimise or at best prevent, an impairment 
of the integrity of both the polymeric membrane and the pellet core as a 
consequence of compression into tablets. 
6.3. Results and Discussion. 
The resistance of individual particles to crushing is related to the 
excipients from which they are composed, their geometric size and shape, 
and any physical parameters incorporated as a result of the manufacturing 
process. 
The physical properties of pellets are influenced by many factors 
including the volume of the granulating fluid; variables associated with 
the mixing/massing processing procedure; the size of the holes of the 
perforated screen and the rate of extrusion of granulate; the 
spheronisation plate weight, residence time and rotation speed; the 
drying technique and therefore the length of the drying process. 
Whichever combination of these parameters exists for any given pellet 
formulation, there will be an influence on the matrix structure and the 
elastic, plastic and fragmentary properties of the resultant product. 
6.3.1. Effect of drug loading on the tensile properties of uncoated 
pellets dried using fluidised bed apparatus. 
Table 6.1 summarises the mechanical properties of uncoated pellets 
containing ibuprofen which were dried using fluidised bed apparatus. 
These parameters were calculated using the data obtained from the 
force-displacement curves, as described in section 6.2.2. A mean of 
approximately forty pellets were evaluated using this quantitative 
fracture test. Graphical evaluation of the data indicated that there 
appeared to be a direct linear relationship between pellet crushing force 
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and diameter; work done in causIng pellet fracture and displacement on 
the application of stress; % strain and pellet displacement: crushing 
force and work done and work done and % strain. There was however a 
substantial degree of scatter in these plots (Appendix II). The quality 
of the spheres, defects in surface characteristics including irregularity 
of shape or penetrative cracks in pellets, the internal pore structure 
and the skeletal density of pellets are all factors which may 
realistically have contributed to this scatter. It was considered that 
the information provided by such graphical interpretations was of limited 
value in isolation and that tensile properties could better be expressed 
either tabulated or In the form of a comparative illustration (as a 
histogram) for a range of related pellet formulations. Using the 
available pellet particle size range therefore (determined largely by the 
screen size of the perforated cylinder of the extruder), mean values were 
determined for the force required to cause pellet fracture, pellet 
displacement, work done, % strain, stress and the elastic modulus for 
pellets of mean particle size. This form of data manipulation enables 
comparative evaluation of the tensile properties of pellets as a 
consequence of formulation factors and processing variables. 
Table 6.1 clearly shows the effect of drug loading and the 
corresponding microcrystalline cellulose (Avicel PH101) content of 
uncoated pellets containing ibuprofen on the tensile properties of 
pellets dried using fluidised bed apparatus. A decrease in the drug 
content with a corresponding increase in the quantity of microcrystalline 
cellulose content of uncoated ibuprofen pellets results in pellets of 
greater mechanical strength (Figure 6.6) exhibiting greater displacement, 
% strain and stress and for which more work is required to cause pellet 
fracture. Figure 6.7 shows that with decreasing Avicel content there is 
a corresponding increase in the elastic modulus representing a decrease 
in the pellet elasticity. The presence of increased microcrystalline 
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cellulose content in pellet formulations has the effect of enhancing the 
cohesion between the components of the blend, therefore those pellets 
containing only 20%w/w Avicel PH101 are less robust and more elastic than 
those containing 40%w/w Avicel PH101. 
In summary, pellets containing a high ibuprofen content exhibit the 
greatest elasticity although the force required to cause pellet fracture 
is less than for those containing the higher microcrystalline cellulose 
content. 
The significance of the drying technique used in the preparation of 
pellets containing ibuprofen (poorly water soluble) and in placebo pellet 
manufacture, with a highly water soluble component (lactose) is discussed 
in section 6.3.2. 
%w/w ibuprofen 
80 70 60 
bead diameter 1107 1091 1125 
(/lm) ·935-1230 976-1212 979-1249 
crushing 2.59 3.45 4.91 
force (N) 1. 30-3.28 2.03-4.88 3.00-7.13 
displacement 86 89 92 
(/lm) 55-145 60-125 45-120 
work done 113 155 229 
(/lJ) 36-202 75-233 74-428 
% strain 7.79 8.16 8.17 
4.58-12.7 5.5-11.89 4.09-10.34 
stress(MPa) 2.72 3.71 4.94 
1.15-3.88 2.28-5.25 2.94-6.36 
n 47 46 48 
NB: all values represent the mean of n samples 
• = range values 
Table 6.1. Effect of drug loading on the mechanical properties of 
uncoated pellets containing ibuprofen. 
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Figure 6.6. Effect of drug loading on the mechanical strength of 
ibuprofen pellets dried using fluidised bed apparatus. 
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Figure 6.7. Effect of drug loading on the elastic modulus (MPa) of 
ibuprofen pellets dried using fluidised bed apparatus. 
221 
6.3.2. Effect of the drying technique on the tensile properties of 
uncoated pellets containing ibuprofen and placebo pellets. 
Tables 6.2 and 6.3 summarise the tensile properties of active 
pellets containing a high percentage of a poorly water soluble drug and 
placebo pellets containing lactose dried by tray drying in a hot aIr 
oven and by fluidised bed methodology. Precise details relating to the 
drying temperatures and times are given in Chapter 2 (section 2.2). 
The main differentiating factor between the two drying methods IS 
the rate of water removal from the pellets. Those pellets dried using 
fluidised bed apparatus achieve the desired moisture content under the 
previously stated drying conditions in a much shorter time, due to the 
rapid evaporation of water from the fluidised particles. 
Water removal from tray dried material is slow by virtue of the fact 
that poor heat and mass transfer is associated with material which IS 
static. The fluidised state of the bed enables water removal from 
individual particles rather than from the bed as a whole. Water removal 
from fluidised particles therefore is more rapid and occurs at a more 
constant rate. Water removal from static particles in a hot air oven 
occurs initially from the surface of the bed and gradually all particles 
including those at the bottom of the bed will achieve an equilibrium 
moisture content. There is however a danger with tray drying that 
overheating of those particles at or near the surface of the bed may 
occur, hence a lower drying temperature is used. 
The free movement of individual fluidised particles leads to rapid 
water removal and minimises the migration of solute particles within the 
pellets; tray dried pellets are more likely to exhibit solute migration 
during the lengthy drying process. Pellets containing lactose, which is 
freely soluble in the granulating fluid, are highly susceptible to the 
process of solute migration as a consequence of the drying times 
associated with static bed dryers. 
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During the drying process any residual moisture 1n the product leads 
to the formation of solid bridges in the granules by fusion at the point 
of contact. For solute particles (for example lactose, dissolved in the 
granulating fluid), crystallisation of the dissolved particles will cause 
a greater of bonding and hence a mechanically stronger particle. Placebo 
pellets therefore are mechanically stronger than drug-containing entities 
(c.f. Figures 6.8 and 6.10). The drying method also has an effect on the 
elastic modulus of both ibuprofen-containing pellets and placebo pellets 
(Figures 6.9 and 6.11). Ibuprofen is virtually insoluble in water and it 
is reasonable to expect little re-crystallisation of solute particles 
during the drying process. Conversely lactose is freely soluble: 
lactose-containing pellets exhibit a high degree of solute migration and 
crystallisation during the drying process. This leads to mechanically 
stronger, less elastic, brittle particles (Figures 6.8 to 6.11). 
Slower water removal from ibuprofen-containing pellets by tray 
drying rather than fluidised bed drying, leads to limited solute 
migration as a consequence of the aqueous solubility of this drug. This 
is supported by the relative drug release rates as indicated by the 
in-vitro dissolution profiles (Figure 2.17). Drug release from tray 
dried pellets is slightly enhanced when compared with that from fluidised 
bed dried particles. 
In summary, the drying technique for a g1ven uncoated pellet 
formulation has a significant effect on the tensile properties of pellets 
prepared by extrusion-spheronisation methodology. Pellets dried by tray 
drying require a greater crushing force and the work done in causing 
pellet fracture is therefore greater. Tray dried entities also exhibit 
greater displacement prior to fracture and are able to withstand greater 
strain and stress than the fluidised bed dried entities. Fluidised bed 
dried pellets however demonstrate greater elasticity; this is reflected 
in the relatively low elastic modulus values obtained. 
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The solubility of the excipients from which pellets are composed 
affects the degree of solute migration occurring during the drying 
process. The drying method, and as a consequence the length of the 
drying process, also affects the degree of solute migration and is 
highlighted by the in-vitro release profile for ibuprofen pellets dried 
using these two methodologies. 
Drying Method 
fluidised 
tray bed 
bead diameter 1093 1086 
(Ilm) *881-1269 878-1343 
crushing 2.81 1. 91 
force (N) 0.9-4.25 1.0-3.05 
displacement 88 67 
(Ilm) 65-170 40-110 
work done 127 67 
(Ill) 32-298 23-167 
% strain 8.1 6.2 
6.3-15.1 4.0-8.9 
stress(MPa) 3.0 2.06 
1.48-4.31 1.14-3.51 
n 48 44 
NB: all values represent the mean of n samples 
* = range values 
Table 6.2. Effect of uncoated pellet drying method on the mechanical 
properties of uncoated pellets containing 80%w/w ibuprofen. 
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of uncoated pellets containing 80%w/w ibuprofen. 
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Drying Method 
fluidised 
tray bed 
bead diameter 1073 1080 
(Ilm) *915-1235 909-1201 
crushing 14.0 9.0 
force (N) 8.8-18.3 5.1-12.8 
displacement 168 122 
(Ilm) 110-270 75-210 
work done 1197 535 
(IlJ) 539-2333 191-903 
% strain 15.7 11.4 
10.3-24.1 6.6-21.5 
stress(MPa) 15.5 9.4 
10.8-23.2 5.9-13.1 
n 40 44 
NB: all values represent the mean of n samples 
* = range values 
Table 6.3. Effect of uncoated pellet drying method on the mechanical 
properties of placebo pellets containing 80%w/w lactose with 
Avicel PH101. 
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6.3.3. Effect of the uncoated formulation on the tensile properties of 
tray dried pellets containing 80%w/w ibuprofen. 
As discussed previously the drying technique employed In uncoated 
pellet manufacture, has a contributory effect on the tensile properties 
of both active and placebo pellets. As processing variables influence 
the mechanical characteristics of pellets, so too do formulation 
variables. Table 6.4 summarises the tensile properties of uncoated 
pellets containing 80%w/w ibuprofen with Avicel PHlOl and with Avicel 
PHlOl l5%w/w and Avicel CL6ll 5%w/w. The virtues of microcrystalline 
cellulose in pellet formulations are well documented in Chapter 2. 
The use of grades of Avicel containing incorporated sodium 
carboxymethylcellulose as an additional binding agent, in addition to 
facilitating the preparation of pellets containing an even higher drug 
content than is possible with Avicel PHlOl alone, facilitate the 
preparation of ibuprofen pellets with a greater mechanical strength. It 
is evident that even very low percentages of Avicel CL6ll in pellet 
formulations, as low as 5%w/w for example have a significant effect on 
the force required to cause pellet fracture. 
Ibuprofen pellets containing 80%w/w drug and 5%w/w Avicel CL6ll with 
Avicel PHl01, reqUIre more work for pellet fracture; they exhibit 
significantly greater strain, stress and displacement on the application 
of load. Those pellets not containing Avicel CL611 require a force for 
fracture of approximately only 56% of that force necessary to fracture 
pellets containing Avicel CL611 (Figure 6.12). Figure 6.13 shows that 
although the presence of CL611 grades of Avicel serves to enhance the 
tensile strength of pellets, it also has the effect of simultaneously 
reducing their elasticity. Pellets containing sodium carboxymethyl-
cellulose grades of Avicel therefore exhibit a higher elastic modulus 
than those which do not. A similar effect was observed for those pellet 
formulations containing Avicel RC591NF. 
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Pellet Composition 
20%w/w 15:5 Avicel 
Avicel PH101 PH101:CL611 
bead diameter 1093 993 
(Ilm) *881-1269 725-1220 
crushing 2.81 5.0 
force (N) 0.9-4.25 2.7-7.7 
displacement 88 141 
(Ilm) 65-170 50-280 
work done 127 352 
(IlJ) 32-298 74-918 
% strain 8.1 14.0 
6.3-15.1 6.3-32.5 
stress(MPa) 3.0 6.0 
1.48-4.31 3.51- 9.13 
n 48 39 
NB: all values represent the mean of n samples 
* = range values 
Table 6.4. Effect of uncoated pellet formulation on the mechanical 
properties of tray dried pellets containing 80%w/w ibuprofen. 
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6.3.4. Effect of the presence of a film coat on the tensile properties 
of pellets containing 80%w/w ibuprofen. 
Table 6.5 summarises the tensile properties of uncoated ibuprofen 
pellets and those coated with aqueous polymeric dispersions of Eudragit 
RS30D/RL30D (polymethacrylate) and Surelease (ethylcellulose). 
Figure 6.14 shows that for pellets coated with Eudragit RS30D/RL30D, 
with increasing polymer loading and therefore increasing membrane 
thickness surrounding the pellet core, the force necessary to cause 
pellet fracture IS correspondingly increased. With increased membrane 
thickness there IS also a corresponding increase in the elasticity of the 
pellets, characterised by a decreasing elastic modulus (Figure 6.15). 
Hence a consequence of coating ibuprofen pellets with a release retarding 
membrane of the polymethacrylates, is enhanced pellet elasticity and 
increased pellet tensile strength. 
Conversely however, the application of a polymeric membrane of 
Surelease to ibuprofen pellets, has the effect of causing a reduction In 
that force necessary to cause pellet fracture (Figure 6.16) and an 
increase in pellet elasticity, characterised by a decrease in the elastic 
modulus (Figure 6.17). The application of such a coating it would 
appear, causes an apparent softening of pellets. Surelease coated 
pellets exhibit a greater displacement on applied stress than uncoated 
pellets of the same batch and are able to withstand greater strain. They 
do however require less work to cause fracture and exhibit less stress 
than their uncoated counterparts. Reasons for this apparent softening it 
is postulated are possibly attributable to incomplete polymer coverage or 
water penetration into pellet cores during the coating process. 
Previously mentioned is the fact that film coating of these small 
multiparticulates using fluidised bed apparatus is not without problems. 
The ethylcellulose formulation exhibits a tendency to form a tacky film 
under the operating conditions of the film coating chamber and careful 
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temperature monitoring is required throughout in order that pellet 
agglomeration is prevented during coating. Furthermore the manufacturers 
claim and this work has confirmed, that an overcoat formulation of Opadry 
is necessary to prevent pellet agglomeration following application of the 
ethylcellulose film. Pellets not coated with the overcoat formulation 
display sticking tendencies even under ambient conditions. It is 
feasible that a certain degree of water penetration into the pellet cores 
occurs during the initial stages of the coating process a consequence of 
which is pellet softening. The conferred enhanced elasticity of pellets 
coated with Surelease is not unexpected due to the exceedingly high 
instantaneous and time-dependent elasticities and low elastic modulus and 
Newtonian viscosity exhibited by free-films of this polymeric formulation 
(Chapter 5). 
6.3.5. Assessment of the mechanism of pellet fracture on applied stress. 
Figures 6.18 and 6.19 show photographs of pellet fracture both prior 
to and after the application of stress. Many photographs were taken 
during pellet fracture; negligible differences were noticeable under 
these test conditions. It has been shown that the presence of a film 
coat surrounding a pellet core serves to enhance the elasticity of such a 
pellet as characterised by the elastic modulus. However, no visibly 
detectable differences were observed in the mechanism of pellet fracture 
during the crushing of these multiparticulates. 
Initially on load application and within the elastic limit of the 
particle, stress is directly proportional to strain. As the elastic 
limit of the particle is exceeded however, permanent deformation is 
followed by particle fracture. The occurrence of permanent deformation 
of a solid results In energy expansion and the formation of cracks; the 
furthest extension of a crack is the area of greatest stress. 
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Coating Status 
Eudragit Eudragit Surelease 
Uncoated 4.5%w/w 12%w/w 10%w/w 
increase lncrease lncrease 
bead diameter 1107 1145 1144 1132 
(11m) ·935-1230 1044-1272 988-1254 959-1248 
crushing 2.59 2.74 2.81 2.13 
force (N) 1. 30-3.28 1.53-3.78 1. 65-3.75 0.78-3.65 
displacement 86 89 94 103 
(11m) 55-145 50-250 65-140 55-200 
work done 113 126 133 108 
(Ill) 36-202 47-473 54-218 41-230 
% strain 7.79 7.81 8.25 9.05 
4.58-12.7 4.27-23.95 5.8-14.17 5.23-15.61 
stress(MPa) 2.72 2.66 2.74 2.13 
1.15-3.88 1. 53-4.42 1.67-4.16 0.78-3.25 
n 47 46 51 43 
NB: all values represent the mean of n samples 
• = range values 
Table 6.5. Effect of the presence of a film coat on the mechanical 
properties of pellets containing 80%w/w ibuprofen. 
233 
C 3.0 
r 
u 2.5 
s 
h 
I 2.0 I 
n ~I uncoated I I I 
9 1.5 [CQI 4.5% Increase l 
F 0112% Increase I 
0 1.0 
r 
c 
e 0.5 
N 0.0 
Figure 6.14. Effect of a film coat of Eudragit RS/RL30D on the 
E 
I 
a 
s 
t 
I 
c 
M 
0 
d 
u 
I 
u 
s 
M 
P 
a 
35 
30 
25 
20 
15 
10 
5 
0 
mechanical strength of fluidised bed dried pellets 
containing 80%w/w ibuprofen. 
~I uncoated I 
~I 4.5% Increase I 
0112% Increase I 
Figure 6.15. Effect of a film coat of Eudragit RS/RL30D on the elastic 
modulus (MPa) of fluidised bed dried pellets containing 
80%w/w ibuprofen. 
234 
C 3.0 
r 
u 2.5 
s 
h 
I 2.0 
n 
9 1.5 ~I uncoated I [I] I 1 0% Increase I 
F 
0 1.0 
r 
c 
e 0.5 
N 0.0 
Figure 6.16. Effect of a film coat of Surelease (ethylcellulose) on the 
mechanical strength of fluidised bed dried pellets 
containing 80%w/w ibuprofen. 
E 
I 35 
a 
s 30 
t 
I 25 c 
M 20 ~[ uncoated I 
0 [1]11 0% Increase I d 15 
u 
I 10 
u 
s 5 
M 
P 0 
a 
Figure 6.17. Effect of a film coat of Surelease (ethylcellulose) on the 
elastic modulus (MPa) of fluidised bed dried pellets 
containing 80%w/w ibuprofen. 
235 
As fracture occurs the point of application of force is dissipated 
throughout the pellet (Figure 6.19). The stress waves generated in the 
particle, the cause of the initial crack formation, release energy 
producing other regions of high stress resulting in new crack formation. 
The application of stress to those pellet formulations exhibiting a 
relatively high elasticity tended on fracture, to result in a few 
relatively large particles and some fines. On fracturing more brittle 
pellet formulations however, the resultant product largely consisted of 
fines. 
6.4. Conclusions. 
Much quantitative and qualitative information is liberated by 
studying the effect of formulation factors and processing variables on 
the tensile properties of both placebo and ibuprofen pellets. 
Of primary importance is the influence of the drying technique on 
the resultant mechanical properties of pellets containing excipients 
which are either poorly or freely water soluble. In summary, pellets 
prepared using extrusion and spheronisation technology and dried using 
fluidised bed methodology, exhibit greater elasticity and lower tensile 
strength than their tray dried counterparts. 
The aqueous solubility of the excipients from which pellets are 
composed also has a significant effect on the tensile strength. For 
pellets containing a freely water-soluble excipient, it is not 
unreasonable to anticipate the formation of solute molecules of this 
component during the wet massing stage due to the addition of an aqueous 
granulating fluid. Water removal from these multiparticulates during 
drying following spheronisation of the material, would thus lead to the 
formation of solid bridges in the granules by fusion at the point of 
contact. 
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Figure 6.18. Photograph of a pellet on a stationary platen prior to 
stress application from the descending load. 
Figure 6.19. Photograph of the pellet during load application. 
For solute particles (for example, lactose dissolved in the aqueous 
granulating fluid) crystallisation of the dissolved particles causes a 
greater degree of bonding and hence the formation pellets of greater 
tensile strength. This is supported by the relative tensile strengths of 
pellets containing 20%w/w microcrystalline cellulose with 80%w/w of 
either ibuprofen or lactose. Fluidised bed dried ibuprofen pellets 
exhibit a tensile strength which is only approximately 21 per cent of 
that of placebo pellets prepared using similar processing techniques. 
The quantity of the spheronisation enhancer microcrystalline 
cellulose (Avicel PHlOl) In pellet formulations has a significant effect 
on the tensile strength and other tensile properties of pellets 
containing ibuprofen. An increase in the Avicel content of pellets and a 
corresponding decrease In the ibuprofen content therefore, has the effect 
of increasing pellet tensile strength (Figure 6.6) with a corresponding 
reduction in pellet elasticity (Figure 6.7). The presence of 
microcrystalline cellulose in pellet formulations serves not only to 
facilitate the production of high quality pellets, but in its capacity as 
a binder this excipient enhances the cohesion between the components of 
the blend, resulting In more robust pellets of greater tensile strength. 
For example, pellets containing only 20%w/w microcrystaline cellulose 
with 80%w/w ibuprofen required a mean force for fracture of 2.59N, 
compared with pellets containing 40%w/w microcrystalline cellulose which 
required a mean force of 4.9lN. In addition, pellets containing only 
20%w/w binder exhibited a mean elastic modulus of 35MPa, whilst pellets 
containing the higher per cent of binder (40%w/w) exhibited a mean 
elastic modulus of approximately 60MPa. 
Grades of microcrystalline cellulose containing sodium carboxy-
methylcellulose (sodium CMC) , when incorporated into pellet formulations 
enhance the binding capacity of the inert component. As previously 
discussed, this facilitates the formation of products containing even 
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higher percentages of drug due to the additional binding capacity 
associated with such excipients. For any given drug loading however. the 
use of sodium CMC grades of microcrystalline cellulose (CL611 and 
RC591NF) leads to a more brittle product exhibiting enhanced tensile 
strength. Considering a specific example therefore: pellets containing 
80%w/w ibuprofen and 20%w/w of Avicel PH10l required a mean force for 
particle fracture of 2.8lN and exhibited an elastic modulus of 37MPa. 
whilst pellets of identical potency containing l5%w/w Avicel PH10l and 
5%w/w Avicel CL6ll (of which approximately 0.75% is NaCMC) exhibited a 
mean diametral strength of 5N and an elastic modulus of 43MPa; both 
formulations were tray dried In a hot air oven and were uncoated. It IS 
therefore apparent that only minor changes in an uncoated pellet 
formulation will have significant ramifications in terms of the tensile 
properties of the resultant product. 
The presence of a film coat applied by means of an aqueous polymeric 
dispersion of the polymethacrylates also influences the tensile strength 
and the elastic properties of ibuprofen pellets. Increasing the polymer 
loading has the effect of increasing the tensile strength of pellets 
whilst simultaneously enhancing pellet elasticity (characterised by a 
reduction in the elastic modulus, Figure 6.15). Elsewhere In this work, 
one of the consequences of increasing the tensile strength of pellets has 
been an increase in the elastic modulus (c.f. drying method and Avicel 
content). It is evident that the effect of a polymer coating surrounding 
a pellet core serves not only to enhance the tensile strength of 
ibuprofen-containing pellets but also to enhance the elasticity of such 
multiparticulates (Figure 6.15). 
The effect of applying a film coating of Surelease (ethylcellulose) 
to ibuprofen pellets causes a reduction in diametral strength from 2.59N 
(uncoated) to 2.13N (pellets coated with a 10% weight increase of 
Surelease) and a corresponding increase in the pellet elasticity (Figure 
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6.17). This apparent reduction in tensile strength may be attributable 
to the penetration of water into the pellet core during the initial 
stages of the coating process; this is however only a postulation. This 
effect was not observed for pellets coated with polymethacrylate aqueous 
system. This conferred elasticity of Surelease-coated ibuprofen pellets 
is not wholly unexpected as a consequence of the quantified tensile 
properties of free-films of this polymer previously presented in Chapter 
5. In summary, Surelease (ethylcellulose) free-films were found to 
exhibit extremely high instantaneous elastic compliance on the 
application of stress (approximately 20 x 10- 8 Pa- 1 compared with that 
of the polymethacrylate formulation of approximately 3.6 x 10- 8 Pa-I). 
Surelease free-films also exhibited the lowest Newtonian viscosity of all 
formulations studied (Figure 5.26) which is indicative of a greater 
tendency for permanent, non-recoverable, plastic deformation under 
applied stress. 
An understanding of the tensile properties of uncoated pellets, 
coated pellets and free polymeric films was considered fundamental in 
facilitating the design of a monolithic tablet formulation comprising 
compacted polymer-coated pellets, in which the integrity of the pellet 
cores and the film coating were to be preserved. Chapter 7 considers 
fundamental tablet design and incorporates a quantitative study of pellet 
distribution within the tablet matrix and drug release from the pellets 
following compaction into tablets. 
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CHAPTER 7 
DESIGN AND QUANTITATIVE EVALUATION OF A RAPIDLY 
DISINTEGRATING SUSTAINED RELEASE TABLET FORMULATION 
COMPRISING POLYMER COATED PELLETS 
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7.1. Introduction. 
It is recognised that a multiple-unit sustained release dosage form 
presents a preferable alternative to a single-unit system for oral 
administration (Davis et al., 1984; Bechgaard and Nielsen. 1978: 
Ganderton, 1985). However, due to the physical limitations associated 
with the size of a hard gelatin capsule shell it has not been possible to 
administer a medium- to high-dose drug in the form of a sustained release 
multiparticulate delivery system. The aim of this work therefore was to 
design a tablet which on oral administration rapidly released intact 
polymer coated pellets with the integrity of the pellet core and the 
release retarding membrane being preserved. 
The successful application of direct compression In pharmaceutical 
tabletting depends on the development of suitable excipients that are 
free flowing, highly compressible, water-soluble, physiologically inert 
and chemically compatible with the active ingredients. Spray-dried 
lactose exhibits these characteristics and it has been widely used as a 
direct compression excipient. There is however an associated problem 
with the use of lactose alone and that is the limited tablet diametral 
strength which may be achieved. The binding capacity of lactose is 
insufficient in facilitating the formation of tablets of low friability 
and of sustainable strength particularly in tablet formulations in which 
the percentage composition of the inert diluent phase is to be minimised. 
Garr and Rubinstein (1991) studied the properties of a direct compression 
excipient made of 25% cellulose and 75% lactose and showed that the 
cellulose-lactose excipient produces stronger tablets than those 
containing lactose alone. 
Microcrystalline cellulose, the characteristics of which have been 
documented earlier in this work (Chapter 2), is highly cohesive and 
possesses favourable flow properties. This excipient facilitates the 
formation of extremely hard tablets exhibiting low friability and which 
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display relatively short disintegration times (FMC product literature. 
Avicel PH200, 1991). As the objective of this stage of the study was to 
design a tablet containing pellets of mean diameter 1mm and in order that 
the occurrence of segregation between the particles of the inert diluent 
blend and the active pellets was minimised, it was deemed necessary to 
elucidate a formula containing large size diluent particles, without 
necessitating an additional wet granulation process. The process of 
segregation within a blend is influenced by component particles 
exhibiting markedly differing particle size, shape and density. Avicel 
PH200 is a large particle size microcrystalline cellulose (average 
particle size 200 ~m), the particle size specifications of which are 
given in Table 7.1. 
Avicel Type % Particle Size Specification 
PH101 1 not greater than 250 ~m 
30 not greater than 75 ~m 
PH102 8 not greater than 250 ~m 
45 not less than 75 ~m 
PH200 10 not less than 250 ~m 
50 not less than 150 ~m 
Table 7.1. Particle size specifications of Avicel grades of 
microcrystalline cellulose. 
Scanning electron microscopy of Avicel PH200 (Figure 7.1) indicates 
that this grade of microcrystalline cellulose is composed of relatively 
spherical aggregates; this is desirable in that not only is the particle 
size more favourable in respect of its potential for compression with 1mm 
diameter pellets, but also the more spherical shape of these particles, 
it is postulated, will reduce the tendency for particle segregation. 
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Figure 7.1. Scanning electron micrograph of Avicel PH200 mlcrocrys-
talline cellulose (magnification x100). 
The shape and particle Slze of this large particle Slze grade of 
microcrystalline cellulose, the manufacturers claim, enhances not only 
the flow properties and reduces the tablet weight variation, but 
favourable compressibility, tablet strength and content uniformity may be 
achieved. 
The compressibility of microcrystalline cellulose is attributable to 
the hydrogen bonding in and between the cellulose structures of this 
excipient and also strong interparticulate bonding. The microcrystalline 
cellulose particles are held together by hydrogen bonding between 
hydroxyl groups on adjacent cellulose molecules, this accounts for the 
strength and coherence within the particles. Each particle is held 
together by a bonding of sub-particles rather than by entanglement of the 
elements comprising a particle; each particle is a coherent porous 
collection of small cellulose subunits. On compression, microcrystalline 
cellulose particles exhibit plastic deformation due to the presence of 
the slip planes and dislocations. Thus on the application of pressure, 
microcrystalline cellulose particles exhibit plastic deformation and 
bonds are formed which remain intact on the release of pressure. Rapid 
disintegration of tablets containing microcrystalline cellulose is 
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attributable to the hydrogen bond energy being significantly reduced as a 
consequence of the presence of water thus causing destruction of the 
mechanical interlocking of these cellulose particles. 
No single ingredient is ideal as a direct-compression vehicle and 
therefore it was considered appropriate to blend excipients of differing 
properties together. A combination of lactose and microcrystalline 
cellulose offers two excipients which display fundamentally different 
fragmentary properties. Previously discussed is the fact that 
microcrystalline cellulose is highly compressible and consolidates by 
plastic deformation. In contrast however, the princip~1 mechanism of 
lactose consolidation IS by fragmentation. 
Microcrystalline cellulose being highly compressible, produces hard 
tablets of low friability which are water insoluble. Lactose possesses 
relatively good compactibility and the resultant tablets are readily 
soluble in water. It is a possibility therefore that a blend of these 
two materials would result in a combination of the properties of the 
individual components. 
The bonding created by the compreSSIon of a blend of lactose and 
microcrystalline cellulose therefore might reasonably be expected to 
involve a combination of plastic deformation associated with the hydrogen 
bonding between the microcrystalline cellulose particles affording 
physical strength to the resultant tablet and extensive fragmentation of 
the lactose component filling the void spaces during compression. The 
prImary objectives of tablet design were therefore to ascertain the 
mInImum quantity of inert diluent blend necessary for satisfactory tablet 
formation and optimisation of the ratio of the microcrystalline cellulose 
and lactose components, such that a rapidly disintegrating product of low 
friability could be achieved and in which the integrity of both the 
pellet core and the film coat were preserved. 
Meggle lactose EP is pure, crystalline a-lactose monohydrate. 
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Various grades of Meggle lactose are available, exhibiting different 
particle size specifications. The largest particle size grade of lactose 
currently available is Meggle lactose, D10 grade. It is a 
coarse-crystalline product exhibiting favourable flow properties. The 
particle size specifications are given in Table 7.2. 
% Particle Size Specification 
100 less than 800 J.lDl 
12 - 35% less than 400 Ilm 
max. 7% less than 200 Ilm 
Table 7.2. Particle size specification of Meggle DlO lactose EP. 
Figure 7.2 shows a electron micrograph of D10 lactose, illustrating 
the coarse crystalline appearance of the product. 
Figure 7.2. Scanning electron micrograph of Meggle D10 lactose EP 
(magnification x100) 
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7.2. Methodology. 
7.2.1. Tablet design. 
In an attempt to prevent segregation of the active pellets (mean 
diameter 1mm) from the diluent particles, the particle size and shape of 
the latter and the relative proportions in the blend were carefully 
optimised. 
7.2.1.1. The role of placebo pellets and their mechanical properties 
relative to ibuprofen-containing entities. 
It was postulated that the anticipated problems associated with 
pellet segregation from the diluent particles during compression, might 
be prevented or at least minimised by using placebo pellets as the inert 
tablet component. The theoretical concept involved designing a placebo 
pellet formulation which on consolidation exhibited fragmentary 
properties rather than plastic deformation and when compressed with 
polymer coated pellets containing ibuprofen, preferentially fractured 
into progeny particles thus facilitating tablet formation. 
The aim was to design a placebo pellet formulation which exhibited 
fragmentation under applied load and which was mechanically less strong 
than the polymer coated entities. In theory at least segregation would 
be minimal. Placebo particles would mirror the physical properties of 
the ibuprofen-containing entities in respect of dimensions and shape and 
preferably density. To this end placebo pellets were prepared containing 
lactose and microcrystalline cellulose (Avicel PH101) using the technique 
of extrusion-spheronisation. The manufacturing plant and equipment is as 
described previously. Those placebo formulations manufactured are 
described in Table 7.3. 
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Excipient %w/w Granulating Comments (dry solids) fluid 
Avicel 100 purified undried - satisfactory 
dried - severe shrinkage 
water poor quality, rock hard 
Avicel 50 purified appearance:satisfactory 
rock hard pellets 
lactose 50 water 
Avicel 50 purified powdery, final product: 
water:IPA less IPA required 
lactose 50 50:50 
Avicel 50 purified appearance:satisfactory 
water:IPA hard pellets 
lactose 50 80:20 
Avicel 30 purified appearance:satisfactory 
rock hard pellets 
lactose 70 water 
Avicel 20 purified appearance:satisfactory, 
evaluate mechanical 
lactose 80 water properties 
Avicel 10 purified appearance:poor shape, 
more Avicel required to 
lactose 90 water improve sphericity 
Table 7.3. Placebo pellet formulations prepared using extrusion-
spheronisation methodology. 
The crushing properties of placebo pellets containing lactose PhEur 
(Pharmatose 200M = lactose monohydrate ground USP) 80%w/w and 
microcrystalline cellulose (Avicel PH101) 20%w/w (expressed as percent 
weight dry solids) were determined using the Single Particle Crushing 
Assembly described in Chapter 6. All other placebo pellet formulations 
described either resulted in poor quality spheres, or the mechanical 
strength of the pellets was greater than the evaluative capacity of the 
crushing assembly. Since the mechanical strength of those placebo pellet 
formulations was much greater than the ibuprofen-containing entities, 
these formulations were therefore discarded. 
The relative mechanical strength of placebo pellets containing 
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80%w/w lactose with microcrystalline cellulose IS discussed In ~.3. 
7.2.1.2. Direct compression blend. 
Coated ibuprofen pellets were blended In a Turbula mIxer with 
Meggle DI0 lactose EP and Avicel PH200 for 15 minutes (see Table 7.4 for 
quantities used). Magnesium stearate BP 0.5%w/w was then added to the 
bulk and blended for a further 10 minutes. The batch size of each blend 
was 250g. 
7.2.2. Pellet compreSSIon. 
The pellet/diluent blend was transferred to the hopper of a Manesty 
F3 (instrumented) tablet machine fitted with pillow shaped concave 
punches of dimensions 25mm x 9mm. The blend was then compressed into 
tablets using a range of compaction pressures, such that the minimum 
compression force needed to produce tablets of low friability, rapid 
disintegration (in which damage to the integrity of the coated pellets 
would be minimised) could be determined. 
Table 7.4 summarises the tablet formulations studied. Details 
relating to the compaction forces, uniformity of weight, uniformity of 
content, diametral crushing force, tablet disintegration and in-vitro 
drug release are given subsequently in section 7.3. 
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blend 
ingredients 
pellets 
lactose 
Avicel PH102 
Mg stearate 
pellets 
lactose 
Avicel PH102 
Mg stearate 
pellets 
lactose 
Avicel PH102 
Mg stearate 
pellets 
lactose 
Avicel PH102 
Mg stearate 
pellets 
lactose 
Avicel PH102 
Mg stearate 
pellets 
lactose 
Avicel PH102 
Mg stearate 
pellets 
lactose 
Avicel PH200 
Mg stearate 
pellets 
lactose 
Avicel PH200 
Mg stearate 
pellets 
lactose 
Avicel PH200 
Mg stearate 
%w/w 
70 
29.5 
0.5 
70 
14.5 
10 
0.5 
60 
39.5 
0.5 
60 
29.5 
10 
0.5 
60 
19.5 
20 
0.5 
60 
19.5 
20 
0.5 
60 
19.5 
20 
0.5 
60 
19.5 
20 
0.5 
60 
19.5 
20 
0.5 
% drug 
(uncoated 
pellets) 
80 
80 
70 
70 
80 
80 
80 
80 
80 
polymer 
ERS/RL 
ERS/RL 
Surelease 
Surelease 
Surelease 
ERS/RL 
ERS/RL 
Silicone 
elastomer 
2: 1 
Silicone 
elastomer 
6: 1 
comments 
insufficient filler: 
29.5%w/w lactose not 
providing adequate 
cohesion for pellets 
30%w/w diluent still 
insufficient even 
with extra binding 
capacity of Avicel 
cushioning effect of 
40%w/w diluent IS 
more satisfactory; 
binder required 
tabletting possible; 
friable on handling 
however with medium 
compaction pressures 
- increase % Avicel 
appearance satisfac-
tory at compaction 
force ~ approx. 3kN 
smooth shiny tablets 
appearance satisfac-
tory at compaction 
force ~ approx. 3kN; 
smooth shiny tablets 
appearance satisfac-
tory at compaction 
force ~ 2.8kN; 
smooth shiny tablets 
immediate elastic 
recovery on removal 
of applied stress; 
no resultant product 
immediate elastic 
recovery on removal 
of applied stress; 
no resultant product 
Table 7.4. Summary of pellet/diluent blends compacted into tablets. 
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7.2.3. Physical properties of compressed pellet formulations. 
7.2.3.1. Diametral crushing strength. 
Mean diametral tablet strength (longitudinal) was determined uSIng a 
Schleuniger 4D Tablet Tester. 
7.2.3.2. Tablet friability. 
Tablet friability was determined uSIng an Erweka Friabilator. The 
operating conditions involved testing samples of five tablets for a 
period of six minutes. 
7.2.3.3. Tablet disintegration. 
Disintegration testing was performed on six tablets uSIng a BP 1988 
basket-rack assembly and purified water at 37°C + 2°C. 
7.2.3.4. Uniformity of weight. 
Preliminary adjustment of tablet weight was made for each pellet 
formulation and compaction pressure prior to compaction. Uniformity of 
weight of the resultant product was determined by weighing samples of ten 
tablets at each compaction pressure. 
7.2.4. In-vitro drug release from compressed pellet formulations. 
In-vitro drug release from compressed pellet formulations containing 
ibuprofen was performed over a period of 24 hours using the methodology 
described in section 4.2 of Chapter 4. Comparative drug release profiles 
from coated pellets and from a compacted pellet formulation are presented 
in section 7.3. 
7.2.5. Uniformity of content. 
Content uniformity of compressed pellet formulations was determined 
by ascertaining the infinity value of % ibuprofen released as a 
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consequence of in-vitro dissolution testing. Pellets were crushed after 
the 24 hour dissolution run in situ (ie. in the dissolution vessels) and 
the absorbance values recorded. 
7.2.6. Qualitative study of the compression process and pellet integrity 
using microphotography. 
Pellets were released from tablets by disintegration of the matrices 
as described in 7.2.3.3. Following release, pellets were recovered from 
the disintegration tubes by filtration and allowed to dry under ambient 
conditions of temperature and humidity. Ambient conditions were employed 
for the drying procedure such that pellet shrinkage might be minimised. 
After the leaching of ibuprofen from these cores it is important to note 
that only 20% by weight of the original core formulation remains; it was 
anticipated that elevated drying temperatures of pellet cores consisting 
of a skeletal network of microcrystalline cellulose surrounded by a 
polymeric membrane may be causative of unnecessary product deformation 
and shrinkage. 
Released pellets were then examined microscopically with particular 
attention being made to the particle shape and any deformation and damage 
caused as a consequence of the compaction process. 
Microphotographic illustrations of coated pellets prior to and after 
release from the tablet matrix and embedded in the tablet core are 
presented in section 7.3. 
7.2.7. Quantitative evaluation of pellet distribution wi~h_L~_1n~ __ tablet 
matrix by image analysis. 
A quantitative evaluation of the distribution of pellets within the 
compacted pellet tablet formulation was made using an Eltime III Image 
Analysis System. This facilitated a study of the tendency of the 
components of the tablet blend to undergo segregation. Samples of 
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ibuprofen-containing pellets were coated and stained with a O.l%w/~ 
aqueous solution of Green S, a water soluble dye used in the food 
industry. Tablets were prepared using the method and equipment discussed 
previously. The distribution of stained pellets embedded in the tablet 
diluent using this technique was presented by a monochrome display of 
grey, representing stained pellets on a white background. Samples of 
tablets were individually analysed ln respect of pellet distribution on 
the tablet surface, the side view and cross-section. Microphotographic 
illustrations of stained pellets forming the tablet surface and embedded 
in the tablet core are presented in section 7.3. 
7.3. Results and Discussion. 
The process of pellet formation leads to a densification of 
materials. This factor together with the high concentrations of drug 
which are feasible for extruded-spheronised multiparticulates, renders 
it possible to present ibuprofen (a low potency/high dose drug) as an 
oral sustained release pellet preparation. 
7.3.1. Mechanical properties of placebo pellets. 
The objective of designing placebo pellets exhibiting fragmentary 
consolidation on the application of minimal applied load was to 
facilitate the compression of a blend of mechanically weak diluent 
particles and polymer coated actives such that the placebo pellets would 
preferentially fracture forming the tablet matrix around intact polymer 
coated pellets. A fundamental design feature underlying this theory was 
that the polymer coated particles must exhibit plastic deformation on the 
application of stress and greater physical strength than the placebo 
pellets. 
It was postulated that by designing placebo pellets of similar SIze 
and shape to the drug-containing entities, the blending process would 
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enable a sustainable random mIX to be achieved with negligible tendency 
for particle segregation during processing. This would have 
ramifications in respect of the uniformity of weight and content of the 
resultant compacted pellet formulations. To this end various placebo 
pellet formulations were prepared using the techniques described 
previously. Table 7.3 shows those pellet formulations prepared. The 
virtues associated with the use of microcrystalline cellulose in 
extrusion-spheronisation pelletization processing is well documented In 
the literature and has been discussed earlier in this work (section 2.3). 
Pellets containing microcrystalline cellulose alone required large 
volumes of granulating fluid (3kg of Avicel PH10l required 3500ml of 
Purified water BP during the massing stage In order that good quality 
extrudate and spheres could be produced). On removal of this large 
volume of water during drying, particle shrinkage occurred to such an 
extent that dried pellets resembled granules rather than spheres; they 
were also extremely hard. Various placebo formulations were therefore 
prepared using a combination of lactose and microcrystalline cellulose. 
Not unreasonably it was anticipated that these two significantly 
different excipients in combination might yield a product which exhibited 
physical properties characteristic of the component materials. That is 
to say, on consolidation of a lactose-microcrystalline cellulose pellet 
one might anticipate a degree of brittle fracture and plastic deformation 
(of the uncoated pellet) depending on the ratio of the component 
excipients and the load applied. Suffice to indicate that whatever the 
anticipated theory underlying the behaviour of such particles on the 
application of stress, all formulations containing lactose and 
microcrystalline cellulose exhibited greater mechanical strength than the 
polymer coated actives. This is attributable to the nature of the 
bonding between component materials during drying. Lactose IS freely 
soluble in water (the granulating fluid) and therefore it is not 
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unreasonable to expect that, during the wet processing stages of product 
manufacture, solute molecules of lactose will be formed and a consequence 
of drying will be crystallisation of the dissolved particles, greater 
bonding and a mechanically stronger product due to crystalline bridge 
formation. Conversely ibuprofen-containing pellets. in which the drug 1S 
virtually insoluble in the granulating fluid are physically less strong: 
negligible drug solvation and crystalline bond formation will occur and 
therefore active pellets containing a poorly water soluble drug less 
physical strength. 
It became evident therefore that placebo pellets containing a high 
lactose component exhibited greater physical strength than the drug-
containing entities due to strong crystalline bonding in the former. In 
addition, placebo pellets containing a high microcrystalline cellulose 
content, by virtue of the inherent binding capacity of this material, 
were exceedingly hard. 
The ability of lactose to dissolve 1n the aqueous granulating fluid 
appeared to be the fundamental problem. Solvation of lactose particles 
and subsequent crystalline bond formation during drying was yielding a 
product exhibiting greater mechanical strength than the drug laden 
pellets. It was therefore postulated that partial replacement of the 
aqueous component with a non-aqueous fluid, for example isopropyl alcohol 
IPA (frequently used in tablet granulations where water is inappropriate 
for example where the drug or another excipient is susceptible to 
hydrolysis), might enable the preparation of relatively soft placebo 
pellets which would preferentially fracture during tablet compression. 
Placebo pellet formulations in which some of the aqueous granulating 
fluid was substituted with IPA however still exhibited greater mechanical 
strength than those prepared using water alone. 
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Figure 7.3. Relative mechanical strength of fluidised bed dried pellets 
containing 80%w/w ibuprofen or lactose with 20%w/w 
microcrystalline cellulose (Avicel PH10l). 
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Figure 7.4. Relative elastic moduli (MPa) of fluidised bed dried 
pellets containing 80%w/w ibuprofen or lactose with 
20%w/w microcrystalline cellulose (Avicel PH10l). 
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Figures 7.3 and 7.4 show the relative mechanical strengths and 
elastic moduli of fluidised bed dried pellets containing 80%w/w ibuprofen 
or lactose with 20%w/w microcrystalline cellulose (Avicel PH101); both 
products were wet massed using purified water and similar processing 
variables and equipment as described previously (section 2.2). These 
figures illustrate that the placebo pellets require a three-fold force 
for particle fracture and exhibit significantly less elasticity than the 
drug-containing entities. 
Other placebo pellet formulations studied and which are detailed in 
Table 7.3 required a crushing force which was quantitatively outside the 
capabilities of the Single Particle Crushing Assembly and in any event 
the physical strength of these pellets was far greater than that of the 
active particles. Further work therefore involved designing a direct 
compression blend composed of large particle size component excipients, 
details of which are discussed subsequently. 
7.3.2. Tablet Design. 
The objective in designing an inert direct compression blend was to 
enable the formation of a mechanically robust tablet of low friability, 
which was rapidly disintegrating in vitro yielding multiparticulates in 
which the integrity of the pellet core and the film coating remained 
intact. 
Tables 7.5 to 7.10 inclusive summarise the more successful 
compressed pellet formulations prepared. 
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% drug in core formulation 70%w/w 
film coating Surelease 
(10 + 1 % weight increase) 
%wLw inert diluent: 40%w/w 
Meggle D10 lactose EP 39.5% 
Magnesium stearate BP 0.5% 
compression force 1.12kN 1.74kN 2.02kN 
diametral crushing strength 21.6 N 50.0 N 66.6 N 
friability 100 % 100 % 100 % 
BP disintegration (seconds) 255 300 345 
target weight (g) ± 5% 2.117g (2.011 - 2.223g) 
uniformity of weight 
mean (g) 2.164 2.179 2.173 
standard deviation (SD) (g) 0.018 0.007 0.008 
% relative SD 0.81 0.30 0.38 
appearance: powdery surface appearance 
COMMENTS: tablets exceedingly friable In respect of 
friability test and on handling; binder required to 
reduce friability and increase tablet strength at lower 
compression forces. Increasing compression force has 
little effect on tablet strength. 
Table 7.5. Compressed pellet formulations (i) containing 800mg ibuprofen 
and 40%w/w inert diluent blend. 
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% drug in core formulation 70%w/w 
film coating Surelease 
(10 + 1 % weight increase) 
%wLw inert diluent: 40%w/w 
Meggle 010 lactose EP 29.5% 
Avicel PH102 10.0% 
Magnesium stearate BP 0.5% 
compression force 1.44kN 3.02kN 5.19kN 
diametral crushing strength 37.2 N 69.6 N 104.9N 
friability 100 % 100 % 45.4 % 
BP disintegration (seconds) 150 150 150 
target weight (g) ± 5% 2.117g (2.011 - 2.223g) 
uniformity of weight 
mean (g) 2.127 2.170 2.197 
standard deviation (SO) (g) 0.006 0.012 0.017 
% relative SO 0.28 0.55 0.77 
appearance: smooth shiny uniform surface characteristics 
(compression force ~ 3kN) 
COMMENTS: tablet friability unsatisfactory; there IS 
an apparent reduction in disintegration time associated 
with the presence of Avicel. 
Table 7.6. Compressed pellet formulations (ii) containing 800mg 
ibuprofen and 40%w/w inert diluent blend. 
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% drug in core formulation SO%w/w 
film coating Surelease 
(10 + 1 % weight increase) 
%wLw inert diluent: 40%w/w 
Meggle D10 lactose EP 19.5% 
Avicel PH102 20.0% 
Magnesium stearate BP 0.5% 
compression force 1.97kN 3.06kN 4.94kN 
diametral crushing strength 66 N 115 N 126 N 
friability 100 % 24.3 % 5.5 % 
BP disintegration (seconds) 60 60 90 
target weight (g) ± 5% 1.S52g (1.759 - 1.945g) 
uniformity of weight 
mean (g) 1.S71 1. 911 1. 916 
standard deviation (SD) (g) 0.013 0.006 0.002 
% relative SD 0.70 0.29 0.12 
COMMENTS: tablet appearance satisfactory at compaction 
pressures ~ approx. 3kN (smooth shiny uniform surface 
characteristics). Increased rate of disintegration with 
increased microcrystalline cellulose content. 
Table 7.7. Compressed pellet formulations (iii) containing SOOmg 
ibuprofen and 40%w/w inert diluent blend. 
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% drug in core formulation 80%w/w 
film coating Eudragit RS/RL300 
(4.5% weight increase) 
%wLw inert diluent: 40%w/w 
Meggle 010 lactose EP 19.5% 
Avicel PH102 20.0% 
Magnesium stearate BP 0.5% 
compression force 2.34kN 3.19kN 4.99kN 
diametral crushing strength 83 N 118 N 155 N 
friability 100 % 21.3 % 1. 98 % 
BP disintegration (seconds) 45 60 75 
target weight (g) ± 5% 1. 742g (1.655 - 1.829g) 
uniformity of weight 
mean (g) 1.809 1.798 1. 801 
standard deviation (SO) (g) 0.0064 0.0166 0.0032 
% relative SO 0.36 0.92 0.18 
appearance: smooth shiny uniform surface characteristics 
(compression force ~ approx. 3kN) 
COMMENTS: increasing diametral crushing strength and 
decreasing tablet disintegration time with increasing 
Avicel content. 
Table 7.8. Compressed pellet formulations (iv) containing 800mg 
ibuprofen and 40%w/w inert diluent blend. 
262 
% drug in core formulation 80%w/w 
film coating Eudragit RS/RL30D 
(4.5% weight increase) 
%wLw inert diluent: 40%w/w 
Meggle D10 lactose EP 19.5% 
Avicel PH200 20.0% 
Magnesium stearate BP 0.5% 
compression force 1. 15 kN 2.80kN 4.75kN 
diametral crushing strength 32.3 N 148 N 198 N 
friability 100 % 5.76 % 1. 74 % 
BP disintegration (seconds) 60 60 90 
target weight (g) ± 5% 1.742g (1.655 - 1.829g) 
uniformity of weight 
mean (g) 1. 744 1. 767 1.777 
standard deviation (SD) (g) 0.0067 0.0055 0.0035 
% relative SD 0.38 0.31 0.20 
appearance: smooth shiny uniform surface characteristics 
(compression force ~ 2.8kN) 
COMMENTS: large particle size microcrystalline cellulose 
(Avicel PH200) enhances diametral crushing strength; 
reduces tablet weight variation; reduces friability and 
improves tablet appearance. 
Table 7.9. Compressed pellet formulations (v) containing 800mg 
ibuprofen and 40%w/w inert diluent blend. 
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% drug in core formulation 80%w/w 
film coating Silicone Elastomer 2:1 
(10 % weight increase) 
%wLw inert diluent: 40%w/w 
Meggle D10 lactose EP 19.5% 
Avicel PH102 20.0% 
Magnesium stearate BP 0.5% 
compression force 5 kN 5 kN 5kN 
diametral crushing strength 
friability 
BP disintegration (seconds) 
target weight (g) + 5% 1.833g (1.741 - 1.925g) 
uniformity of weight 
mean (g) 
standard deviation (SD) (g) 
% relative SD 
appearance: no product 
COMMENTS: at compression force of 5kN (max) it was not 
possible to produce tablets. Instantaneous elastic 
recovery of the coated pellets occurred immediately on 
removal of applied stress, resulting in tablets which 
crumbled into the original blend from which they were 
intended to be composed after release from the die. 
Table 7.10. Compressed pellet formulations (vi) containing 800mg 
ibuprofen and 40%w/w inert diluent blend. 
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Within the course of designing a direct compression diluent blend 
suitable for compression with spherical particles of mean diameter Imm 
the following facts were elucidated. 
On compression of pellets and a diluent consisting solely of 
lactose, increasing the compression force does not necessarily result In 
a proportionate increase in the diametral crushing strength of the 
tablets. It is not possible to form very strong tablets where lactose IS 
the single or main component of the diluent (Tables 7.5 and 7.6). 
The incorporation of a binder for example microcrystalline cellulose 
into the diluent blend renders it possible to produce stronger tablets: a 
further effect of the incorporation of or an increase in the percentage 
of the microcrystalline cellulose present, is a reduction in the tablet 
disintegration time (cf. Tables 7.5, 7.6 and 7.7). Briefly increasing 
the quantity of microcrystalline cellulose in the diluent formulation 
increases the tablet strength at a given compaction pressure and enhances 
the rate of disintegration of the tablet. 
Compaction of pellets with lactose as the sole component of the 
diluent formulation, results in a product which is exceedingly friable to 
handle and which is unable to sustain its integrity as a consequence of 
the friability test (Table 7.5). 
The use of a large particle Slze grade of microcrystalline cellulose 
(Avicel PH200; mean particle size 200 micrometers) leads to a reduction 
In the friability of the tablets at a given compression force. This may 
be explained by the fact that segregation may be occurring in blends 
containing the PHI02 grade rather than the PH200 grade of Avicel. 
Therefore those tablets containing the PHI02 grade (Table 7.8) 
effectively contain less binder per tablet than those compressed with 
Avicel PH200 (Table 7.9) as a consequence of containing 
disproportionately more lactose than is indicated by the diluent formula. 
Pellets coated with both polymethacryiate and ethylcelluiose 
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polymers compacted satisfactorily into tablets with respect to 
appearance. Those pellets coated with the silicone elastomer 
formulations however exhibited such a degree of instantaneous elastic 
recovery following release from the tablet die that they literally 
disintegrated into their component excipients prior to compression. This 
effect was observed even for those pellets subjected to compression 
forces In excess of 5kN (Table 7.10); this should be compared with those 
ibuprofen pellets coated with a 4.5% weight increase of the Eudragit 
RS/RL30D formulation which displayed a diametral crushing strength of 
198N when compacted under a force of 4.75kN. 
7.3.3. Detailed study of the properties of the optimised compr~sse9 
pellet formulation. 
The optimised diluent blend formulation consisted of lactose 
19.5%w/w (Meggle Lactose EP D10 grade mean particle size 500~m), 
microcrystalline cellulose 20%w/w (Avicel PH200) and magnesium stearate 
BP (Table 7.9). The minimum quantity of inert diluent blend which was 
necessary to fill the void volume within such a tablet comprising polymer 
coated pellets (such that the integrity of the pellets was maintained and 
yet a mechanically strong tablet of low friability was produced) was 
found to be 40%w/w. Less than 40%w/w diluent blend resulted in a product 
ranging from friable (<40%w/w >30%w/w) to incomplete tablet formation 
(<30%w/w inert diluent blend). 
This ibuprofen compressed pellet formulation rapidly disintegrates 
in-vitro releasing apparently intact coated pellets within 90 seconds 
(compression force 4.75kN). 
7.3.3.1. In vitro drug release from polymer coated compressed pellets 
compared with non-compressed pellets. 
In order to quantify the extent of pellet damage it is necessary to 
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consider the effect of compaction on the in-~Titro drug release profiles 
from those multiparticulates which have been subjected to the compression 
process and those which have not. 
Figure 7.5 shows the effect of the compression process on drug 
release. It is evident that slight damage is caused to pellets as a 
consequence of compaction; this is highlighted by an increase in the rate 
of drug release from compacted, compared with non-compacted entities. 
The extent of physical damage of the film coat resulting from pellet 
compaction may be quantified by examining these differences in the 
in-vitro release profiles. Figure 7.6 is the square root time plot for 
ibuprofen pellets coated with a 4.5% weight increase of the 
polymethacrylate aqueous dispersion (see Table 7.9 for formulation 
details). Figure 7.6 illustrates a largely linear release for both free 
pellets and those presented as tablets. It IS postulated that although 
pellet compaction may enhance the rate of drug release by causing 
physical damage to the film coat of some pellets particularly those at 
the tablet surface, it appears to have little effect on the mechanism of 
drug release; first-order release kinetics are apparent at this level of 
polymer coating both before and after pellet compression. Also worthy of 
note in respect of the error bars shown in Figure 7.5 is the fact that 
whilst drug release from non-compacted pellets is exceptionally uniform, 
a consequence of pellet compaction is an apparent increase in the range 
of per cent drug released in replicate in-vitro tests. 
It is apparent from Figures 7.5 and 7.6 that by increasing the force 
of compaction from 2.80kN to 4.75kN there is negligible effect on the 
damage inflicted to these multiparticulates. Consequences of a 
significant increase in the compaction force include an increase in 
diametral crushing strength, a reduction in product friability, 
enhancement of product appearance but no apparent additional damage to 
these sub-units. This indicates at this stage that under these 
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conditions impairment of either the integrity of the film coat or the 
pellet core is not related to the magnitude of the compaction force but 
to the actual act of pellet compaction. 
7.3.3.2. Uniformity of content. 
The properties of the optimised tablet formulation containing 800mg 
ibuprofen in the form of compacted polymer coated sustained release 
pellets are summarised in Table 7.11. Despite the apparent random 
packing arrangement of coated pellets within these tablets as highlighted 
by the microphotographic evidence and image analysis data presented 
subsequently, the uniformity of content of these compacted pellet 
formulations indicates that the variation in ibuprofen content falls 
within a target specification value of 5% relative standard deviation 
(RSD); the inference being that under the pilot scale conditions in which 
these tablets were prepared, segregation of the diluent blend from the 
active pellets does not appear to be a problem. 
7.3.3.3. Qualitative study of the compreSSIon process and pellet 
integrity using microphotography. 
Microphotographs of coated pellets prior to compaction (Figure 7.7) 
and those released from the tablet following disintegration (Figures 7.8 
and 7.9) show that some pellets appear to undergo a degree of physical 
deformation as a consequence of the compaction process. 
Investigations to determine the nature of the damage to the film 
coat were carried out using scanning electron microscopy (SEM) and 
evidence is presented subsequently illustrating that limited damage IS 
being incurred by some pellets, particularly those at the tablet surface 
which are unprotected from contact with the punches during compaction by 
the tablet diluent. 
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% drug in core formulation 80 %w/w 
film coating Eudragit RS/RL30D 
(4.5% weight increase) 
%wLw inert diluent: 40.0%w/w 
Meggle DI0 lactose EP 19.5%w/w 
Avicel PH200 20.0%w/w 
Magnesium stearate BP 0.5%w/w 
compression force 4.75 kN 
diametral crushing strength 198 N 
friability 1. 74 %w/w 
BP disintegration 90 seconds 
uniformity of weight 
mean (g) 1. 7767 
standard deviation (SD) (g) 0.0035 
% relative SD 0.2 
uniformity of content 
mean 102.4% 
standard deviation (SD) 4.33 
% relative SD 4.22 
appearance smooth shiny surface 
drug release (see Figs. 7.5 and 7.6) 
Table 7.11. Summary of physical properties of the optimised compressed 
pellet formulation containing 800mg ibuprofen. 
7.3.3.4. Quantitative evaluation of pellet distribution within the 
tablet matrix by image analysis. 
Image analysis was performed on tablet surface, cross-section and 
side sections (Figure 7.11). Table 7.12 quantifies the ratio of that 
area occupied by the stained pellets to that by the diluent blend in 
respect of these three parameters. 
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ratio black/white surface side VIew cross-section 
mean 1.7020 0.5886 1.3779 
n 20 20 20 
SD 0.3999 0.2063 0.7884 
%RSD 23.5 35.1 57.2 
area occupied by 62.99 + 14.8 37.05 + 13.0 57.95 + 33.2 
- - -
pellets(%) 
Table 7.12. Summary of data showing the distribution of sustained 
release ibuprofen pellets in tablets containing 800mg 
ibuprofen. 
The high relative standard deviation (RSD) values obtained by image 
analysis of the various tablet sections indicate that the internal 
structure of these tablets comprising compacted polymer coated pellets 
exhibits a somewhat random packing arrangement. Figure 7.11 shows 
computer images of samples studied. It is evident that some pellets are 
not buffered from contact with each other by the diluent as a consequence 
of the compaction process. 
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Figure 7.7. Microphotograph of polymer coated pellets prlor to 
compaction into a tablet matrix ; magnification x25 
Figure 7 .8. Microphotogr aph of polymer coated pellets after release 
f r om a tab l e t matrix; magnification x_5 
2 -~ I _ 
Figure 7.9. Microphotograph of polymer coated pellets after re l ease 
from a tablet matrix; magnification xlO 
Figure 7 .1 0. Mi cropho tograph of a tablet cross-section comprl In 
compacted polymer coated pellets; magnification -1 
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a. surface b. surface 
c. side VIew d. side VIew 
e. cross-section f. cross-section 
Figure 7.11. Computer generated images of tablet sections:(2cm=1mm 
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Disintegration of the tablet matrix however yields discrete. visibly 
intact single entities. Figures 7.11a and 7.11b. show the effect of 
compaction on those pellets forming the tablet surface. They appear to 
be more susceptible to physical deformation and damage, as a consequence 
of direct contact with the tablet punches. This is highlighted by 
Figures 7.12 and 7.13. 
Microphotographs of tablet cross-sections reinforce the postulation 
that those pellets forming a tablet surface have a greater tendency 
towards physical deformation (Figure 7.16). It would appear that 
although this unstructured packing arrangement might indicate that there 
may be a tendency for segregation to occur, this does appear to be the 
case. 
Figures 7.8 and 7.9 indicate that the effect of the compaction 
process on the pellet core integrity appears to be of little consequence; 
there is however an unquestionable influence on the smoothness of the 
pellet surface and the quality of the spheres. 
The effect of compaction on the nature and integrity of the release 
retarding polymeric membrane is shown in Figures 7.18, 7.19 and 7.20. 
The surface characteristics of this particle under different 
magnifications must be compared with that illustrated in Figure 4.2~. 
Figure 4.25 IS a scanning electron micrograph (SEM) of the surface of an 
identically processed ibuprofen pellet coated with the same 
polymethacrylate aqueous dispersion prior to compaction; there is no 
evidence of holes or craters of the magnitude of those evident In Figures 
7.18, 7.19 and 7.20 which represent those pellets which have been 
subjected to the compaction process. It must be stressed however that 
these latter figures are not representative of all pellets which have 
been compacted into tablets; they illustrate the nature of the physical 
damage which may be incurred by pellets as a consequence of the 
compaction process. 
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Figure 7.12. Microphotograph of exposed stained pellets embedded In 
the diluent blend (surface ) ; magnification x50 
Figure 7 .1 3 . Mi crophotograph of exposed stained pellets embedded in 
the di luent b lend (surface): magnification "100 
_ 6 
Figure 7.14. Microphotograph of exposed stained pellets embedded in 
the diluent blend (side view); magnification x50 
Figure 7.15. Microphotograph of exposed stained pellets embedded In 
the diluent blend (side view)' magnification xl-O 
Figure 7.16. Microphotograph of exposed stained pellets embedded in 
the diluent blend (cross-section ) ; magnificat i on x20 
Figure 7 .1 7 . Microphot ograph of exposed stained pellets embedded in 
the dil uent blend (cross-section: magnification 0 
2iS 
Figure 7.18. SEM of the surface of a pellet coated with ERS/RL30D 
after release from a tablet matrix; magnification x240 
Figure 7.19. SEM of the surface of a pellet coated with ERS/RL30D 
after release from a tablet matrix; magnification x400 
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Figure 7.20. SEM of the surface of a pellet coated with ERS/RL30D 
after release from a tablet matrix; magnification x800 
7.3.4. Mathematical interpretation. 
7.3.4.1. Calculation of Hoop Stress. 
The application of external pressure to a polymer coated pellet 
during compression causes a tensile stress to be established within the 
surrounding polymeric membrane due to the tendency of the sphere to 
deform under pressure. This tangential stress is dissipated within the 
membrane shell until the applied pressure is so great as to cause pellet 
fracture. 
The thin-walled spherical particle is subjected to an external 
pressure p which induces in the film coat a circumferential stress a 
which has the same value in all tangential directions and is assumed to 
be constant over membrane thickness t. Considering the cross-section of 
a sphere surrounded by a membrane, the forces acting on one half of the 
pellet are two fold: 
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i). the diametral force due to the applied pressure p 
1uF 
= pressure x cross-sectional area = p --
4 
Equation 7.1. 
ii). the resisting force due to the circumferential stress o. acting 
on the section of the surrounding membrane. 
Assuming the membrane thickness t is small compared with the particle 
diameter d, then a may be considered uniform and therefore the resisting 
force 
= stress x area of film = ondt Equation 7.2. 
Equating these two forces and rearranging enables calculation of the 
tangential stress: 
mF 
ondt = p --
4 
Therefore the tangential (hoop) stress 
pd pr 
a= = 
4 t 2 t 
where r IS the particle radius. 
Equation 7.3. 
Equation 7.4. 
In summary the tangential (hoop) stress associated with the 
polymeric membrane surrounding a spherical particle, is directly 
proportional to the external pressure applied and the diameter of the 
particle; it IS inversely proportional to the thickness of the 
surrounding membrane. 
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7.3.4.2. Calculation of Volumetric Strain. 
Assuming the diameter of the polymer coated sphere decreases by an 
amount Bd when the external pressure is increased from zero to p as a 
consequence of pellet compression, then the volumetric strain E\· 
final volume - original volume 
Ev = Equation -:.5. 
original volume 
final volume 
Ev = - 1 Equation 7.6. 
original volume 
( 1r/6 ) (d - B d) 3 
Ev = - 1 Equation 7.7. 
( 1r/6) cf3 
cf3 - 3cJ2Bd - 3d BcJ2 - Bcf3 
Ev = - 1 Equation 7.8. 
cf3 
(ignoring products of small terms) 
cJ2 Bd 
Ev = 1 - 3 - 1 Equation 7.9. 
cf3 
Bd 
Ev = - 3 Equation 7.10. 
d 
1 • e. the volumetric strain = 3 x diametral strain 
= - 3 x circumferential strain 
where the volumetric strain Ev. may be defined as the change in volume 
per unit volume. 
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Therefore the volumetric strain 
30 
Ev = 
E 
Equation 7.11. 
where E IS the modulus of elasticity, therefore the volumetric strain 
3pd 
Ev = -- Equation 7.12. 
4tE 
since 0 = pd/4t (Equation 7.4). 
7.3.4.3. Change in particle volume. 
The change in volume of the sphere (oV) equals Ev x original 
volume i.e. 
3pd 1U:f3 
oV = - Equation 7.13. 
4 tE 6 
oV = - Equation 7.14. 
8tE 
(the change in particle volume is negative representing a volume decrease 
with applied external pressure). 
The above theory assumes that the pellet core itself does not contribute 
to that force resisting the application of pressure due to pellet 
compression; this however is not the case. 
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7.3.5. Practical application. 
7.3.5.1. Determination of the hoop stress of an applied film. 
In order to quantify that hoop stress associated with the 
application of force to a coated particle, it IS necessary to determine 
that stress associated with the pellet core. By considering the stress 
of an uncoated pellet on the application of load just prior to fracture 
and comparing this with that associated with a coated entity. it is 
possible to quantify that hoop stress provided by the physical presence 
of the film coat. 
Consider an uncoated ibuprofen pellet containing 80%w/w drug 
(expressed as % weight dry solids) of particle diameter 1107~m exhibiting 
a diametral crushing strength of 2.59N, a stress of 2.72MPa and a strain 
of 0.0779 (data extracted from Table 6.5). Since this particle IS 
without film coat, the entire force is absorbed by the pellet core: this 
IS reflected in a particle stress of 2.72MPa. 
In contrast to this a particle coated with polymeric membrane to a 
pellet weight increase of 4.5%, has a mean diameter of 1145~m and 
exhibits a crushing force of 2.74N, a stress of 2.66MPa and strain of 
0.0781. In addition to this a particle coated with a polymer film of 
weight increase 12% has a mean diameter of 1144~m and exhibits a crushing 
force of 2.81N, a stress of 2.74MPa and strain of 0.0825 (data extracted 
from Table 6.5). 
Considering pellets coated with the 4.5% weight increase: the film 
thickness t is (1145 - 1107)/2, equivalent to 19~m. Substituting in 
Equation 7.4 therefore, by considering that additional force required to 
fracture a coated pellet when compared to the pellet core, the hoop 
stress a = pd/4t = pr/2t and p = F/A, where F is the force for fracture 
and A is the cross-sectional area. 
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Therefore the hoop stress of a membrane associated with a 4.5% 
weight increase 
[(2.74 - 2.59)/nr2] x 1.107 
= = 2.27 MPa 
4 x 0.019 
For a 12% polymer solids loading, the hoop stress associated with the 
presence of the film 
[(2.81 - 2.59)/nr2] x 1.107 
= = 3.42 MPa 
4 x 0.0185 
This appears to indicate that for ibuprofen pellets coated with a 4.5% 
weight increase, it is the weakness of the film which enables pellet 
fracture since the uncoated pellet is able to withstand a greater stress 
(2.66MPa) than the polymeric film (2.27MPa). 
For a 12% weight increase however the film IS able to withstand a 
greater stress (3.42MPa) than the uncoated pellet (2.66MPa) and it is the 
relative weakness of the pellet core which facilitates pellet fracture 
under applied load. 
The ability of the pellet core and film coating In combination to 
withstand stress IS related to the particle diameter in addition to the 
diametral crushing strength. Therefore it is not unreasonable that there 
is a reduction in the stress associated with a pellet coated with a 
4.5%w/w solids increase, since the particle size is increased. It is 
apparent that further application of solids to the pellets (to 12%w/w) 
does not result in an increase in the pellet diameter; this may be 
explained by the fact that the additional weight gain is associated with 
bridging of "gaps" within the newly formed film itself. In-vitro release 
profiles support this postulation (Figure 4.7) since the drug release 
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rate is time dependent (first-order) at low polymer loading (4.S%w/w) 
but becomes time independent at higher polymer levels (12%w/w). 
The underlying theory in support of this claim is that under 
conditions of low polymer loading (below the CCL) drug release is pore 
controlled, whilst above the CCL drug release appears to exhibit 
barrier-controlled or zero-order kinetics. It is postulated that a 
polymeric film is created by a build-up of continuous layers of 
overlapping segments and until all of the "holes" associated with this 
gradual build-up are covered and a complete membrane envelopes each 
individual pellet there will be imperfections and areas of incomplete 
coverage of individual pellets. 
An effect of coating pellets with a polymeric film results in 
enhanced pellet deformability under stress and an increase in the work 
required to cause pellet fracture. The strain exhibited by pellets is 
also increased (Table 6.5). 
7.3.5.2. Calculation of volumetric strain. 
The volumetric strain exhibited by the polymer film may be 
calculated using Equation 7.12. Therefore with polymer loading of 
4.5%w/w 
Ev = 
3 x [(2.74 - 2.S9)/1Z"r2] x 1.107 
4 x 0.019 x E 
E for the polymer film = 30.55MPa, and therefore Ev = - 0.223. 
With a polymer loading of 12%w/w the volumetric strain 
Ev = 
and Ev = - 0.336. 
3 x [(2.81 - 2.59)/1Z"r2] x 1.107 
4 x 0.0185 x E 
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Strain is an expreSSlon of the elastic deformation of a particle and 
expresses the relative change in dimension in the direction of the 
applied force. Since the volumetric strain is equivalent to thrice the 
diametral strain, the theoretical diametral strain exhibited by the 
polymeric membrane at 4.5 and 12% weight increase is equal to 0.074 and 
0.112 respectively (c.f. strain exhibited by the coated pellets of 0.0~81 
and 0.0825 respectively). The strain exhibited by a similar uncoated 
particle is 0.079 and it therefore appears that the strain exhibited by a 
polymeric film lncreases with increasing physical strength for a given 
particle Slze. 
The following table shows the relative elastic moduli E of the 
uncoated pellet formulation containing 80%w/w ibuprofen, the coated 
pellets and the polymer itself; the data source is quoted accordingly. 
Product E (MPa) Source 
uncoated pellet 34.92 Table 6.5 
coated pellet (4.5%) 34.06 Table 6.5 
coated pellet (12%) 33.21 Table 6.5 
ERS/RL free-film 30.55 Table 5.5 
Table 7.12. Summary of experimentally determined elastic moduli values 
E (MPa) for the pellet component products. 
It is apparent that the elasticity of the optimised polymeric film 
formulation is not significantly different from that displayed by 
uncoated pellets. The effect of applying a polymeric film to an uncoated 
pellet formulation is increased elasticity with increased polymer 
loading. The success of the formulation in respect of pellet coat. core 
integrity and compression is thought to be a consequence of the not 
dissimilar elastic properties of the uncoated pellet and the free-film 
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formulations. This particular Eudragit formulation most closely mimicked 
the elastic behaviour of the uncoated pellets (see Tables 5.5 to 5.14). 
Those films exhibiting relatively low elastic modulus values (ie. were 
more elastic) for example the Silicone Elastomer free-films, with values 
as low as 5.0MPa, were as previously discussed non-compressible due to 
instantaneous elastic recovery on removal of the applied load. 
7.3.5.3. Change in particle volume. 
The change in particle volume may be calculated using Equation 7.14: 
oV = -
8tE 
Therefore for ibuprofen pellets coated with 4.5% and 12% weight increases 
respectively, the maximum change in pellet volume oV = - 0.158mm3 and 
- 0.239mm3 respectively; the change in volume is negative representing a 
decrease in particle volume with applied external pressure. 
The minimum volume Vf a coated particle will contract to just prior 
to fracture on the application of stress may be calculated using the 
following equation: 
Vo - oV 
Vf = x 100 Equation 7.15. 
Vo 
where Vo is the original volume of the coated sphere prior to the 
application of stress. The volume of a spherical particle = 4/3Hi3. 
where the coated particle radius must now taken into consideration; the 
coated particle volume therefore = 0.786mm3 . 
Using the above examples therefore the Vf values are 79.9% and 69.6% 
respectively; a pellet coated with a 4.5% weight increase may occupy a 
minimum volume of approximately 80% of that of its original volume under 
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applied load and a pellet coated with a 12% weight Increase may occupy as 
little as approximately 70% of its original volume under applied load. 
7.4. Conclusions. 
The aim of this work was to design a monolithic delivery device for 
a model medium to high dose drug which on oral administration rapidly 
disintegrates releasing polymer coated sustained release pellets. ~ith 
the integrity of the pellet core and the polymeric membrane being 
maintained. 
It is apparent that with careful optimisation of the pellet core. 
the film coat and the inert diluent formulations, it is possible to 
present a rapidly disintegrating monolithic sustained release drug 
delivery system for oral administration comprising compacted polymer-
coated pellets. 
The optimised diluent blend formulation comprIses 40%w/w of the 
tablet matrix; the remaining 60%w/w being occupied by the coated pellets. 
Large particle size excipients appear to provide the most satisfactory 
product. In the quest to achieve a rapidly disintegrating tablet which 
is able to satisfy the requirements of the friability test, it was 
necessary to use a blend of microcrystalline cellulose and lactose to 
impart properties characteristic of the combined components. It was not 
possible to produce strong, rapidly disintegrating tablets with lactose 
alone forming the tablet matrix, but in combination with microcrystalline 
cellulose the resulting tablets exhibit desirable diametral strength and 
rapid disintegration. 
The aqueous polymeric dispersion which formed a film displaying 
similar elastic and tensile properties to the uncoated pellet 
formulation, resulted in the most satisfactory film coating for 
application to spherical particles which must withstand compaction. 
Those polymeric films exhibiting significantly greater elasticity than 
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the uncoated pellet cores were inappropriate for film coating pellets 
which were to be compacted into tablets. This was due to the tendency of 
these films to exhibit instantaneous elastic recovery on the removal of 
the load associated with compaction, such that even maximum compaction 
forces were not capable of producing cohesive tablets containing these 
polymer coated entities. 
Pellets are rapidly released from the matrix on disintegration of 
the tablet. Released pellets are visibly intact although there is 
evidence of a deleterious effect on the smoothness of the surface and the 
quality of the shape of the spheres (Figures 7.8 and 7.9). In-vitro 
release profiles for compacted pellet formulations at different 
compaction forces and for non-compacted entities do indicate that some 
physical damage is being caused to at least some of the 
multiparticulates. The extent of the damage however does not appear to 
be dependent upon the magnitude of the compaction force (Figures 7.5 and 
7.6), but upon the actual process of compaction. The minimum force 
necessary to enable the formation of a tablet which will satisfy the 
friability testing requirements resulted in pellet damage of a similar 
extent to that displayed by tablets compressed with a significantly 
greater compaction force and which exhibit a correspondingly greater 
diametral strength. 
Microphotographs of stained pellets have illustrated that pellet 
distribution appears to be uniform throughout the tablet matrix. 
Quantitative evaluation of pellet distribution within the compacted 
formulation using image analysis however appears to indicate that pellets 
are randomly distributed. Uniformity of weight, uniformity of content 
and in-vitro drug release data however shows that under these conditions 
there is little tendency for particle segregation. It is accepted that 
this may be not be the case on scaling up the operation however. 
Evidence suggests that those pellets most susceptible to physical 
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damage as a consequence of the compaction process appear to occur at the 
tablet surface. Those pellets making contact with the tablet punches 
during compaction are not buffered to the same extent by the diluent 
particles as those not forming a tablet surface. Pellets forming an 
integral part of the tablet surface exhibit severe deformities which are 
manifest as linear edges and sharp corners; these are visible both in 
tablet cross-sections composed of stained pellets (Figure ~.16) and on 
pellets which have been released from the tablet matrix by disintegration 
(Figures 7.8 and 7.9). 
Scanning electron micrographs have illustrated the nature of the 
type of damage to pellets which may occur as a consequence of compaction 
into tablets (Figures 7.18 to 7.20). 
The hoop stress associated with the physical presence of a polymeric 
membrane surrounding a pellet core is capable of enhancing the diametral 
strength of a coated pellet, providing that sufficient polymer IS 
applied. Increasing the amount of film coating solids applied to pellets 
has the effect of enhancing the physical strength, the elasticity 
(reflected in a reduction of the elastic modulus of pellets with 
increased polymer loading) and the deformability or strain exhibited by 
the particle under load and for a given particle size; there is also an 
increase in the stress the particle will withstand prior to fracture. 
The application of external pressure to a particle causes a tensile 
stress to be established within the polymeric membrane and the pellet 
core, due to the tendency of the pellet to contract. Mathematically it 
has been shown that the volumetric strain a particle will exhibit is 
three times the diametral strain. This has been applied in a practical 
situation to coated pellets and gives an insight into the effect of the 
physical presence of a polymer coating on the particle deformability. 
In summary, this work has shown qualitatively and quantitatively 
that with careful optimisation of formulation variables, it is possible 
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to present a rapidly disintegrating monolithic sustained release drug 
delivery system for oral administration comprising compacted pol~~er­
coated pellets. In order to minimise physically damaging 
multiparticulates as a consequence of compaction. it is prudent to 
ascertain and understand the physical and mechanical properties of the 
components of the dosage form and to utilise this information to generate 
a product in which the benefits of this investigative research may be 
applied. 
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CHAPTER 8 
FINAL SUMMARY 
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An oral sustained release drug delivery system comprising compacted 
polymer-coated pellets confers pharmacological and pharmaceutical 
advantages associated with the administration of a once daily product. A 
sustained release multiparticulate dosage form which rapidly releases 
intact sub-units on oral administration improves patient compliance as a 
result of reduced frequency of dosing, reduced fluctuations in plasma 
drug concentrations and greater predictability and reproducibility of the 
therapeutic effect. 
This work has incorporated a study of formulation and processIng 
variables of pellets prepared by extrusion and spheronisation and their 
effect on the physical and release properties of uncoated pellets. 
Furthermore elucidation of the tensile properties of free-films prepared 
from aqueous polymeric dispersions and a study of the effect of the 
physical presence of a polymeric membrane on the tensile properties of 
coated pellets has enabled the presentation of polymer coated 
multiple-units as a rapidly disintegrating single-unit drug delivery 
system for a low potency drug. 
Those variable parameters influencing the physical characteristics 
of uncoated pellets are indeed numerous and are well documented. This 
work however has revealed that the drying methodology used and 
consequently the rate of the drying process for pelletized material has 
a significant effect on the skeletal, tensile and release properties of 
uncoated pellets containing ibuprofen. Pellets dried by tray drying 
exhibit greater diametral strength, are less elastic and display a 
slightly enhanced rate of drug release compared with their fluidised 
bed dried counterparts. 
The drying technique also imposes its effect upon the surface 
characteristics and quality of uncoated pellets prepared using this 
technique. Pellets dried rapidly using a fluidised bed apparatus are 
smoother with more uniform surface characteristics than tray dried 
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entities. Fluidised bed dried pellets therefore lend themselves more 
favourably to the application of a release retarding polymeric membrane 
due to the excellent surface smoothness which is evident with particles 
dried in this manner. 
The aqueous solubility of the excipients of the uncoated pellet 
formulation influences the type of bonding which is responsible for the 
maintenance of pellet integrity. Excipients which are freely soluble in 
the granulating fluid appear to be more susceptible to the phenomena of 
solute migration during drying. Where the granulating fluid IS aqueous 
and the excipients are freely water soluble, crystallisation of the 
solute molecules during drying leads to the formation of solid bridges 
and particles of great diametral strength. Where the main excipient 
exhibits poor aqueous solubility as does ibuprofen, the pellets are 
largely held together by binder hardening during drying. Increasing the 
binder concentration of the uncoated pellets therefore has the effect of 
enhancing the particle strength and reducing particle elasticity. 
A prerequisite of complete film formation and polymer coalescence 
for aqueous polymeric dispersions, in addition to optimised processing 
variables, is a reduction in the minimum film forming temperature (MFT) 
to well below the operating conditions of the coating chamber. Providing 
this is achieved it does not appear to be necessary to subject polymer 
coated pellets to a post-coating "curing" stage following that drying 
facility provided by the film coating operation. This is illustrated by 
the negligible difference in the in-vitro release profiles of pellets 
subjected to the post-coating "curing" stage and those which were not. 
A study of the tensile properties of free-films and polymer-coated 
pellets was made in order to ascertain that polymeric film formulation 
which was best able to sustain the effect of the applied stress 
associated with pellet compaction. A search for those physical 
properties responsible for providing that combination of strength and 
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elasticity was made and this enabled the compaction of pellets ~ith 
minimum particle damage. Qualitative film evaluation was made possible 
using microphotography and scanning electron microscopy and quantitative 
film evaluation was performed using in-vitro dissolution testing. 
An analysis of elastic and plastic deformation of polymer films was 
provided using the technique of indentation hardness testing of 
free-films. Quantifiable parameters using this technique included the 
instantaneous and time-dependent elastic deformation and recovery of the 
films, the elastic modulus and the Newtonian viscosity. An effect of 
increasing the plasticiser content of a particular film formulation 
serves to increase the instantaneous and time-dependent elastic 
components and cause a reduction in the elastic modulus and the apparent 
Newtonian viscosity. In general the permanent non-recoverable plastic 
deformation associated with applied stress, increases with increasing 
plasticiser concentration. 
The presence of other excipients within a film may also exert an 
influence on the resultant tensile properties. This effect is however 
product specific. 
It 1S evident from studying the tensile properties of free-films 
that those polymeric films exhibiting a high elastic compliance, both 
instantaneous and time-dependent, are unlikely to satisfy the 
requirements for favourable pellet compaction, due to elastic recovery 
occurring immediately on removal of the applied stress associated with 
tablet compression. It is apparent from this work that those films 
exhibiting a relatively high elastic modulus and apparent Newtonian 
viscosity provide greater protection to the integrity of the pellet core 
and the film coat on pellet compression. 
The predominant drug release mechanism from polymer coated pellets 
is a function of polymer loading. There appears to be a critical coating 
level below which film coverage may be considered incomplete, drug 
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release is diffusion controlled and first-order kinetics are obser\·ed. 
Above this critical coating level, drug release appears to become 
membrane controlled and zero-order kinetics are evident. The drug 
release rate appears to become time independent once a certain polymer 
level has been achieved. 
With careful optimisation of the pellet core formulation and 
processing technique, the film coating and the inert diluent blend, it IS 
possible to present a rapidly disintegrating sustained release tablet 
matrix suitable for oral administration, comprising polymer coated 
multiparticulates. 
The magnitude of the compaction force on the extent of particle 
damage appears to be of little consequence. Rather that the actual 
process of compaction as opposed to the magnitude of the load applied to 
the pellets appears to be responsible for any damage which is caused to 
particles during compression. The minimum compaction force necessary for 
tablet formation which enables tablets to fulfill the requirements of 
friability test, results in similar damage to that caused to pellets 
compacted with a far greater force with a corresponding diametral 
strength. In addition to microphotographic evidence, this suggests that 
those pellets most susceptible to damage as a consequence of compaction 
are at the tablet surface. Those pellets forming the surface are not 
buffered by surrounding diluent particles from contact with the tablet 
punches. In particular those particles forming a tablet surface are 
especially vulnerable to impaired integrity and may exhibit severe 
deformities in the form of sharp corners and linear edges, which it IS 
postulated are responsible for the slightly increased rate of drug 
release which is apparent with the compacted pellet formulation (Figure 
8.1). The magnitude of pellet damage was assessed by scanning electron 
microscopy of the film coat following pellet compaction and by comparison 
of the in-vitro release profiles of compacted and non-compacted pellets. 
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Figure 8.la. Microphotograph of the cross-section of a tablet comprising 
compacted stained pellets; magnification x20. 
Figure 8.1b. Microphotograph of the cross-section of a tablet compri ing 
compacted stained pellets; magnification x20. 
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Image analysis of tablet sections comprising stained pellets enabled 
a study of pellet distribution within the tablet matrix and the 
inclination of the components of the blend towards particle segregation. 
Image analysis, microphotography and uniformity of weight and content 
data present negligible evidence of segregation. 
Further development work might involve a scaling-up of this concept 
In order that a full investigation into the tendency of the components of 
the tablet blend to undergo particle segregation may be ascertained. 
Although in this study ibuprofen was used as a model high dose or low 
potency drug, it would be interesting to apply this technique to other 
drugs of differing aqueous solubility and physicochemical properties. It 
is clear that the diametral strength and tensile properties of uncoated 
pellets are very much dependent upon processing variables and formulation 
factors and therefore the use of different compounds would yield 
additional fundamental data relating to other excipients in respect of 
the tensile properties of pellets prepared using these techniques. 
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APPENDIX I 
Principle of operation of the Multivolume Pycnometer. 
The Micromeritics Multivolume Helium Pycnometer 1305 IS a gas 
displacement pycnometer, which measures the volume of solids whether 
powdered or as single entities. Figure 2.4 is a simplified illustration 
of the principle behind the apparatus. 
Veell 
Vsamp 
va lve 
*-----4 
Vexp 
Figure 2.4. Simplified block diagram of Helium Pycnometer 1305. 
where Veell = calibrated sample cell volume 
Vsamp = sample volume 
and Vexp = calibrated expansion volume. 
Assuming that Veell and Vexp are at ambient pressure Pa and temperature 
Ta and that the valve is closed, then if Veell is charged to an elevated 
pressure PI, then the mass balance equation across the sample Veel1 is 
PI ( Vee I I - V sam p) = ne RT a Equation 2.1 
where ne = number of moles of gas in the sample cell 
R = gas constant 
and Ta = ambient temperature. 
The mass equation for the expanSIon volume IS 
Pa Vexp = neRTa Equation 2.2 
where ne = number of moles of gas in the expanSlon volume. 
When the valve is opened, the pressure will fall to an intermediate 
value P2 and the mass balance equation becomes 
P2 (Veell - Vsamp + Vexp) = neRT. + neRTa Equation ~.3 
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Substituting from equations 2.1 and 2.2 into 2.3 
P2 (Veell - Vsamp + Vexp ) = PI (Veell - Vsamp ) + PaVexp 
rearranging 
P2Vee ll - P2Vsamp + P2Vexp = PlVeell - PIVsamp + PaVexp 
- P2Vee il P2Vsamp = PIVeeil PIVsamp + PaVexp P2Vexp 
- P2Vee ll P2Vsamp = PIVeell PIVs amp + (Pa P2 )Vexp 
- P2Vee il P2Vsamp PIVeell + PlVsamp = (Pa - P2)Vexp 
- (P2 - PI) (Veell - Vsamp ) = (Pa - P2) Vexp 
or 
Veell - Vsamp = 
rearranging 
(Pa - P2) Vexp 
P2 - PI 
- Vs amp = - Veell + (Pa - P2) Vexp 
(P2 - Pal - (PI - Pal 
dividing by (Pa - P2) 
Vsamp = Vee 11 - Vexp 
-1 - (PI - Pa ) 
(Pa - P2 ) 
or 
Vsamp = Veell - Vexp 
( PI - Pa} -1 
(P2 - Pa) 
Equation 2.4 
Equation 2.5 
Equation 2.6 
Equation 2.7 
Equation 2.8 
Equation 2.9 
Since PI, P2 and Pa are expressed in equations 2.1 to 2.9 as absolute 
pressures, and equation 2.9 is arranged such that Pa is subtracted from 
both PI and P2 before use, new Plg and P2g may be redefined as gauge 
pressures 
PIg = PI - Pa 
P2g = P2 - Pa 
therefore equation 2.9 becomes 
Vsamp = Veell - Vexp 
flA - 1 
P2g 
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Equation 2.10 
Equation 2.11 
Equation 2.12 
Equation 2.12 is the working equation for the Multivolume Pycnometer 
1305. Calibration procedures using a steel sphere of precise dimensions 
enabled determination of Veell and Vexp . PI and P2 were measured by 
means of a gauge pressure transducer. 
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Figure 6.20. Linear regression plot of pellet diameter (~m) versus 
diametral strength (N) for fluidised bed dried pellets 
containing 80%w/w ibuprofen (uncoated). 
Curve statistics: 
X-data: mean pellet diameter = 1083.51~m 
SD = 109.18Jlm 
V-data: mean diametral strength = 1.910N 
SD = 0.579N 
Curve-fit: (y) = 0.003215(x) - 1.5738 
n = 49 
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